{
    "id": 1909,
    "name": "melanoma",
    "source": "DOID",
    "definition": "A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from melanocytes which are found in skin, the bowel and the eye. [url:http\\://en.wikipedia.org/wiki/Melanoma, url:https\\://www.ncbi.nlm.nih.gov/pubmed/22123420]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:1909",
    "evidence": [
        {
            "id": 554,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial (BREAK-3) that supported FDA approval, Tafinlar (dabrafenib) improved median progression-free survival compared to Deticene (dacarbazine) (5.1 vs 2.7 months, HR=0.3, p<0.0001) in patients with BRAF V600E positive melanoma (PMID: 22735384; NCT01227889).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 232,
                    "pubMedId": 22735384,
                    "title": "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22735384"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 586,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BRIM-3) that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival (OS) (13.6 vs 9.7 months, HR=0.81, p=0.03) in patients with BRAF V600E-positive metastatic melanoma, with estimated OS rates of 56%, 30%, 21%, and 17% at 1, 2, 3, and 4 years, respectively (PMID: 28961848, PMID: 21639808; NCT01006980), and BRAF V600E is included on the companion diagnostic (FDA.gov).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 222,
                    "pubMedId": 21639808,
                    "title": "Improved survival with vemurafenib in melanoma with BRAF V600E mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21639808"
                },
                {
                    "id": 11411,
                    "pubMedId": 28961848,
                    "title": "Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961848"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15452,
                    "pubMedId": null,
                    "title": "Zelboraf (vemurafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202429"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10334,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III clinical trial, treatment with Binimetinib (MEK162) improved median progression-free survival compared to treatment with Deticene (dacarbazine) (2.8 mo. vs. 1.5 mo.), but did not improve overall survival in patients with NRAS-mutant melanoma (PMID: 28284557).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 8316,
                    "pubMedId": 28284557,
                    "title": "Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28284557"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 709,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 180,
                    "pubMedId": 23414587,
                    "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 178,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Mekinist (trametinib) resulted in complete response in 7% (2/30), partial response in 33% (10/30), and stable disease in 37% (11/30) of BRAF-mutant melanoma patients (PMID: 22805292; NCT00687622).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 233,
                    "pubMedId": 22805292,
                    "title": "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805292"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1912,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K positive metastatic melanoma (PMID: 22663011; NCT01245062).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 468,
                    "pubMedId": 22663011,
                    "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22663011"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15457,
                    "pubMedId": null,
                    "title": "Mekinist (trametinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 183,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor, selumetinib (AZD6244), in cell culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 306,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human melanoma cell line (PMID: 22319199).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1002,
                "therapyName": "RXDX-105",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 203,
                    "pubMedId": 22319199,
                    "title": "CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22319199"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 386,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lenvima (lenvatinib) was demonstrated to be well tolerated and displayed anti-tumor activity in patients with melanoma and renal cell carcinoma (PMID: 22516948).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 62,
                    "pubMedId": 22516948,
                    "title": "A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22516948"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 452,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF265 inhibited the growth of melanoma tumors orthotopically implanted in mice, including tumors wild-type for BRAF (PMID: 22351689).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 61,
                    "pubMedId": 22351689,
                    "title": "RAF265 inhibits the growth of advanced human melanoma tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351689"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12624,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10503,
                    "pubMedId": 28719152,
                    "title": "A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28719152"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 503,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 inhibited growth of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 291,
                    "pubMedId": 18287029,
                    "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18287029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 504,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 did not inhibit growth of BRAF wild-type melanoma cells in culture or in cell line xenograft models (PMID: 18287029).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 291,
                    "pubMedId": 18287029,
                    "title": "Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18287029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 505,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 506,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 1061,
                "therapyName": "PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1117,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alisertib (MLN8237) impaired mitosis, induced senescence and blocked growth in xenograft models of patient-derived and cell line-derived melanoma tumors (PMID: 23180582).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 308,
                    "pubMedId": 23180582,
                    "title": "Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-\u03baB impairs this drug-induced senescence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23180582"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 509,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 294,
                    "pubMedId": 22394203,
                    "title": "Sorafenib in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22394203"
                },
                {
                    "id": 3156,
                    "pubMedId": 16880785,
                    "title": "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16880785"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 510,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 294,
                    "pubMedId": 22394203,
                    "title": "Sorafenib in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22394203"
                },
                {
                    "id": 3156,
                    "pubMedId": 16880785,
                    "title": "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16880785"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 535,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Cyramza (ramucirumab), with or without Deticene (dacarbazine), demonstrated safety and efficacy in patients with metastatic melanoma. The combined therapy appeared to be associated with improved progression free survival relative to monotherapy (J Clin Oncol 28:15s, 2010 (suppl; abstr 8519)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 886,
                "therapyName": "Ramucirumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 315,
                    "pubMedId": null,
                    "title": "A phase II randomized study of ramucirumab (IMC-1121B) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM).",
                    "url": "http://meetinglibrary.asco.org/content/50441-74"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 536,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study in patients with metastatic melanoma, Inlyta (axitinib) was well tolerated and demonstrated antitumor activity (PMID: 21976544).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 316,
                    "pubMedId": 21976544,
                    "title": "Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21976544"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 541,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Votrient (pazopanib) administered with Gemzar (gemcitabine) was shown to be tolerated with one partial response (metastatic melanoma) and prolonged disease stabilization in three patients (metastatic melanoma, cholangiocarcinoma, and colorectal carcinoma) (PMID: 23064954).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1478,
                "therapyName": "Gemcitabine + Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 319,
                    "pubMedId": 23064954,
                    "title": "A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23064954"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 552,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) induced cell death in human melanoma cell lines harboring BRAF activating mutations in culture and inhibited tumor growth in xenograft models (PMID: 22084396).",
            "molecularProfile": {
                "id": 696,
                "profileName": "BRAF act mut"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 353,
                    "pubMedId": 22084396,
                    "title": "Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22084396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 553,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II study, Dovitinib (TKI258) was demonstrated safe, but of limited clinical benefit in patients with advanced melanoma (PMID: 21976540).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 322,
                    "pubMedId": 21976540,
                    "title": "Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21976540"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 666,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal-regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID:24463458).",
            "molecularProfile": {
                "id": 846,
                "profileName": "MAP2K1 K57E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 384,
                    "pubMedId": 24463458,
                    "title": "BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24463458"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 685,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Caprelsa (vandetanib) resulted in a significant reduction in tumor outgrowth in mouse xenograft models of melanoma (PMID: 22075979).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 416,
                    "pubMedId": 22075979,
                    "title": "Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22075979"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 686,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, Encorafenib (LGX818) treatment of human melanoma xenograft models with BRAF V600E significantly decreased Mek activation and resulted in tumor regression (Cancer Res: 72(8) Suppl 1, Abstract #3790).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 417,
                    "pubMedId": null,
                    "title": "Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor",
                    "url": "http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/3790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 689,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID:24791855).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 422,
                    "pubMedId": 24791855,
                    "title": "Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24791855"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 699,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, one metastatic melanoma patient carrying a BRAF L597S mutation, had a partial response to the MEK inhibitor, TAK-733 (PMID: 22798288).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 932,
                "therapyName": "TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3,
                    "pubMedId": 22798288,
                    "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22798288"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 713,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial in patients with advanced melanoma, 5/6 patients exhibiting a response to selumetinib had BRAF-mutant tumors (PMID: 22048237).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 228,
                    "pubMedId": 22048237,
                    "title": "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22048237"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 714,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a favorable response rate to Selumetinib (AZD6244) was observed in mutant BRAF, but not BRAF wild-type, melanoma patients (PMID: 22048237).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 228,
                    "pubMedId": 22048237,
                    "title": "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22048237"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 819,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the shRNA knockdown of NF1 in a BRAF V600E melanoma cell line conferred resistance to RAF inhibitor PLX4720 through sustained MAPK pathway activation (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 821,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combined shRNA knockdown of NF1 and RAF1 in a melanoma cell line with BRAF V600E mutation was sensitive to RAF inhibitor PLX4720 (PMID: 23288408).",
            "molecularProfile": {
                "id": 1178,
                "profileName": "BRAF V600E NF1 dec exp RAF1 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 822,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of NF1 in a BRAF V600E melanoma cell line conferred resistance to MEK inhibitor selumetinib (AZD6244) through sustained MAPK pathway activation (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 823,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of C-RAF in a BRAF V600E melanoma cell line with decreased NF1 expression restored sensitivity to the MEK inhibitor selumetinib (AZD6244) (PMID: 23288408).",
            "molecularProfile": {
                "id": 1178,
                "profileName": "BRAF V600E NF1 dec exp RAF1 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 824,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, shRNA knockdown of NF1 in a BRAF V600E melanoma cell line demonstrated partial resistance to the pan-RAF inhibitor AZ628 (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 825,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, inhibition of NF1 in a melanoma cell line harboring a BRAF V600E mutation did not affect sensitivity to the ERK inhibitor VTX-11e (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1094,
                "therapyName": "VTX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 826,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the shRNA knockdown of NF1 in a BRAF V600E melanoma cell line confers resistance to RAF inhibitor Zelboraf (vemurafenib) through sustained MAPK pathway activation (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 827,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, shRNA knockdown of NF1 in a BRAF V600E melanoma cell line confered resistance to the RAF inhibitor GDC0879 through sustained MAPK pathway activation (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 828,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NF1 knockdown in a BRAF V600E melanoma cell line conferred partial resistance to the combined treatment of the RAF inhibitor PLX4720 and the MEK inhibitor selumetinib (AZD6244) (PMID: 23288408).",
            "molecularProfile": {
                "id": 1177,
                "profileName": "BRAF V600E NF1 dec exp"
            },
            "therapy": {
                "id": 1061,
                "therapyName": "PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 473,
                    "pubMedId": 23288408,
                    "title": "A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23288408"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 940,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, the CDK4/6 inhibitor LY2835129 reversed resistance to vemurafenib due to CCND1 upregulation in melanoma xenograft models (PMID: 25122067).",
            "molecularProfile": {
                "id": 1571,
                "profileName": "CCND1 over exp"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 616,
                    "pubMedId": 25122067,
                    "title": "The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25122067"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 990,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KIT N505I induced phosphorylation of KIT, ERK, and AKT, and was inhibited by Nexavar (sorafenib) in cell culture of melanocytes, demonstrating sensitivity of N505I to sorafenib (PMID: 24317392).",
            "molecularProfile": {
                "id": 1642,
                "profileName": "KIT N505I"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 651,
                    "pubMedId": 24317392,
                    "title": "A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24317392"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 991,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) decreased phosphorylation of KIT, AKT, and ERK in melanocytes expressing KIT N505I in culture (PMID: 24317392).",
            "molecularProfile": {
                "id": 1642,
                "profileName": "KIT N505I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 651,
                    "pubMedId": 24317392,
                    "title": "A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24317392"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1120,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Binimetinib (MEK162) treatment resulted in a partial response in 20% (8/41) of melanoma patients harboring BRAF V600 mutations, including V600E (33/41), V600K (5/41), and V600R (1/41) (PMID: 23414587; NCT01320085).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 180,
                    "pubMedId": 23414587,
                    "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 876,
                    "pubMedId": null,
                    "title": "Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.",
                    "url": "http://meetinglibrary.asco.org/content/114757-132"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11978,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MLN2480 resulted in a median progression free survival of 4.6 months and a partial response in 50% (8/16) of melanoma patients harboring a BRAF mutation (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 410P; NCT01425008).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9943,
                    "pubMedId": null,
                    "title": "Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK- 580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1129,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, PD-0325901 demonstrated some efficacy in previously treated melanoma patients, however, there was significant toxicity above 10 mg BID (PMID: 21516509).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 170,
                    "pubMedId": 21516509,
                    "title": "Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21516509"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1130,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Refametinib (BAY86-9766) inhibited growth of melanoma cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 888,
                "therapyName": "Refametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 877,
                    "pubMedId": 19706763,
                    "title": "RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19706763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1131,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a favorable response rate to selumetinib (AZD6244) was observed in mutant BRAF but not BRAF wild-type melanoma patients (PMID: 22048237).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 228,
                    "pubMedId": 22048237,
                    "title": "Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22048237"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1135,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cobimetinib (GDC-0973) induced cell death in several human melanoma cell lines in culture and inhibited tumor growth in xenograft models (PMID: 22084396).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 353,
                    "pubMedId": 22084396,
                    "title": "Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22084396"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1211,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, combination treatment with Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months compared to 7.2 months with Zelboraf (vemurafenib) alone among patients with BRAF V600-mutated metastatic melanoma (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1233,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 1067,
                    "pubMedId": 20664172,
                    "title": "Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20664172"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1256,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, 10% (4/39) of wild-type BRAF melanoma patients had a partial response to Mekinist (trametinib) (PMID: 22805292; NCT00687622).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 233,
                    "pubMedId": 22805292,
                    "title": "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805292"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1267,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the Hsp90 inhibitor, Ganetespib, in combination with the MEK1/2 inhibitor TAK-733, caused the regression of tumors in vemurafenib-resistant cell line xenograft models of melanoma (PMID: 24398428).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1684,
                "therapyName": "Ganetespib + TAK-733",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 249,
                    "pubMedId": 24398428,
                    "title": "Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24398428"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1314,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494).",
            "molecularProfile": {
                "id": 21996,
                "profileName": "KDR positive"
            },
            "therapy": {
                "id": 984,
                "therapyName": "Anti-VEGFR2 CAR CD8 lymphocytes",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1027,
                    "pubMedId": 23633494,
                    "title": "Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23633494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1406,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring B2M C45W displayed greatly reduced expression of HLA class I molecules, which was not corrected by treatment with interferon gamma (PMID: 16648140).",
            "molecularProfile": {
                "id": 36050,
                "profileName": "B2M C45W"
            },
            "therapy": {
                "id": 1733,
                "therapyName": "interferon gamma",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1149,
                    "pubMedId": 16648140,
                    "title": "Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16648140"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1469,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the NMDA antagonist, Dizocilpine (MK-801), demonstrated effectiveness against melanoma cells in culture (PMID: 24240127).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1787,
                "therapyName": "Dizocilpine",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1340,
                    "pubMedId": 24240127,
                    "title": "The combination of glutamate receptor antagonist MK-801 with tamoxifen and its active metabolites potentiates their antiproliferative activity in mouse melanoma K1735-M2 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24240127"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 1475,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590).",
            "molecularProfile": {
                "id": 2594,
                "profileName": "BRAF L505H"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1371,
                    "pubMedId": 24283590,
                    "title": "Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24283590"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1482,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I and Phase II clinical trials, treatment with the CTLA4 blocking antibody Tremelimumab resulted in tumor regression in patients with metastatic melanoma (PMID: 23748107).",
            "molecularProfile": {
                "id": 1061,
                "profileName": "CTLA4 wild-type"
            },
            "therapy": {
                "id": 1652,
                "therapyName": "Tremelimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1377,
                    "pubMedId": 23748107,
                    "title": "CTLA-4 blockade and the renaissance of cancer immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23748107"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12034,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (COMBI-AD) that supported FDA approval, adjuvant treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved estimated 3-year relapse-free survival rate (58% vs 39%, HR=0.47, P<0.001) and 3-year overall survival rate (86% vs 77%, HR=0.57; 95% CI, 0.42 to 0.79, P=0.0006) compared to placebo in stage III melanoma patients harboring BRAF V600E or V600K mutations (PMID: 28891408; NCT01682083).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9986,
                    "pubMedId": 28891408,
                    "title": "Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28891408"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1909,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10781,
                    "pubMedId": 25399551,
                    "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25399551"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4933,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4804,
                    "pubMedId": 26811525,
                    "title": "Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26811525"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1533,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAH-p53-8 treatment of TP53 wild-type melanoma cells over expressing MDM4 inhibited growth in culture and in xenograft models (PMID: 22820643).",
            "molecularProfile": {
                "id": 2644,
                "profileName": "MDM4 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 1836,
                "therapyName": "SAH-p53-8",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1453,
                    "pubMedId": 22820643,
                    "title": "MDM4 is a key therapeutic target in cutaneous melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22820643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1537,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in BRAF V600E melanoma cell lines resulted in resistance to vemurafenib or selumetinib (PMID: 23178117).",
            "molecularProfile": {
                "id": 2649,
                "profileName": "BRAF V600E MED12 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1538,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in BRAF V600E melanoma cell lines resulted in resistance to vemurafenib or selumetinib (PMID: 23178117).",
            "molecularProfile": {
                "id": 2649,
                "profileName": "BRAF V600E MED12 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1577,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MLN2480 inhibited growth of RAS mutant melanoma and colorectal cancer cell lines in culture (Mol Cancer Ther November 2013 12; C146).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 1034,
                "therapyName": "MLN2480",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 421,
                    "pubMedId": null,
                    "title": "Abstract C146: Combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 inhibits the growth of BRAF mutant and RAS mutant preclinical models of melanoma and CRC.",
                    "url": "https://mct.aacrjournals.org/content/12/11_Supplement/C146"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1787,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 2285,
                "therapyName": "CGM097 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7241,
                    "pubMedId": null,
                    "title": "Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma",
                    "url": "http://cancerres.aacrjournals.org/content/74/19_Supplement/5466"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1811,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1812,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Sutent (sunitinib) (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1813,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1814,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1653,
                "profileName": "KIT A829P"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1815,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1657,
                "profileName": "KIT T670I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1816,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Tasigna (nilotinib) (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1657,
                "profileName": "KIT T670I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1817,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Sprycel (dasatinib) (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1657,
                "profileName": "KIT T670I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1818,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sutent (sunitinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT T670I (PMID: 23582185, PMID: 25594040).",
            "molecularProfile": {
                "id": 1657,
                "profileName": "KIT T670I"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2193,
                    "pubMedId": 23582185,
                    "title": "Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23582185"
                },
                {
                    "id": 2194,
                    "pubMedId": 25594040,
                    "title": "Resistance to c-Kit inhibitors in melanoma: insights for future therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25594040"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1859,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human melanoma cells expressing MAP2K1 P124L demonstrated resistance to the MEK inhibitor, Selumetinib (AZD6244) (PMID: 19915144).",
            "molecularProfile": {
                "id": 3892,
                "profileName": "MAP2K1 P124L"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2091,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with the combination of Genasense (oblimersen), Temodar (temozolomide), and Abraxane (nab-paclitaxel) resulted in an objective response rate of 40.6% (13/32) and disease control rate of 75% (24/32) in patients with advanced melanoma (PMID: 23064957).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2582,
                "therapyName": "Nab-paclitaxel + Oblimersen + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2568,
                    "pubMedId": 23064957,
                    "title": "Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23064957"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2184,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF activating mutations and loss of NF1 were resistant to treatment with Zelboraf (vemurafenib) in culture and in xenograft models (PMID: 23171796).",
            "molecularProfile": {
                "id": 5928,
                "profileName": "BRAF act mut NF1 loss"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2712,
                    "pubMedId": 23171796,
                    "title": "Elucidating distinct roles for NF1 in melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23171796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2185,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of melanoma cells derived from NF1-null and BRAF mutant mouse models in culture and in allograft animal models (PMID: 23171796).",
            "molecularProfile": {
                "id": 5928,
                "profileName": "BRAF act mut NF1 loss"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2712,
                    "pubMedId": 23171796,
                    "title": "Elucidating distinct roles for NF1 in melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23171796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2202,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a phase I clinical trial, Fresolimumab (GC1008) demonstrated safety and preliminary evidence of antitumor activity in patients with malignant melanoma (PMID: 24618589).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2707,
                "therapyName": "Fresolimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 2759,
                    "pubMedId": 24618589,
                    "title": "Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24618589"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2262,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 A189V demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6848,
                "profileName": "MAPK1 A189V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2263,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 A189V demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6848,
                "profileName": "MAPK1 A189V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2264,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 A189V demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6848,
                "profileName": "MAPK1 A189V"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11414,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a median progression-free survival of 6.7 months, a partial response in 25% (4/16), and stable disease in 44% (7/16) of NRAS mutant melanoma patients (J Clin Oncol 35, 2017 (suppl; abstr 9519)).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 5,
                "therapyName": "Binimetinib + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9296,
                    "pubMedId": null,
                    "title": "Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).",
                    "url": "http://meetinglibrary.asco.org/record/147511/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2265,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a partial response in 43% (6/14) and stable disease in 43% (6/14) of NRAS mutant melanoma patients (J Clin Oncol 32:5s, 2014 (Suppl;abstr 9009)).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 5,
                "therapyName": "Binimetinib + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2946,
                    "pubMedId": null,
                    "title": "A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity",
                    "url": "http://meetinglibrary.asco.org/content/130034-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2266,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).",
            "molecularProfile": {
                "id": 6894,
                "profileName": "CDKN2A loss NRAS mut"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2947,
                    "pubMedId": null,
                    "title": "A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer",
                    "url": "http://meetinglibrary.asco.org/content/111069-132"
                },
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2268,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines with CDKN2A loss demonstrated a greater sensitivity to Alvocidib (flavopiridol) as compared to melanoma cell lines positive for CDKN2A (PMID: 12777976).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 628,
                "therapyName": "Alvocidib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2838,
                    "pubMedId": 12777976,
                    "title": "The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12777976"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2274,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring a BRAF V600E mutation and amplification of CCND1 in culture (PMID: 22351686).",
            "molecularProfile": {
                "id": 6907,
                "profileName": "BRAF V600E CCND1 amp"
            },
            "therapy": {
                "id": 970,
                "therapyName": "XL888",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2956,
                    "pubMedId": 22351686,
                    "title": "The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2275,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 970,
                "therapyName": "XL888",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2956,
                    "pubMedId": 22351686,
                    "title": "The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2276,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring a BRAF V600E mutation and over expression of MAP3K8 (COT) in cell culture (PMID: 22351686).",
            "molecularProfile": {
                "id": 6910,
                "profileName": "BRAF V600E MAP3K8 over exp"
            },
            "therapy": {
                "id": 970,
                "therapyName": "XL888",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2956,
                    "pubMedId": 22351686,
                    "title": "The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2277,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with XL888 increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant human melanoma cell lines harboring a BRAF V600E mutation and over expression of PDGFRB in cell culture and in xenograft models (PMID: 22351686).",
            "molecularProfile": {
                "id": 6908,
                "profileName": "BRAF V600E PDGFRB over exp"
            },
            "therapy": {
                "id": 970,
                "therapyName": "XL888",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2956,
                    "pubMedId": 22351686,
                    "title": "The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22351686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2278,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of PDGFRB conferred acquired resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",
            "molecularProfile": {
                "id": 6908,
                "profileName": "BRAF V600E PDGFRB over exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2959,
                    "pubMedId": 21107323,
                    "title": "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21107323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2279,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2959,
                    "pubMedId": 21107323,
                    "title": "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21107323"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2296,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 C65Y demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6947,
                "profileName": "MAPK1 C65Y"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2297,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 D321G demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6853,
                "profileName": "MAPK1 D321G"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2298,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 D321G demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6853,
                "profileName": "MAPK1 D321G"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2299,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 D321G demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6853,
                "profileName": "MAPK1 D321G"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2300,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 G37S demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6854,
                "profileName": "MAPK1 G37S"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2301,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 G37S demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6854,
                "profileName": "MAPK1 G37S"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2302,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 P58L demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6891,
                "profileName": "MAPK1 P58L"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2303,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 P58L demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6891,
                "profileName": "MAPK1 P58L"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2304,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 P58S demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7007,
                "profileName": "MAPK1 P58S"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2305,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 P58T demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6892,
                "profileName": "MAPK1 P58T"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2306,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 S202P demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6893,
                "profileName": "MAPK1 S202P"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2307,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 S202P demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6893,
                "profileName": "MAPK1 S202P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2308,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 S202P demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6893,
                "profileName": "MAPK1 S202P"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2309,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131C demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6931,
                "profileName": "MAPK1 Y131C"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2310,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131C demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6931,
                "profileName": "MAPK1 Y131C"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2311,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131C demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6931,
                "profileName": "MAPK1 Y131C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2312,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131F demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6932,
                "profileName": "MAPK1 Y131F"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2313,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131F demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6932,
                "profileName": "MAPK1 Y131F"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2314,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131F demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6932,
                "profileName": "MAPK1 Y131F"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2318,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y64N demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6937,
                "profileName": "MAPK1 Y64N"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2319,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y36H demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6935,
                "profileName": "MAPK1 Y36H"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2320,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y36H demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6935,
                "profileName": "MAPK1 Y36H"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2321,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y36N demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6936,
                "profileName": "MAPK1 Y36N"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2322,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y36N demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6936,
                "profileName": "MAPK1 Y36N"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2327,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131S demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7011,
                "profileName": "MAPK1 Y131S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2328,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131S demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7011,
                "profileName": "MAPK1 Y131S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2329,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 Y131S demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7011,
                "profileName": "MAPK1 Y131S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2330,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 E322K demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6671,
                "profileName": "MAPK1 E322K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2331,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 E322K demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6671,
                "profileName": "MAPK1 E322K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2332,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK1 E322K demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 6671,
                "profileName": "MAPK1 E322K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2333,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Y81C demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7023,
                "profileName": "MAPK3 Y81C"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2334,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Y53H demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7022,
                "profileName": "MAPK3 Y53H"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2335,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Y53H demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7022,
                "profileName": "MAPK3 Y53H"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2336,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 A206V demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7012,
                "profileName": "MAPK3 A206V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2337,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 A206V demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7012,
                "profileName": "MAPK3 A206V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2338,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 A206V demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7012,
                "profileName": "MAPK3 A206V"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2339,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 C82Y demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7013,
                "profileName": "MAPK3 C82Y"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2340,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 C82Y demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7013,
                "profileName": "MAPK3 C82Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2341,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 G54A demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7014,
                "profileName": "MAPK3 G54A"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2342,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 G54A demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7014,
                "profileName": "MAPK3 G54A"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2343,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 G54S demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7015,
                "profileName": "MAPK3 G54S"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2344,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 G54S demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7015,
                "profileName": "MAPK3 G54S"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2345,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 P75L demonstrated resistance to VX-11e in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7016,
                "profileName": "MAPK3 P75L"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2346,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 P75L demonstrated resistance to SCH772984 in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7016,
                "profileName": "MAPK3 P75L"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2348,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Q90R demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7024,
                "profileName": "MAPK3 Q90R"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2349,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Q90R demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7024,
                "profileName": "MAPK3 Q90R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2350,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Q90R demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7024,
                "profileName": "MAPK3 Q90R"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2351,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 R84H demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7018,
                "profileName": "MAPK3 R84H"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2352,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 R84H demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7018,
                "profileName": "MAPK3 R84H"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2353,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 R84H demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7018,
                "profileName": "MAPK3 R84H"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2354,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 S219P demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7019,
                "profileName": "MAPK3 S219P"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2355,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 S219P demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7019,
                "profileName": "MAPK3 S219P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2356,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 S219P demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7019,
                "profileName": "MAPK3 S219P"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2357,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Y148H demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7020,
                "profileName": "MAPK3 Y148H"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2358,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Y148H demonstrated resistance to Mekinist (trametinib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7020,
                "profileName": "MAPK3 Y148H"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2359,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines expressing MAPK3 Y148H demonstrated resistance to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 25320010).",
            "molecularProfile": {
                "id": 7020,
                "profileName": "MAPK3 Y148H"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2868,
                    "pubMedId": 25320010,
                    "title": "ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25320010"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12030,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, adjuvant Opdivo (nivolumab) treatment resulted in improved rate of recurrence-free survival at 12-months compared to Yervoy (ipilimumab) (70.5% vs 60.8%, HR=0.65, P<0.001) in patients with resected stage III or IV melanoma (PMID: 28891423, NCT02388906).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9984,
                    "pubMedId": 28891423,
                    "title": "Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28891423"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2450,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Yervoy (ipilimumab) resulted in an improved overall survival of 10.1 months in patients with metastatic melanoma, compared to 6.4 months in those treated with gp100 peptide vaccine alone (PMID: 20525992, PMID: 21900389).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3060,
                    "pubMedId": 21900389,
                    "title": "Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21900389"
                },
                {
                    "id": 3061,
                    "pubMedId": 20525992,
                    "title": "Improved survival with ipilimumab in patients with metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20525992"
                },
                {
                    "id": 15570,
                    "pubMedId": null,
                    "title": "Yervoy (ipilimumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2512,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of RAF1 G361A conferred resistance to Zelboraf (vemurafenib) in human melanoma cells harboring BRAF V600E in culture (PMID: 23737487).",
            "molecularProfile": {
                "id": 8790,
                "profileName": "BRAF V600E RAF1 G361A"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3186,
                    "pubMedId": 23737487,
                    "title": "C-RAF mutations confer resistance to RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23737487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2513,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of RAF1 G361A conferred resistance to PLX4720 in human melanoma cells harboring BRAF V600E in culture (PMID: 23737487).",
            "molecularProfile": {
                "id": 8790,
                "profileName": "BRAF V600E RAF1 G361A"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3186,
                    "pubMedId": 23737487,
                    "title": "C-RAF mutations confer resistance to RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23737487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2514,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of RAF1 P261T conferred resistance to Zelboraf (vemurafenib) in human melanoma cells expressing BRAF V600E in culture (PMID: 23737487).",
            "molecularProfile": {
                "id": 8791,
                "profileName": "BRAF V600E RAF1 P261T"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3186,
                    "pubMedId": 23737487,
                    "title": "C-RAF mutations confer resistance to RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23737487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2515,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of RAF1 P261T conferred resistance to PLX4720 in human melanoma cells expressing BRAF V600E in culture (PMID: 23737487).",
            "molecularProfile": {
                "id": 8791,
                "profileName": "BRAF V600E RAF1 P261T"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3186,
                    "pubMedId": 23737487,
                    "title": "C-RAF mutations confer resistance to RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23737487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2516,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of RAF1 S257P conferred resistance to Zelboraf (vemurafenib) in human melanoma cells harboring BRAF V600E in culture (PMID: 23737487).",
            "molecularProfile": {
                "id": 8792,
                "profileName": "BRAF V600E RAF1 S257P"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3186,
                    "pubMedId": 23737487,
                    "title": "C-RAF mutations confer resistance to RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23737487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2517,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of RAF1 S257P conferred resistance to PLX4720 in human melanoma cells harboring BRAF V600E in culture (PMID: 23737487).",
            "molecularProfile": {
                "id": 8792,
                "profileName": "BRAF V600E RAF1 S257P"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3186,
                    "pubMedId": 23737487,
                    "title": "C-RAF mutations confer resistance to RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23737487"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2529,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 blocked survival and growth of vemurafenib/PLX4720-resistant melanoma cells harboring BRAF V600E splice variants in culture (PMID: 24422853).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 195,
                    "pubMedId": 24422853,
                    "title": "Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24422853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2614,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and navitoclax (ABT-263) worked synergistically to inhibit growth and increase apoptosis of BRAF V600E mutant melanoma cells in culture and in xenografts (PMID: 24983357).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2960,
                "therapyName": "Navitoclax + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3334,
                    "pubMedId": 24983357,
                    "title": "Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24983357"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2821,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) inhibited downstream signaling and growth of a human melanoma cell line harboring AGK-BRAF in culture (PMID: 23890088).",
            "molecularProfile": {
                "id": 10262,
                "profileName": "AGK - BRAF"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3413,
                    "pubMedId": 23890088,
                    "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2822,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring AGK-BRAF were resistant to Zelboraf (vemurafenib)-mediated growth inhibition in culture (PMID: 23890088).",
            "molecularProfile": {
                "id": 10262,
                "profileName": "AGK - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3413,
                    "pubMedId": 23890088,
                    "title": "Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23890088"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15099,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring AGK-BRAF showed no response when treated with Zelboraf (vemurafenib), as demonstrated by a lack of decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 10262,
                "profileName": "AGK - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2923,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).",
            "molecularProfile": {
                "id": 10733,
                "profileName": "CDKN2A loss NRAS Q61K"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3528,
                    "pubMedId": 22983396,
                    "title": "Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22983396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2980,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ERBB3 (HER3)-positive melanoma cells were sensitive to Canertinib, resulting in decreased metastasis in mouse models (PMID: 25000258).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 2136,
                "therapyName": "Canertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3548,
                    "pubMedId": 25000258,
                    "title": "ERBB3 is required for metastasis formation of melanoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25000258"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3293,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NMS-P715 inhibited tumor growth in melanoma cell line xenograft models (PMID: 21159646).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3107,
                "therapyName": "NMS-P715",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3716,
                    "pubMedId": 21159646,
                    "title": "Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21159646"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11853,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).",
            "molecularProfile": {
                "id": 1214,
                "profileName": "KIT mutant"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9871,
                    "pubMedId": 28843487,
                    "title": "STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28843487"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3305,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222).",
            "molecularProfile": {
                "id": 1214,
                "profileName": "KIT mutant"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3306,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3307,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3308,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3730,
                    "pubMedId": 17210691,
                    "title": "Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17210691"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3309,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3730,
                    "pubMedId": 17210691,
                    "title": "Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17210691"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3315,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).",
            "molecularProfile": {
                "id": 3375,
                "profileName": "NRAS Q61L"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3728,
                    "pubMedId": 23431193,
                    "title": "Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23431193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3316,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).",
            "molecularProfile": {
                "id": 3375,
                "profileName": "NRAS Q61L"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3728,
                    "pubMedId": 23431193,
                    "title": "Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23431193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3317,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 did not inhibit growth of melanoma cells harboring NRAS Q61L in culture or in cell line xenograft models (PMID: 25500121, PMID: 23431193).",
            "molecularProfile": {
                "id": 3375,
                "profileName": "NRAS Q61L"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3728,
                    "pubMedId": 23431193,
                    "title": "Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23431193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3318,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3319,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3334,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iressa (gefitinib) in combination with PLX4720 inhibited proliferation and tumorigenicity in human melanoma cell line harboring BRAF V600E and resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3131,
                "therapyName": "Gefitinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3755,
                    "pubMedId": 23242808,
                    "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3335,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3755,
                    "pubMedId": 23242808,
                    "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3336,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, saracatinib inhibited proliferation of human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 912,
                "therapyName": "Saracatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3755,
                    "pubMedId": 23242808,
                    "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3341,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, S3I-201 inhibited cell invasion and Stat3 signaling in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3124,
                "therapyName": "S3I-201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3755,
                    "pubMedId": 23242808,
                    "title": "Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23242808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3564,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF V600E treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853).",
            "molecularProfile": {
                "id": 13538,
                "profileName": "BRAF L505H BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3825,
                    "pubMedId": 25515853,
                    "title": "Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25515853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3688,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).",
            "molecularProfile": {
                "id": 14782,
                "profileName": "BRAF mut NRAS mut"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3734,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD-6244) inhibited MEK signaling and growth of melanoma cells harboring activating mutations in GRM3 in culture (PMID: 21946352).",
            "molecularProfile": {
                "id": 15080,
                "profileName": "GRM3 act mut"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4059,
                    "pubMedId": 21946352,
                    "title": "Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21946352"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3783,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-69A11 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3308,
                "therapyName": "BI-69A11",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                },
                {
                    "id": 4139,
                    "pubMedId": 20531415,
                    "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3784,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640756 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3306,
                "therapyName": "SBI-0640756",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                },
                {
                    "id": 4139,
                    "pubMedId": 20531415,
                    "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3785,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640726 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3307,
                "therapyName": "SBI-0640726",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                },
                {
                    "id": 4139,
                    "pubMedId": 20531415,
                    "title": "Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20531415"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3786,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-69A11 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 3308,
                "therapyName": "BI-69A11",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3787,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640756 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 3306,
                "therapyName": "SBI-0640756",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3788,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640726 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 3307,
                "therapyName": "SBI-0640726",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3789,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-755199 induced cell death in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3309,
                "therapyName": "SBI-755199",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3790,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) in combination with SBI-0640756 inhibited the association of eIF4G1 and eIF4E in Zelboraf (vemurafenib) resistant human melanoma cell lines harboring BRAF V600E in culture and reduced tumor growth in xenograft models (PMID: 26603897).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3310,
                "therapyName": "SBI-0640756 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3791,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).",
            "molecularProfile": {
                "id": 10733,
                "profileName": "CDKN2A loss NRAS Q61K"
            },
            "therapy": {
                "id": 3306,
                "therapyName": "SBI-0640756",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3796,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).",
            "molecularProfile": {
                "id": 15931,
                "profileName": "BRAF mut NRAS wild-type"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3797,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).",
            "molecularProfile": {
                "id": 1299,
                "profileName": "BRAF wild-type NRAS mut"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3798,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3994,
                    "pubMedId": 26169970,
                    "title": "Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26169970"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3803,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SBI-0640756 inhibited growth and transformation of human melanomas cells harboring NF1 mutations (PMID: 26603897).",
            "molecularProfile": {
                "id": 1239,
                "profileName": "NF1 mutant"
            },
            "therapy": {
                "id": 3306,
                "therapyName": "SBI-0640756",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4137,
                    "pubMedId": 26603897,
                    "title": "SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603897"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3805,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MS417 inhibited cell proliferation and decreased tumor growth of melanoma cells harboring BRD4 amplification in culture and in xenograft models (PMID: 23950209).",
            "molecularProfile": {
                "id": 16028,
                "profileName": "BRD4 amp"
            },
            "therapy": {
                "id": 3335,
                "therapyName": "MS417",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4172,
                    "pubMedId": 23950209,
                    "title": "BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23950209"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4027,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 treatment inhibited cell growth via suppression of downstream tumor suppressor gene targets and induced apoptosis in melanoma cells harboring EZH2 Y646N in culture (PMID: 26304929).",
            "molecularProfile": {
                "id": 1175,
                "profileName": "EZH2 Y646N"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4379,
                    "pubMedId": 26304929,
                    "title": "Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26304929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4028,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell lines harboring BRAF V600E mutation in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4030,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to Zelboraf (vemurafenib) in melanoma cell lines harboring BRAF V600, resulting in decreased sensitivity to Zelboraf (vemurafenib)-induced inhibition of MAPK pathway activation and cell proliferation in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7037,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4378,
                    "pubMedId": 21383288,
                    "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4031,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4380,
                    "pubMedId": 24448821,
                    "title": "Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24448821"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4079,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and sensitivity was associated with wild-type PTEN (PMID: 23039341).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4086,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In retrospective study of a Phase III trial, melanoma patients harboring KRAS amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater overall survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",
            "molecularProfile": {
                "id": 1413,
                "profileName": "KRAS amp"
            },
            "therapy": {
                "id": 3428,
                "therapyName": "Carboplatin + Paclitaxel + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4403,
                    "pubMedId": 26307133,
                    "title": "Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26307133"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4087,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In retrospective study of a Phase III trial, melanoma patients harboring RAF1 amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater progression free survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",
            "molecularProfile": {
                "id": 17293,
                "profileName": "RAF1 amp"
            },
            "therapy": {
                "id": 3428,
                "therapyName": "Carboplatin + Paclitaxel + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4403,
                    "pubMedId": 26307133,
                    "title": "Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26307133"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4088,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In retrospective study of a Phase III trial, melanoma patients harboring CCND1 amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater progression free survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",
            "molecularProfile": {
                "id": 1420,
                "profileName": "CCND1 amp"
            },
            "therapy": {
                "id": 3428,
                "therapyName": "Carboplatin + Paclitaxel + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4403,
                    "pubMedId": 26307133,
                    "title": "Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26307133"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4360,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",
            "molecularProfile": {
                "id": 17823,
                "profileName": "RB1 wild-type TP53 wild-type"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4449,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Keytruda (pembrolizumab), compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196).",
            "molecularProfile": {
                "id": 13314,
                "profileName": "PTEN dec exp"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4450,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, melanoma patients with PTEN expression in less than 10% of tumor cells demonstrated decreased response to anti-PD-1 antibodies, including Opdivo (nivolumab), as compared to patients in which PTEN is present in over 10% of tumor cells (PMID: 26645196).",
            "molecularProfile": {
                "id": 13314,
                "profileName": "PTEN dec exp"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4451,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196).",
            "molecularProfile": {
                "id": 18161,
                "profileName": "PTEN positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4452,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Opdivo (nivolumab) (PMID: 26645196).",
            "molecularProfile": {
                "id": 18161,
                "profileName": "PTEN positive"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4453,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells with PTEN loss were sensitive to GSK2636771, resulting in decreased activation of Akt and some inhibition of tumor growth (PMID: 26645196).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4455,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 3518,
                "therapyName": "GSK2636771 + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4456,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 765,
                "therapyName": "GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4457,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4507,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YAP1 knockdown enhanced sensitivity of human melanoma cells harboring BRAF V600E to Zelboraf (vemurafenib) inhibition in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 18268,
                "profileName": "BRAF V600E YAP1 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4508,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 blocked tumor growth of human melanoma cells harboring BRAF V600E with targeted knockdown of YAP1 in xenografts (PMID: 25665005).",
            "molecularProfile": {
                "id": 18268,
                "profileName": "BRAF V600E YAP1 dec exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4509,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, targeted knockdown of YAP1 enhanced sensitivity of human melanoma cell lines harboring BRAF V600E to Mekinist (trametinib) in culture and in human cell line xenograft models (PMID: 25665005).",
            "molecularProfile": {
                "id": 18268,
                "profileName": "BRAF V600E YAP1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4518,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YAP1 knockdown enhanced sensitivity of human melanoma cell lines harboring NRAS Q61R to Mekinist (trametinib) in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 18274,
                "profileName": "NRAS Q61R YAP1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4519,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YAP1 knockdown enhanced sensitivity of human melanoma cell lines harboring NRAS Q61L to Mekinist (trametinib) inhibition in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 18275,
                "profileName": "NRAS Q61L YAP1 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4526,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3530,
                "therapyName": "Navitoclax + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4529,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1386,
                "therapyName": "Navitoclax + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4530,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3532,
                "therapyName": "Trametinib + TW-37",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4533,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3531,
                "therapyName": "TW-37 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4582,
                    "pubMedId": 25665005,
                    "title": "The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25665005"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4763,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tubastatin A inhibited proliferation of NRAS mutant melanoma cell lines in culture (PMID: 25957812).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 3635,
                "therapyName": "Tubastatin A",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4713,
                    "pubMedId": 25957812,
                    "title": "Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25957812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4764,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tubastatin A inhibited proliferation of BRAF mutant melanoma cell lines in culture (PMID: 25957812).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3635,
                "therapyName": "Tubastatin A",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4713,
                    "pubMedId": 25957812,
                    "title": "Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25957812"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4782,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AT13148 inhibited human melanoma cell motility in invasion assays in culture (PMID: 25840982).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3653,
                "therapyName": "AT13148",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4738,
                    "pubMedId": 25840982,
                    "title": "Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25840982"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4783,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT129254 inhibited motility of two human melanoma cell lines in invasion assays in culture and inhibited metastasis in a mouse melanoma cell line xenograft model (PMID: 25840982).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3654,
                "therapyName": "CCT129254",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4738,
                    "pubMedId": 25840982,
                    "title": "Rho kinase inhibitors block melanoma cell migration and inhibit metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25840982"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4800,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BX-320 treatment resulted in decreased tumor growth when administered to mouse models injected with melanoma cells (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3656,
                "therapyName": "BX-320",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4953,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and Cediranib (AZD-2171) worked synergistically to inhibit cell growth and induce apoptosis in PLX4720-resistant human melanoma cell lines harboring BRAF V600E in culture and to suppress tumor growth in xenograft models (PMID: 26461489).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3698,
                "therapyName": "Cediranib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4807,
                    "pubMedId": 26461489,
                    "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4954,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1061,
                "therapyName": "PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4807,
                    "pubMedId": 26461489,
                    "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4955,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720, Cediranib (AZD-2171) and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3699,
                "therapyName": "Cediranib + PLX4720 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4807,
                    "pubMedId": 26461489,
                    "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4956,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3700,
                "therapyName": "PLX4720 + Tivozanib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4807,
                    "pubMedId": 26461489,
                    "title": "Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26461489"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4960,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 inhibited tumor growth in xenograft models of melanoma cell lines harboring PTEN deficiency (PMID: 24387221).",
            "molecularProfile": {
                "id": 13314,
                "profileName": "PTEN dec exp"
            },
            "therapy": {
                "id": 1052,
                "therapyName": "SAR260301",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4811,
                    "pubMedId": 24387221,
                    "title": "Discovery and optimization of pyrimidone indoline amide PI3K\u03b2 inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24387221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4981,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, xenograft models of melanoma harboring BRAF V600E treated with the combination of BI 882370 and Mekinist (trametinib) demonstrated tumor regression with no regrowth during the 5 weeks of treatment (PMID: 26916115).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3709,
                "therapyName": "BI 882370 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4823,
                    "pubMedId": 26916115,
                    "title": "A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26916115"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5184,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5185,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 3774,
                "therapyName": "BEZ235 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5186,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 3772,
                "therapyName": "Vemurafenib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5187,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 3771,
                "therapyName": "Selumetinib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5188,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5190,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 617,
                "therapyName": "A66",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5191,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5192,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",
            "molecularProfile": {
                "id": 20300,
                "profileName": "BRAF V600E/K PIK3CA wild-type"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4903,
                    "pubMedId": 26137449,
                    "title": "Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26137449"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5269,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human melanoma cell line harboring NRAS Q61K with PLK1 over expression was sensitive to the combination of Mekinist (trametinib) and Volasertib, which produced a synergistic effect in cell line xenograft models, resulting in decreased cell viability and tumor regression (PMID: 26016894).",
            "molecularProfile": {
                "id": 20451,
                "profileName": "NRAS Q61K PLK1 over exp"
            },
            "therapy": {
                "id": 3805,
                "therapyName": "Trametinib + Volasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4976,
                    "pubMedId": 26016894,
                    "title": "Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26016894"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5270,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human melanoma cell line harboring NRAS G12D with PLK1 over expression was sensitive to the combination of Mekinist (trametinib) and Volasertib, which produced a synergistic effect in xenograft models, resulting in decreased cell viability and tumor regression (PMID: 26016894).",
            "molecularProfile": {
                "id": 20450,
                "profileName": "NRAS G12D PLK1 over exp"
            },
            "therapy": {
                "id": 3805,
                "therapyName": "Trametinib + Volasertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4976,
                    "pubMedId": 26016894,
                    "title": "Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26016894"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5317,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sirtinol inhibited growth of human melanoma cell lines in culture (PMID: 25486469).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3830,
                "therapyName": "Sirtinol",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5015,
                    "pubMedId": 25486469,
                    "title": "Sirtuin deacetylases: a new target for melanoma management.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25486469"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5318,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ex-527 inhibited growth of human melanoma cell lines in culture (PMID: 25486469).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3831,
                "therapyName": "Ex-527",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5015,
                    "pubMedId": 25486469,
                    "title": "Sirtuin deacetylases: a new target for melanoma management.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25486469"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5323,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dalantercept (ACE-041) in combination with Adria (doxorubicin) resulted in decreased tumor growth in cell line xenograft models of melanoma, with increased efficacy over either agent alone (PMID: 26373572).",
            "molecularProfile": {
                "id": 391,
                "profileName": "ALK wild-type"
            },
            "therapy": {
                "id": 3837,
                "therapyName": "Dalantercept + Doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5020,
                    "pubMedId": 26373572,
                    "title": "Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26373572"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613).",
            "molecularProfile": {
                "id": 641,
                "profileName": "KDR Q472H"
            },
            "therapy": {
                "id": 3842,
                "therapyName": "unspecified VEGFR2 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4818,
                    "pubMedId": 26631613,
                    "title": "Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26631613"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5454,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLLL32 inhibited Stat3 signaling and induced apoptosis in melanoma cell lines in culture (PMID: 20576164).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3862,
                "therapyName": "FLLL32",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5067,
                    "pubMedId": 20576164,
                    "title": "The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20576164"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5564,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5613,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641H in culture (PMID: 26936398).",
            "molecularProfile": {
                "id": 674,
                "profileName": "EZH2 Y641H"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5127,
                    "pubMedId": 26936398,
                    "title": "Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5614,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641N in culture (PMID: 26936398).",
            "molecularProfile": {
                "id": 672,
                "profileName": "EZH2 Y641N"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5127,
                    "pubMedId": 26936398,
                    "title": "Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5616,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 inhibited H3K27 trimethylation in human melanoma cells harboring wild-type EZH2 in culture (PMID: 26936398).",
            "molecularProfile": {
                "id": 535,
                "profileName": "EZH2 wild-type"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5127,
                    "pubMedId": 26936398,
                    "title": "Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK126 reversed transcriptional silencing in human melanoma cells harboring wild-type EZH2 Y641S in culture (PMID: 26936398).",
            "molecularProfile": {
                "id": 673,
                "profileName": "EZH2 Y641S"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5127,
                    "pubMedId": 26936398,
                    "title": "Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26936398"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5624,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with BRAF mutations (PMID: 23039341).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5625,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type NRAS (PMID: 23039341).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5626,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type HRAS (PMID: 23039341).",
            "molecularProfile": {
                "id": 575,
                "profileName": "HRAS wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5627,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 and LY294002 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations in culture, regardless of PTEN mutation status (PMID: 23039341).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 3911,
                "therapyName": "E6201 + LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5628,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).",
            "molecularProfile": {
                "id": 21306,
                "profileName": "BRAF mut PTEN mut"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5629,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1840,
                    "pubMedId": 23039341,
                    "title": "Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23039341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5661,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a Spitzoid melanoma harboring ZKSCAN1-BRAF displayed a clinical response within 14 days to treatment with Mekinist (trametinib) (PMID: 26314551).",
            "molecularProfile": {
                "id": 21340,
                "profileName": "ZKSCAN1 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5129,
                    "pubMedId": 26314551,
                    "title": "The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26314551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5776,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8547,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line xenograft model harboring BRAF V600E treated with PD-0325901 demonstrated stable tumor growth, but by day 44, growth ensued and thus, demonstrated no benefit (PMID: 27488531).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5778,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5784,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study CI-1040 (PD-184352) inhibited melanoma progression in a transgenic zebrafish model of melanoma expressing HRAS G12V (PMID: 26267534).",
            "molecularProfile": {
                "id": 2794,
                "profileName": "HRAS G12V"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5785,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21619,
                "profileName": "BRAF V600E NRAS G12V"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21619,
                "profileName": "BRAF V600E NRAS G12V"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5811,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21628,
                "profileName": "BRAF V600E MAP2K1 I103N"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5812,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5816,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21628,
                "profileName": "BRAF V600E MAP2K1 I103N"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5817,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5820,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5821,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5891,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Voruciclib (P1446A-05) and Zelboraf (vemurafenib) combination therapy demonstrated safety and preliminary efficacy, resulted in complete response in 33% (1/3) and partial response in 67% (2/3) of BRAFi-na\u00efve melanoma patients harboring BRAF mutations (J Clin Oncol 33, 2015 (suppl; abstr 9076)).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1238,
                "therapyName": "Vemurafenib + Voruciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5185,
                    "pubMedId": null,
                    "title": "Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma.",
                    "url": "http://meetinglibrary.asco.org/content/153239-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5949,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5950,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS A146T"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5951,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5952,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5953,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5954,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5955,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5956,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS A146T"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5957,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5958,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5959,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5960,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS A146T"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5961,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5962,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5963,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5964,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5965,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5966,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS A146T"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5967,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5968,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5969,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5970,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5971,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5972,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5973,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5974,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5975,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5976,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5977,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5978,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 6906,
                "profileName": "BRAF V600E NRAS Q61K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5979,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22097,
                "profileName": "BRAF V600E NRAS Q61K NRAS A146T"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5980,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5981,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5982,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Talfinlar (dabrafenib) and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5983,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5984,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22045,
                "profileName": "BRAF V600E MAP2K1 K59del"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5985,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5986,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5987,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12837,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10781,
                    "pubMedId": 25399551,
                    "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25399551"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10549,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, BRAF V600E positive melanoma patients who progressed on treatment with BRAF inhibitors or the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) were treated again with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) after 12 weeks off treatment, which resulted in a partial response in 35% (8/25) and stable disease in 40% (10/25) (PMID: 28268064).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8631,
                    "pubMedId": 28268064,
                    "title": "Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28268064"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5988,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5989,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS A146T"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5990,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5991,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22042,
                "profileName": "BRAF V600E NRAS A146T"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5992,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22037,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS A146T"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5993,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22043,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5994,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22046,
                "profileName": "BRAF V600E MAP2K1 P387S NRAS Q61K NRAS A146T"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5995,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 3027,
                "therapyName": "GSK2126458 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5996,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",
            "molecularProfile": {
                "id": 22095,
                "profileName": "BRAF V600K NRAS Q61K"
            },
            "therapy": {
                "id": 4004,
                "therapyName": "Dabrafenib + GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2092,
                    "pubMedId": 22389471,
                    "title": "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22389471"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6075,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).",
            "molecularProfile": {
                "id": 22385,
                "profileName": "BRAF V600E CSF1R pos"
            },
            "therapy": {
                "id": 1339,
                "therapyName": "Pexidartinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5274,
                    "pubMedId": 25939769,
                    "title": "Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25939769"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 659,
                "therapyName": "AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 2514,
                "therapyName": "TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6099,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6100,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6101,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 3714,
                "therapyName": "Alpelisib + AZD6482",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6102,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4042,
                "therapyName": "Alpelisib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6103,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4044,
                "therapyName": "AZD6482 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6104,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4045,
                "therapyName": "GSK2636771 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6105,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4046,
                "therapyName": "NVP-AEW541 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6106,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4047,
                "therapyName": "Alpelisib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6107,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4044,
                "therapyName": "AZD6482 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4045,
                "therapyName": "GSK2636771 + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6109,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4056,
                "therapyName": "Encorafenib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6110,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4048,
                "therapyName": "AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6111,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4055,
                "therapyName": "Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6113,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4049,
                "therapyName": "Alpelisib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6115,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4053,
                "therapyName": "Binimetinib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6117,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4054,
                "therapyName": "AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6118,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4052,
                "therapyName": "Binimetinib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6119,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6121,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4054,
                "therapyName": "AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6122,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4052,
                "therapyName": "Binimetinib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6123,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4048,
                "therapyName": "AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6124,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 21308,
                "profileName": "BRAF mut PTEN wild-type"
            },
            "therapy": {
                "id": 4055,
                "therapyName": "Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6125,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4062,
                "therapyName": "Alpelisib + AZD6482 + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6126,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4061,
                "therapyName": "AZD6482 + Encorafenib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6127,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4059,
                "therapyName": "Alpelisib + AZD6482 + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6128,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4060,
                "therapyName": "AZD6482 + Binimetinib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6130,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4064,
                "therapyName": "AZD6482 + Binimetinib + Encorafenib + NVP-AEW541",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6131,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4063,
                "therapyName": "Alpelisib + AZD6482 + Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6133,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4065,
                "therapyName": "Alpelisib + Encorafenib + GSK2636771",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6136,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4067,
                "therapyName": "GSK2636771 + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6137,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4068,
                "therapyName": "Encorafenib + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6138,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",
            "molecularProfile": {
                "id": 22705,
                "profileName": "BRAF mut PTEN inact mut"
            },
            "therapy": {
                "id": 4069,
                "therapyName": "Encorafenib + GSK2636771 + unspecified IGF-1R antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5314,
                    "pubMedId": 26577700,
                    "title": "Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26577700"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6303,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited migration and growth of mouse melanoma cells with MET over expression in culture (PMID: 25637314).",
            "molecularProfile": {
                "id": 5392,
                "profileName": "MET over exp"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6318,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6320,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).",
            "molecularProfile": {
                "id": 23100,
                "profileName": "BRAF V600D PTEN loss"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12031,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CheckMate 238) that supported FDA approval, adjuvant Opdivo (nivolumab) treatment resulted in improved rate of recurrence-free survival at 12-month compared to Yervoy (ipilimumab) (70.5% vs 60.8%, HR=0.65, P<0.001) in patients with resected stage III or IV melanoma (PMID: 28891423, NCT02388906).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9984,
                    "pubMedId": 28891423,
                    "title": "Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28891423"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11500,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In an analysis of two Phase III trial, Opdivo (nivolumab) treatment after disease progression demonstrated safety and clinical benefit, with 76% (65/85) of patients still alive at time of analysis in melanoma patients who received the last dose of Opdivo (nivolumab) more than 6 weeks after progression (PMID: 28662232).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9562,
                    "pubMedId": 28662232,
                    "title": "Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28662232"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6431,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CheckMate 037) that supported FDA approval, 31.7% (38/120) of patients with advanced melanoma treated with Opdivo (nivolumab) experienced an objective response whereas only 10.6% (5/47) of advanced melanoma patients treated with investigator's choice of therapy demonstrated an objective response (PMID: 25795410; NCT01721746).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5592,
                    "pubMedId": 25795410,
                    "title": "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25795410"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15158,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Opdivo (nivolumab) monotherapy resulted an overall response rate (ORR) of 25% (3/12) and pathologic complete response rate (pCR) of 25% (3/12) in patients with stage III or IV melanoma, compared to a ORR of 73% (8/11) and pCR of 45% (5/11) with the combination of Opdivo (nivolumab) and Yervoy (ipilimumab), but demonstrated lower toxicity than the combination therapy (PMID: 30297909; NCT02519322).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12751,
                    "pubMedId": 30297909,
                    "title": "Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30297909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6438,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited proliferation and ERBB3 (HER3)-AKT signaling in a human melanoma cell line with autocrine ERBB3 (HER3) signaling in culture (PMID: 26880266).",
            "molecularProfile": {
                "id": 10756,
                "profileName": "ERBB3 positive"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6494,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) treatment resulted in senescence in melanoma cell lines harboring BRAF V600E and CDK4 R24C in culture (PMID: 26988987).",
            "molecularProfile": {
                "id": 23598,
                "profileName": "BRAF V600E CDK4 R24C"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5666,
                    "pubMedId": 26988987,
                    "title": "Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26988987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6495,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) treatment resulted in apoptosis in melanoma cell lines harboring BRAF V600E and CDK4 R24C in culture (PMID: 26988987).",
            "molecularProfile": {
                "id": 1853,
                "profileName": "CDK4 R24C"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5666,
                    "pubMedId": 26988987,
                    "title": "Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26988987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6497,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Ibrance (palbociclib) and Zelboraf (vemurafenib) treatment resulted in reduced cytotoxicity of Zelboraf (vemurafenib) in melanoma cell lines harboring BRAF V600E and CDK4 R24C in culture (PMID: 26988987).",
            "molecularProfile": {
                "id": 23598,
                "profileName": "BRAF V600E CDK4 R24C"
            },
            "therapy": {
                "id": 4129,
                "therapyName": "Palbociclib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5666,
                    "pubMedId": 26988987,
                    "title": "Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26988987"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6502,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) treatment resulted in cell cycle arrest in Zelboraf (vemurafenib)-resistant melanoma cell lines harboring BRAF V600E and wild-type CDK4, CDK6 in culture, and stable disease in cell line xenograft models (PMID: 26988987).",
            "molecularProfile": {
                "id": 23599,
                "profileName": "BRAF V600E CDK4 wild-type CDK6 wild-type"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5666,
                    "pubMedId": 26988987,
                    "title": "Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26988987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6503,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Rapamune (sirolimus) synergistically inhibited colony formation in melanoma cell lines harboring BRAF V600E and CDK4 R24C in culture (PMID: 26988987).",
            "molecularProfile": {
                "id": 23598,
                "profileName": "BRAF V600E CDK4 R24C"
            },
            "therapy": {
                "id": 4130,
                "therapyName": "Palbociclib + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5666,
                    "pubMedId": 26988987,
                    "title": "Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26988987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6504,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) and Rapamune (sirolimus) synergistically inhibited colony formation in Zelboraf (vemurafenib)-resistant melanoma cell lines harboring BRAF V600E and wild-type CDK4,CDK6 in culture (PMID: 26988987).",
            "molecularProfile": {
                "id": 23599,
                "profileName": "BRAF V600E CDK4 wild-type CDK6 wild-type"
            },
            "therapy": {
                "id": 4130,
                "therapyName": "Palbociclib + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5666,
                    "pubMedId": 26988987,
                    "title": "Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26988987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6537,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of E7449 and Temodar (temozolomide) inhibited tumor growth in mouse melanoma models, with increased efficacy compared to either agent alone (PMID: 26513298).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4142,
                "therapyName": "E7449 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4121,
                    "pubMedId": 26513298,
                    "title": "E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26513298"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth, downstream MAPK signaling and soft agar growth in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6591,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61K in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 646,
                "profileName": "NRAS Q61K"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6592,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23638,
                "profileName": "BRAF G469R NRAS Q61K"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6593,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS G13D in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3361,
                "profileName": "NRAS G13D"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6594,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61L in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3375,
                "profileName": "NRAS Q61L"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6595,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring TP53 D259Y in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23639,
                "profileName": "TP53 D259Y"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6596,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring MAP3K9 T598M in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 14622,
                "profileName": "MAP3K9 T598M"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6601,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cell lines harboring NRAS Q61K in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 646,
                "profileName": "NRAS Q61K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6602,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring NRAS G13D in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3361,
                "profileName": "NRAS G13D"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6603,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23638,
                "profileName": "BRAF G469R NRAS Q61K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6604,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring NRAS Q61L in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3375,
                "profileName": "NRAS Q61L"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6606,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring MAP3K9 T598M in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 14622,
                "profileName": "MAP3K9 T598M"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6607,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring TP53 D259Y in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23639,
                "profileName": "TP53 D259Y"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6608,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of human melanoma cells TP53 D259Y in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23639,
                "profileName": "TP53 D259Y"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6609,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring NRAS Q61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 646,
                "profileName": "NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6610,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring NRAS G13D were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3361,
                "profileName": "NRAS G13D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6611,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring NRAS Q61L were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3375,
                "profileName": "NRAS Q61L"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6612,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23638,
                "profileName": "BRAF G469R NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6613,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cells harboring MAP3K9 T598M were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 14622,
                "profileName": "MAP3K9 T598M"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6615,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring a mutation in NRAS were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6616,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth of NRAS mutant human melanoma cell lines in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6673,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DETD-35 inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4230,
                "therapyName": "DETD-35",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5730,
                    "pubMedId": 27048951,
                    "title": "A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048951"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6674,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4232,
                "therapyName": "DETD-35 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5730,
                    "pubMedId": 27048951,
                    "title": "A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048951"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6675,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DETD-35 treatment resulted in reduced tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss (PMID: 27048951).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 4230,
                "therapyName": "DETD-35",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5730,
                    "pubMedId": 27048951,
                    "title": "A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048951"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6676,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DETD-35 and Zelboraf (vemurafenib) combination treatment resulted in further reduction of tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss when compared to single agent treatment (PMID: 27048951).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 4232,
                "therapyName": "DETD-35 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5730,
                    "pubMedId": 27048951,
                    "title": "A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048951"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6720,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a clinical analysis, NF1 mutations are associated with higher mutational load and better response rate to anti-programmed death-1/ligand treatments in melanoma patients (J Clin Oncol 34, 2016 (suppl; abstr 105)).",
            "molecularProfile": {
                "id": 1239,
                "profileName": "NF1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5782,
                    "pubMedId": null,
                    "title": "Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1.",
                    "url": "http://abstracts.asco.org/176/AbstView_176_163406.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6824,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 23745,
                "profileName": "MAP2K1 V60E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6825,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 23745,
                "profileName": "MAP2K1 V60E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6895,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).",
            "molecularProfile": {
                "id": 23996,
                "profileName": "BRAF V600E MAP2K1 H119P"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7002,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24281,
                "profileName": "BRAF V600E MAP2K1 V60E"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7003,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7004,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24282,
                "profileName": "BRAF V600E MAP2K1 P124S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7005,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24283,
                "profileName": "BRAF V600E MAP2K1 G128V"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7006,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 C125S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24308,
                "profileName": "BRAF V600E MAP2K2 C125S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7007,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 L46F demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24311,
                "profileName": "BRAF V600E MAP2K2 L46F"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7008,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 N126D demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24309,
                "profileName": "BRAF V600E MAP2K2 N126D"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7009,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 V35M demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24313,
                "profileName": "BRAF V600E MAP2K2 V35M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7010,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and over expressing MITF demonstrated resistance to treatment with PLX4720 (PMID: 24265153).",
            "molecularProfile": {
                "id": 24318,
                "profileName": "BRAF V600E MITF over exp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7014,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-11e inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 Q60P in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24360,
                "profileName": "BRAF V600E MAP2K2 Q60P"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7017,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K2 Q60P conferred resistance to Tafinlar (dabrafenib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24360,
                "profileName": "BRAF V600E MAP2K2 Q60P"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7019,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K2 Q60P conferred resistance to Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24360,
                "profileName": "BRAF V600E MAP2K2 Q60P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7020,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K2 Q60P conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24360,
                "profileName": "BRAF V600E MAP2K2 Q60P"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7025,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24366,
                "profileName": "BRAF V600E MAP2K1 P162S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7027,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24366,
                "profileName": "BRAF V600E MAP2K1 P162S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7030,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of BRAF V600E-mutant melanoma cells expressing MAP2K2 P162S in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24366,
                "profileName": "BRAF V600E MAP2K1 P162S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7031,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K2 C125S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24308,
                "profileName": "BRAF V600E MAP2K2 C125S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7032,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7033,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",
            "molecularProfile": {
                "id": 24283,
                "profileName": "BRAF V600E MAP2K1 G128V"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6036,
                    "pubMedId": 24265154,
                    "title": "MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7035,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).",
            "molecularProfile": {
                "id": 24282,
                "profileName": "BRAF V600E MAP2K1 P124S"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 429,
                    "pubMedId": 22197931,
                    "title": "Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22197931"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7036,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF K601E and MAP2K2 E207K demonstrated decreased sensitivity to Selumetinib (AZD6244) in culture (PMID: 22197931).",
            "molecularProfile": {
                "id": 24367,
                "profileName": "BRAF K601E MAP2K2 E207K"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 429,
                    "pubMedId": 22197931,
                    "title": "Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22197931"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7038,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4378,
                    "pubMedId": 21383288,
                    "title": "Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21383288"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7050,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 V35M demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24313,
                "profileName": "BRAF V600E MAP2K2 V35M"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7051,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 L46F demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24311,
                "profileName": "BRAF V600E MAP2K2 L46F"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7052,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 N126D demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24309,
                "profileName": "BRAF V600E MAP2K2 N126D"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7053,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 V35M demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24313,
                "profileName": "BRAF V600E MAP2K2 V35M"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7054,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 L46F demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24311,
                "profileName": "BRAF V600E MAP2K2 L46F"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7055,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 N126D demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24309,
                "profileName": "BRAF V600E MAP2K2 N126D"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7056,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24281,
                "profileName": "BRAF V600E MAP2K1 V60E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7057,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24282,
                "profileName": "BRAF V600E MAP2K1 P124S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7058,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24283,
                "profileName": "BRAF V600E MAP2K1 G128V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24283,
                "profileName": "BRAF V600E MAP2K1 G128V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7061,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24282,
                "profileName": "BRAF V600E MAP2K1 P124S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7068,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistance-associated mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24385,
                "profileName": "BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7070,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24387,
                "profileName": "BRAF V600X BRAF amp NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7072,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation treated with a RAF inhibitor developed resistance-associated mutations, BRAF amplification and MAP2K2 L46F (PMID: 24265153).",
            "molecularProfile": {
                "id": 24388,
                "profileName": "BRAF V600X BRAF amp MAP2K2 L46F"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7074,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation treated with a RAF inhibitor developed resistance-associated mutations, BRAF amplification and MAP2K2 L46F (PMID: 24265153).",
            "molecularProfile": {
                "id": 24388,
                "profileName": "BRAF V600X BRAF amp MAP2K2 L46F"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7079,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and over expressing MITF demonstrated resistance to treatment with Selumetinib (AZD6244) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24318,
                "profileName": "BRAF V600E MITF over exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7080,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and over expressing MITF demonstrated resistance to treatment with VRT11E (PMID: 24265153).",
            "molecularProfile": {
                "id": 24318,
                "profileName": "BRAF V600E MITF over exp"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7081,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 4358,
                "therapyName": "Pictilisib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7082,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance-associated mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24398,
                "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7083,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).",
            "molecularProfile": {
                "id": 24401,
                "profileName": "BRAF V600X PTEN H93D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7193,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-006) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic melanoma, with a 6-month PFS rate of 47.3% for the every 2 week schedule and 46.4% for the every 3 week schedule versus 26.5% with Yervoy (ipilimumab) (PMID: 25891173; NCT01866319).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6181,
                    "pubMedId": 25891173,
                    "title": "Pembrolizumab versus Ipilimumab in Advanced Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25891173"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15939,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (KEYNOTE-002) that supported FDA approval, treatment with Keytruda (pembrolizumab) resulted in improved progression-free survival (PFS) compared to chemotherapy in patients with Yervoy (ipilimumab)-refractory melanoma, with a HR of 0.57 (p<0.0001) in the 2mg/kg group and a HR of 0.50 (p<0.0001) in the 10mg/kg group (PMID: 26115796; NCT01704287).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14047,
                    "pubMedId": 26115796,
                    "title": "Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26115796"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16065,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (KEYNOTE-054) that supported FDA approval, Keytruda (pembrolizumab) treatment resulted in significantly improved recurrence-free survival rate at 1 year (75.4% vs 61.0%, HR=0.57, p<0.001) compared to placebo in patients with resected, high-risk stage III melanoma (PMID: 29658430; NCT02362594).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14173,
                    "pubMedId": 29658430,
                    "title": "Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29658430"
                },
                {
                    "id": 15508,
                    "pubMedId": null,
                    "title": "Keytruda (pembrolizumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7201,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells overexpressing Abl1 and Abl2 demonstrated sensitivity to Tasigna (nilotinib) in vitro and in mouse models, resulting in decreased Abl2 activity and inhibition of metastasis (PMID: 21892207).",
            "molecularProfile": {
                "id": 24779,
                "profileName": "ABL1 over exp ABL2 over exp"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6201,
                    "pubMedId": 21892207,
                    "title": "c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21892207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8056,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in melanoma cell lines harboring BRAF V600E in culture (PMID: 26208524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5280,
                    "pubMedId": 26208524,
                    "title": "BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26208524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7229,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, BGB-283 resulted in partial response in 1 of 2 melanoma patients harboring BRAF V600E, who remained on treatment for over 249 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4025,
                "therapyName": "BGB-283",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6230,
                    "pubMedId": null,
                    "title": "Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=dc4584a4-d39b-485a-9579-be210c4876e9&cKey=46a0776a-1444-49d6-b533-4f68e298c39d&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7254,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited growth and induced apoptosis in melanoma cells harboring ERBB4 E317K in culture (PMID: 19718025).",
            "molecularProfile": {
                "id": 24619,
                "profileName": "ERBB4 E317K"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 566,
                    "pubMedId": 19718025,
                    "title": "Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19718025"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7256,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited growth and induced apoptosis in melanoma cells harboring ERBB4 E452K in culture (PMID: 19718025).",
            "molecularProfile": {
                "id": 24620,
                "profileName": "ERBB4 E452K"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 566,
                    "pubMedId": 19718025,
                    "title": "Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19718025"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7257,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) induced apoptosis in melanoma cells harboring ERBB4 R544W in culture (PMID: 19718025).",
            "molecularProfile": {
                "id": 24624,
                "profileName": "ERBB4 R544W"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 566,
                    "pubMedId": 19718025,
                    "title": "Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19718025"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7258,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E563K in culture (PMID: 19718025).",
            "molecularProfile": {
                "id": 24621,
                "profileName": "ERBB4 E563K"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 566,
                    "pubMedId": 19718025,
                    "title": "Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19718025"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7259,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited survival of melanoma cells harboring ERBB4 R393W in culture (PMID: 19718025).",
            "molecularProfile": {
                "id": 24809,
                "profileName": "ERBB4 R393W"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 566,
                    "pubMedId": 19718025,
                    "title": "Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19718025"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7393,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with KDM5A over expression treated with Zelboraf (vemurafenib) demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401).",
            "molecularProfile": {
                "id": 2711,
                "profileName": "KDM5A over exp"
            },
            "therapy": {
                "id": 4486,
                "therapyName": "CPI-455 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6341,
                    "pubMedId": 27214401,
                    "title": "An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7394,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with KDM5A over expression treated with AZ628 demonstrated increased sensitivity when co-treated with CPI-455 in culture, resulting in decreased survival of cells, in particular the cells that eventually develop drug resistance (PMID: 27214401).",
            "molecularProfile": {
                "id": 2711,
                "profileName": "KDM5A over exp"
            },
            "therapy": {
                "id": 4487,
                "therapyName": "AZ628 + CPI-455",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6341,
                    "pubMedId": 27214401,
                    "title": "An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27214401"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7458,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Abemaciclib (LY2835219) in melanoma patients resulted in a disease control rate of 27% (7/26), a partial response in one patient and six patients with stable disease (PMID: 27217383).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 802,
                "therapyName": "Abemaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6356,
                    "pubMedId": 27217383,
                    "title": "Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217383"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7475,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 419 days developed disease progression likely due to the secondary resistance mutation, JAK1 Q503* (PMID: 27433843).",
            "molecularProfile": {
                "id": 25519,
                "profileName": "JAK1 Q503*"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6365,
                    "pubMedId": 27433843,
                    "title": "Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27433843"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7476,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon, leading to a loss of protein expression (PMID: 27433843).",
            "molecularProfile": {
                "id": 25521,
                "profileName": "JAK2 inact mut"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6365,
                    "pubMedId": 27433843,
                    "title": "Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27433843"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7477,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 453 days, developed disease progression likely due to the secondary resistance mutation, B2M S14fs (PMID: 27433843).",
            "molecularProfile": {
                "id": 25524,
                "profileName": "B2M S14fs"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6365,
                    "pubMedId": 27433843,
                    "title": "Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27433843"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7515,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHP099 did not inhibit proliferation or ERK activation in a melanoma cell line harboring BRAF V600E in culture (PMID: 27362227).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4504,
                "therapyName": "SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6394,
                    "pubMedId": 27362227,
                    "title": "Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27362227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25914,
                "profileName": "BRAF V600E MAP2K1 K57E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7593,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25915,
                "profileName": "BRAF V600E MAP2K1 P124Q"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7599,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25916,
                "profileName": "BRAF V600K MAP2K1 P124L"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7600,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25916,
                "profileName": "BRAF V600K MAP2K1 P124L"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7601,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 2804,
                "therapyName": "VX-11e",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7602,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25913,
                "profileName": "BRAF V600K MAP2K1 P124Q"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7603,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",
            "molecularProfile": {
                "id": 25916,
                "profileName": "BRAF V600K MAP2K1 P124L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6439,
                    "pubMedId": 25370473,
                    "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25370473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7606,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, Yervoy (ipilimumab) in combination with local tumor treatment consisting of radiotherapy or electrochemotherapy resulted in improved median overall survival (93 weeks) compared to Yervoy (ipilimumab) alone (42 weeks) in advanced melanoma patients (PMID: 27466265).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4523,
                "therapyName": "Ipilimumab + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6441,
                    "pubMedId": 27466265,
                    "title": "Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27466265"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7729,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAH-p53-8 in combination with Zelboraf (vemurafenib) resulted in enhanced growth inhibition of TP53 wild-type melanoma cells over expressing MDM4 in culture (PMID: 22820643).",
            "molecularProfile": {
                "id": 2644,
                "profileName": "MDM4 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4554,
                "therapyName": "SAH-p53-8 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1453,
                    "pubMedId": 22820643,
                    "title": "MDM4 is a key therapeutic target in cutaneous melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22820643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7765,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a melanoma patient harboring KIT L576P demonstrated sensitivity to the combination treatment of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in a partial response for 8 months (PMID: 25363205).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 4517,
                "therapyName": "Bevacizumab + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6478,
                    "pubMedId": 25363205,
                    "title": "Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25363205"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7771,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1052,
                "therapyName": "SAR260301",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7773,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 1225,
                "therapyName": "SAR260301 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7774,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",
            "molecularProfile": {
                "id": 18163,
                "profileName": "BRAF mut PTEN loss"
            },
            "therapy": {
                "id": 4573,
                "therapyName": "SAR260301 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6491,
                    "pubMedId": 27196754,
                    "title": "Concomitant Inhibition of PI3K\u03b2 and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K\u03b2-Selective Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7789,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Cediranib (AZD-2171) in melanoma patients resulted in only two patients with stable disease at 6 months, no objective responses, and a short median time to progression of 3.5 months thereby demonstrating no benefit (PMID: 26841902).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1001,
                "therapyName": "Cediranib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6496,
                    "pubMedId": 26841902,
                    "title": "A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26841902"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7790,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7791,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7792,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7793,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26042,
                "profileName": "BRAF mut STAG2 dec exp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7794,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26045,
                "profileName": "NRAS mut STAG2 dec exp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7795,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag3 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26043,
                "profileName": "BRAF mut STAG3 dec exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7796,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing Stag3 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) in culture and in cell line xenograft models (PMID: 27500726).",
            "molecularProfile": {
                "id": 26043,
                "profileName": "BRAF mut STAG3 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7797,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreasing both Stag2 and Stag3 expression levels through shRNA knockdown in BRAF mutated melanoma cells resulted in further decreased response to Zelboraf (vemurafenib) in culture (PMID: 27500726).",
            "molecularProfile": {
                "id": 26044,
                "profileName": "BRAF mut STAG2 dec exp STAG3 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6497,
                    "pubMedId": 27500726,
                    "title": "Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27500726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7823,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of melanoma cell lines harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models of BRAF V600E-positive melanoma, including models with BRAF-inhibitor resistance (PMID: 25873592).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7827,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of BRAF-mutant melanoma cell lines in culture, and inhibited tumor growth melanoma cell line xenograft models harboring BRAF mutations, including models with BRAF inhibitor resistance (PMID: 25873592).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7829,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 14782,
                "profileName": "BRAF mut NRAS mut"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26062,
                "profileName": "BRAF mut KRAS mut"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to PDGFRB over expression in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26063,
                "profileName": "BRAF mut PDGFRB over exp"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7836,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to CCND1 amplification in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26064,
                "profileName": "BRAF mut CCND1 amp"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7837,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to MAP3K8 amplification in culture (PMID: 25873592).",
            "molecularProfile": {
                "id": 26066,
                "profileName": "BRAF mut MAP3K8 amp"
            },
            "therapy": {
                "id": 1059,
                "therapyName": "BI-847325",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6506,
                    "pubMedId": 25873592,
                    "title": "The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25873592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7871,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PAC-1 and Zelboraf (vemurafenib) resulted in a synergistic effect when treating melanoma cells harboring BRAF V600E in culture and xenograft models, demonstrating increased apoptosis and decreased tumor volume (PMID: 27297867).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4604,
                "therapyName": "PAC-1 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6518,
                    "pubMedId": 27297867,
                    "title": "The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27297867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7872,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of PAC-1 to Mekinist (trametinib) and Zelboraf (vemurafenib) led to greater levels of caspase-3 activity and apoptosis in melanoma cells harboring BRAF V600E when compared to Zelboraf (vemurafenib) and Mekinist (trametinib) treatment without PAC-1 (PMID: 27297867).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4603,
                "therapyName": "PAC-1 + Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6518,
                    "pubMedId": 27297867,
                    "title": "The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27297867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7873,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 inhibited survival of melanoma cell lines harboring BRAF V600E in cell culture, cell line xenograft and patient-derived xenograft (PDX) models (PMID: 19276360).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7889,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 26086,
                "profileName": "BRAF wild-type NRAS Q61K"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7890,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells in cell culture, cell line xenograft models, and patient-derived xenograft models (PMID: 19276360).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1095,
                "therapyName": "GDC0879",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 4605,
                "therapyName": "GDC0879 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6516,
                    "pubMedId": 19276360,
                    "title": "Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19276360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited survival of melanoma cell lines harboring monomeric BRAF V600E as well as cells harboring the Zelboraf (vemurafenib)-resistant dimeric BRAF V600E in culture (PMID: 26466569).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6521,
                    "pubMedId": 26466569,
                    "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26466569"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7908,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7910,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7911,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7936,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7937,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7938,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7940,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7945,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7946,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SB590885 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4281,
                "therapyName": "SB590885",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7947,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7948,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7950,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7951,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7952,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7953,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7954,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7955,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7957,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7960,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7961,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9030,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF V600R treated with Tafinlar (dabrafenib) demonstrated a reduction in lesion size after 2.5 months and at 5 months, stable disease, however, after 7 months progression ensued (PMID: 27255157).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6880,
                    "pubMedId": 27255157,
                    "title": "Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27255157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7962,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 654,
                "profileName": "BRAF V600R"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7963,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 3324,
                "profileName": "BRAF G466E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7965,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 26096,
                "profileName": "BRAF D594G NRAS G12D"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7976,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Afinitor (everolimus) treatment resulted in tumor shrinkage, progression free survival for more than 10 weeks, and stable disease in 100% (6/6) of melanoma patients harboring MTOR mutations (J Clin Oncol 33, 2015 (suppl; abstr e20007)).",
            "molecularProfile": {
                "id": 1247,
                "profileName": "MTOR mutant"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6529,
                    "pubMedId": null,
                    "title": "A phase II study of everolimus for advanced melanoma patients with mTOR mutations.",
                    "url": "http://meetinglibrary.asco.org/content/149762-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8097,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).",
            "molecularProfile": {
                "id": 3307,
                "profileName": "BRAF mut TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26172,
                "profileName": "AKT1 E17K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8106,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26173,
                "profileName": "AKT1 Q79K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8125,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 26173,
                "profileName": "AKT1 Q79K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 4635,
                "therapyName": "MK2206 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8160,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8161,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8163,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1322,
                "therapyName": "Buparlisib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8164,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1974,
                "therapyName": "Buparlisib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8165,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4652,
                "therapyName": "Buparlisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8166,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4635,
                "therapyName": "MK2206 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8167,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4653,
                "therapyName": "MK2206 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8168,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26183,
                "profileName": "BRAF V600X PTEN neg"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8253,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8257,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8321,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AS1409 treatment in patients with either melanoma or renal cell carcinoma resulted in stable disease in 46% (6/13) of patients and in two patients with melanoma, one demonstrated a partial response while another showed tumor shrinkage, which lasted beyond 12 months (PMID: 21447719).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4700,
                "therapyName": "AS1409",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6606,
                    "pubMedId": 21447719,
                    "title": "A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21447719"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8462,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring NF1 loss in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8478,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8479,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring NF1 loss in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8491,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD-6244) inhibited proliferation of melanoma cells harboring NF1 loss in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8534,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8535,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8537,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line deficient for CDKN2A demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8538,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an NRAS wild-type melanoma cell line demonstrated inhibition of cell growth when treated with Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8539,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8540,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with CDKN2A loss demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in inhibition of cell growth (PMID: 27488531).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8542,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture when compared to either agent alone (PMID: 27488531).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8543,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring an NRAS mutation and positive for BIRC5 demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture compared to treatment with either agent alone (PMID: 27488531).",
            "molecularProfile": {
                "id": 26353,
                "profileName": "BIRC5 pos NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8544,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a BRAF wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8545,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an NRAS wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 481,
                "profileName": "NRAS wild-type"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8546,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531).",
            "molecularProfile": {
                "id": 26352,
                "profileName": "BRAF mut RB1 loss"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8548,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Ibrance (palbociclib) in a melanoma cell line xenograft model harboring BRAF V600E resulted in no benefit, demonstrating low but continuous growth (PMID: 27488531).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8549,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in significant tumor regression in melanoma cell line xenograft models harboring BRAF V600E and demonstrated a 56% (5/9) complete response rate (PMID: 27488531).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1823,
                "therapyName": "Palbociclib + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8551,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrates a lack of benefit (PMID: 27488531).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17043,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cell lines were sensitive to treatment with Ibrance (palbociclib) in culture, demonstrating decreased cell viability, colony formation, and pathway activity, and increased cell cycle arrest (PMID: 30819666).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8552,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrated a lack of benefit (PMID: 27488531).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8553,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in tumor regression in 33% (2/6) of melanoma xenograft models harboring an NRAS mutation (PMID: 27488531).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 1823,
                "therapyName": "Palbociclib + PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6683,
                    "pubMedId": 27488531,
                    "title": "An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27488531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8609,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two patients with melanoma harboring KIT L576P, one who had progressed on Gleevec (imatinib), demonstrated initial clinical benefit following treatment with Sprycel (dasatinib); however, one patient progressed after 3 months, and the other patient progressed after 4 months of treatment (PMID: 19671763).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6696,
                    "pubMedId": 19671763,
                    "title": "Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19671763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12288,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT L576P in culture (PMID: 29035277).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8613,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment resulted in a partial response in a patient with metastastic anal melanoma harboring a 21 base-pair duplication in KIT exon 11, and reduced pulmonary metastasis by 60% (PMID: 20372153).",
            "molecularProfile": {
                "id": 19852,
                "profileName": "KIT exon11"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6700,
                    "pubMedId": 20372153,
                    "title": "Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20372153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8615,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment resulted in initial tumor reduction, but was followed by disease progression at all tumor sites in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 6700,
                    "pubMedId": 20372153,
                    "title": "Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20372153"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8616,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nexavar (sorafenib) treatment resulted in stable disease with 27% reduction in target lesions at 4 weeks in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153).",
            "molecularProfile": {
                "id": 1650,
                "profileName": "KIT D820Y"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6700,
                    "pubMedId": 20372153,
                    "title": "Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20372153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8677,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8681,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring NF1 inactivating mutations in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 5934,
                "profileName": "NF1 inact mut"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8682,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26406,
                "profileName": "BRAF mut KRAS G12V"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BRAF mutant melanoma cells with decreased Nf1 expression level via shRNA knock-down were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26407,
                "profileName": "BRAF mut NF1 dec exp"
            },
            "therapy": {
                "id": 4791,
                "therapyName": "AZ628 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8685,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and RAF265 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4793,
                "therapyName": "RAF265 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8687,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) and MLN2480 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4794,
                "therapyName": "MLN2480 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in melanoma cells harboring both BRAF mutation and NF1 inactivating mutation in culture (PMID: 26351322).",
            "molecularProfile": {
                "id": 26403,
                "profileName": "BRAF mut NF1 inact mut"
            },
            "therapy": {
                "id": 4795,
                "therapyName": "AZ628 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6708,
                    "pubMedId": 26351322,
                    "title": "Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26351322"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0617B inhibited survival of melanoma cells with activated Stat3 signaling in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27439479).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 4822,
                "therapyName": "Debio 0617B",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6765,
                    "pubMedId": 27439479,
                    "title": "Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27439479"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9039,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4864,
                "therapyName": "S63845 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9040,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in NRAS-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 4864,
                "therapyName": "S63845 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9041,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of S63845 and Zelboraf (vemurafenib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Zelboraf (vemurafenib) alone (PMID: 27760111).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 4865,
                "therapyName": "S63845 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6851,
                    "pubMedId": 27760111,
                    "title": "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760111"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9092,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/Ib trial, treatment with IMC-20D7S in patients with melanoma resulted in stable disease in 37% (10/27) and one complete response (PMID: 27797971).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4897,
                "therapyName": "IMC-20D7S",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6907,
                    "pubMedId": 27797971,
                    "title": "An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27797971"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9195,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, SERPINB3 mutations were associated with prolonged survival following treatment with anti-CTLA4 therapy, such as Yervoy (ipilimumab), in patients with melanoma (PMID: 27668655).",
            "molecularProfile": {
                "id": 26773,
                "profileName": "SERPINB3 mutant"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6986,
                    "pubMedId": 27668655,
                    "title": "Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27668655"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9196,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, SERPINB3 mutations were associated with prolonged survival following treatment with anti-CTLA4 therapy, such as Tremelimumab, in patients with melanoma (PMID: 27668655).",
            "molecularProfile": {
                "id": 26773,
                "profileName": "SERPINB3 mutant"
            },
            "therapy": {
                "id": 1652,
                "therapyName": "Tremelimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6986,
                    "pubMedId": 27668655,
                    "title": "Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27668655"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9197,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, SERPINB4 mutations were associated with prolonged survival following treatment with anti-CTLA4 therapy, such as Yervoy (ipilimumab), in patients with melanoma (PMID: 27668655).",
            "molecularProfile": {
                "id": 26774,
                "profileName": "SERPINB4 mutant"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6986,
                    "pubMedId": 27668655,
                    "title": "Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27668655"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9198,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, SERPINB4 mutations were associated with prolonged survival following treatment with anti-CTLA4 therapy, such as Tremelimumab, in patients with melanoma (PMID: 27668655).",
            "molecularProfile": {
                "id": 26774,
                "profileName": "SERPINB4 mutant"
            },
            "therapy": {
                "id": 1652,
                "therapyName": "Tremelimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6986,
                    "pubMedId": 27668655,
                    "title": "Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27668655"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9440,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing Dtl demonstrated sensitivity to MLN4924, resulting in inhibition of cell proliferation in culture and suppressed tumor growth in xenograft models (PMID: 27333051).",
            "molecularProfile": {
                "id": 26847,
                "profileName": "DTL positive"
            },
            "therapy": {
                "id": 1688,
                "therapyName": "MLN4924",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9442,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF and NRAS wild-type and expressing DTL demonstrated tumor growth inhibition in xenograft models when treated with MLN4924 (PMID: 27333051).",
            "molecularProfile": {
                "id": 26849,
                "profileName": "BRAF wild-type DTL pos NRAS wild-type"
            },
            "therapy": {
                "id": 1688,
                "therapyName": "MLN4924",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9443,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring a BRAF mutation and expressing DTL, and resistant to BRAF inhibitors, demonstrated sensitivity to MLN4924 in xenograft models, resulting in some inhibition of tumor growth (PMID: 27333051).",
            "molecularProfile": {
                "id": 26850,
                "profileName": "BRAF mut DTL pos"
            },
            "therapy": {
                "id": 1688,
                "therapyName": "MLN4924",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9444,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MLN4924 and PLX4720 resulted in a synergistic effect in a melanoma cell line xenograft model resistant to BRAF inhibitors, and harboring a BRAF mutation and DTL expression (PMID: 27333051).",
            "molecularProfile": {
                "id": 26850,
                "profileName": "BRAF mut DTL pos"
            },
            "therapy": {
                "id": 5017,
                "therapyName": "MLN4924 + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7190,
                    "pubMedId": 27333051,
                    "title": "Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27333051"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9447,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IPI-549 inhibited tumor growth in cell line xenograft models of melanoma through reducing the immune-suppressive tumor-associated myeloid cells (PMID: 27828943).",
            "molecularProfile": {
                "id": 26851,
                "profileName": "PIK3CG positive"
            },
            "therapy": {
                "id": 3363,
                "therapyName": "IPI-549",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7194,
                    "pubMedId": 27828943,
                    "title": "Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27828943"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9573,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, A-1210477 demonstrated a synergistic effect when combined with Cotellic (cobimetinib), resulting in decreased expression of MCL1 and increased apoptotic activity in melanoma cells harboring BRAF V600E in culture (PMID: 27765849).",
            "molecularProfile": {
                "id": 26906,
                "profileName": "BRAF V600E MCL1 pos"
            },
            "therapy": {
                "id": 5091,
                "therapyName": "A-1210477 + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7284,
                    "pubMedId": 27765849,
                    "title": "Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27765849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9647,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LDC1267 treatment resulted in decreased metastasis in a mouse model of metastatic melanoma (PMID: 24553136).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5113,
                "therapyName": "LDC1267",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7359,
                    "pubMedId": 24553136,
                    "title": "The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24553136"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9660,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Gleevec (imatinib) and PLX4720 enhanced antitumor efficacy of melanoma cells harboring BRAF V600E, demonstrating decreased cell survival in xenograft models, and decreased phosphorylation of Mapk1 in culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5118,
                "therapyName": "Imatinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9662,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Alpelisib (BYL719) and PLX4720 enhanced antitumor activity in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Akt signaling in culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5119,
                "therapyName": "Alpelisib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9663,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Zolinza (vorinostat) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Rb phosphorylation in culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5121,
                "therapyName": "PLX4720 + Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9664,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Adriamycin (doxorubicin) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and inhibition of cell growth in culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5122,
                "therapyName": "Doxorubicin + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9665,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PLX4720 and Tarceva (erlotinib) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models and culture (PMID: 27924459).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5120,
                "therapyName": "Erlotinib + PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7369,
                    "pubMedId": 27924459,
                    "title": "Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27924459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9744,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line treated with CCG-203971 resulted in inhibition of cell migration, invasion, and decreased cell growth in culture, and a reduced tumor burden in xenograft models (PMID: 27837031).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5186,
                "therapyName": "CCG-203971",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7518,
                    "pubMedId": 27837031,
                    "title": "Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27837031"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9885,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Ontak (denileukin diftitox) and Rapamune (sirolimus) resulted in a greater decrease in tumor volume compared to treatment with either agent alone in a melanoma mouse model (PMID: 27737881).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5283,
                "therapyName": "Denileukin diftitox + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7744,
                    "pubMedId": 27737881,
                    "title": "Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27737881"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9912,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with TMB-high melanoma harboring JAK1 P429S did not respond to treatment with Keytruda (pembrolizumab) (PMID: 27903500).",
            "molecularProfile": {
                "id": 33671,
                "profileName": "JAK1 P429S TMB high"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7756,
                    "pubMedId": 27903500,
                    "title": "Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27903500"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9924,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a loss of IRF8 demonstrated resistance to treatment with Yervoy (ipilimumab) (PMID: 27667683).",
            "molecularProfile": {
                "id": 27168,
                "profileName": "IRF8 loss"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7761,
                    "pubMedId": 27667683,
                    "title": "Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27667683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9927,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mouse melanoma cells with decreased expression of IFNGR1 via knockdown demonstrated resistance to Yervoy (ipilimumab) in culture, resulting in tumor growth (PMID: 27667683).",
            "molecularProfile": {
                "id": 27161,
                "profileName": "IFNGR1 dec exp"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7761,
                    "pubMedId": 27667683,
                    "title": "Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27667683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9928,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring losses of IFIT1, IFIT2, IFIT3, and IFIT1B demonstrated resistance to treatment with Yervoy (ipilimumab) (PMID: 27667683).",
            "molecularProfile": {
                "id": 27186,
                "profileName": "IFIT1 loss IFIT1B loss IFIT2 loss IFIT3 loss"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7761,
                    "pubMedId": 27667683,
                    "title": "Loss of IFN-\u03b3 Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27667683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10069,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Altiratinib (DCC-2701) to Tafinlar (dabrafenib) therapy resulted in decreased proliferation and ERK activation in a melanoma cell line harboring BRAF V600E with HGF-mediated resistance to Tafinlar (dabrafenib) in culture (PMID: 26285778).",
            "molecularProfile": {
                "id": 27234,
                "profileName": "BRAF V600E HGF pos"
            },
            "therapy": {
                "id": 5361,
                "therapyName": "Altiratinib + Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10070,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Altiratinib (DCC-2701) to Mekinist (trametinib) therapy resulted in decreased proliferation of a BRAF-mutant melanoma cell line with HGF-mediated resistance to Mekinist (trametinib) in culture (PMID: 26285778).",
            "molecularProfile": {
                "id": 27235,
                "profileName": "BRAF mut HGF pos"
            },
            "therapy": {
                "id": 5362,
                "therapyName": "Altiratinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10120,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5400,
                "therapyName": "Binimetinib + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10121,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring an NRAS mutation (PMID: 27307593).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 5400,
                "therapyName": "Binimetinib + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10122,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 15933,
                "profileName": "BRAF wild-type NRAS wild-type"
            },
            "therapy": {
                "id": 5400,
                "therapyName": "Binimetinib + Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10123,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Encorafenib (LGX818) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1337,
                "therapyName": "Buparlisib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10124,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring a BRAF mutation resulted in inhibition of brain tumor growth (PMID: 27307593).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10125,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring an NRAS mutation resulted in inhibition of brain tumor growth and an improved survival benefit (PMID: 27307593).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8051,
                    "pubMedId": 27307593,
                    "title": "PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27307593"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10238,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Valproic acid and Temodar (temozolomide) induced greater apoptotic activity in melanoma cells over expressing HDAC1/2/3 in culture compared to either agent alone, and suppressed tumor growth and reduced RAD51 and FANCD2 protein expression in melanoma cell line xenograft models (PMID: 26980768).",
            "molecularProfile": {
                "id": 27328,
                "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp"
            },
            "therapy": {
                "id": 5427,
                "therapyName": "Temozolomide + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8198,
                    "pubMedId": 26980768,
                    "title": "Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26980768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10239,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells over expressing HDAC1/2/3 demonstrated increased sensitivity to Fotemustine when treatment was combined with Valproic acid in culture, resulting in elevated apoptotic activity (PMID: 26980768).",
            "molecularProfile": {
                "id": 27328,
                "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp"
            },
            "therapy": {
                "id": 5429,
                "therapyName": "Fotemustine + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8198,
                    "pubMedId": 26980768,
                    "title": "Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26980768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10240,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells over expressing HDAC1/2/3 demonstrated increased sensitivity to radiotherapy when treatment was combined with Valproic acid in culture, resulting in elevated apoptotic activity (PMID: 26980768).",
            "molecularProfile": {
                "id": 27328,
                "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp"
            },
            "therapy": {
                "id": 5430,
                "therapyName": "Radiotherapy + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8198,
                    "pubMedId": 26980768,
                    "title": "Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26980768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10241,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Valproic acid resulted in increased sensitivity to Lynparza (olaparib) treatment in melanoma cells over expressing HDAC1/2/3 in culture, demonstrating greater apoptotic activity (PMID: 26980768).",
            "molecularProfile": {
                "id": 27328,
                "profileName": "HDAC1 over exp HDAC2 over exp HDAC3 over exp"
            },
            "therapy": {
                "id": 4549,
                "therapyName": "Olaparib + Valproic acid",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8198,
                    "pubMedId": 26980768,
                    "title": "Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26980768"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10245,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line demonstrated sensitivity to A-674563, resulting in apoptotic activity and inhibition of Akt1 activity in culture, and inhibition of tumor growth in xenograft models (PMID: 26970307).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5437,
                "therapyName": "A-674563",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8226,
                    "pubMedId": 26970307,
                    "title": "Pre-clinical assessment of A-674563 as an anti-melanoma agent.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26970307"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10288,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of Miransertib (ARQ092) and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692).",
            "molecularProfile": {
                "id": 27343,
                "profileName": "BRAF V600E PIK3CA H1047K"
            },
            "therapy": {
                "id": 5456,
                "therapyName": "Miransertib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8234,
                    "pubMedId": 26469692,
                    "title": "Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26469692"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10291,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BI-69A11 resulted in antitumor activity in a melanoma cell line harboring a PTEN mutation, including induction of cell death in culture, and in xenograft models, tumor growth inhibition and tumor regression (PMID: 19175524).",
            "molecularProfile": {
                "id": 1213,
                "profileName": "PTEN mutant"
            },
            "therapy": {
                "id": 3308,
                "therapyName": "BI-69A11",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4138,
                    "pubMedId": 19175524,
                    "title": "BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19175524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10407,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Cometriq (cabozantinib) treatment resulted in partial response in 5% (4/77) and sttable disease in 39% (30/77) of patients with metastatic melanoma, with a median overall progression free survival of 3.8 months (PMID: 28103611).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8425,
                    "pubMedId": 28103611,
                    "title": "Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28103611"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10421,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).",
            "molecularProfile": {
                "id": 21626,
                "profileName": "MAP2K1 L115P"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10422,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).",
            "molecularProfile": {
                "id": 21626,
                "profileName": "MAP2K1 L115P"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10426,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144).",
            "molecularProfile": {
                "id": 21625,
                "profileName": "MAP2K1 I103N"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10427,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144).",
            "molecularProfile": {
                "id": 21625,
                "profileName": "MAP2K1 I103N"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10468,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K2 C125S conferred resistance to Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24308,
                "profileName": "BRAF V600E MAP2K2 C125S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10469,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MAP2K2 C125S conferred resistance to Tafinlar (dabrafenib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24308,
                "profileName": "BRAF V600E MAP2K2 C125S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10494,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in a partial response in a patient with melanoma harboring GOPC-ROS1 fusion that was treatment-naive (PMID: 28183697).",
            "molecularProfile": {
                "id": 10684,
                "profileName": "GOPC - ROS1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8566,
                    "pubMedId": 28183697,
                    "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183697"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10626,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of PLX7486 and anti-CTLA4 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive melanoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01).",
            "molecularProfile": {
                "id": 5967,
                "profileName": "NTRK1 positive"
            },
            "therapy": {
                "id": 5566,
                "therapyName": "PLX7486 + unspecified CTLA4 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8673,
                    "pubMedId": null,
                    "title": "Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy",
                    "url": "http://cancerimmunolres.aacrjournals.org/content/5/3_Supplement/PR01"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10627,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of PLX7486 and anti-PD-1 immunotherapy resulted in enhanced anti-tumor effect compared to single therapy in animal models of Ntrk-positive melanoma (Cancer Immunol Res 2017;5(3 Suppl): Abstract nr PR01).",
            "molecularProfile": {
                "id": 5967,
                "profileName": "NTRK1 positive"
            },
            "therapy": {
                "id": 5567,
                "therapyName": "PLX7486 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8673,
                    "pubMedId": null,
                    "title": "Blocking Colony Stimulating Factor 1 Receptor (CSF-1R) and Tropomyosin Receptor Kinase (Trk) improves antitumor efficacy of immunotherapy",
                    "url": "http://cancerimmunolres.aacrjournals.org/content/5/3_Supplement/PR01"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10699,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line xenograft model demonstrated cell death of metastasized tumor cells within a small region of the brain when treated with GNE-317 (PMID: 27521448).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3856,
                "therapyName": "GNE-317",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8757,
                    "pubMedId": 27521448,
                    "title": "Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27521448"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10708,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8774,
                    "pubMedId": 21239882,
                    "title": "PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21239882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10743,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-BHG712 and Platinol (cisplatin) synergistically inhibited tumor growth and induced apoptosis in cell line xenograft models of melanoma that acquired Platinol (cisplatin) resistance by upregulating Ephb4 expression (PMID: 26390965).",
            "molecularProfile": {
                "id": 16746,
                "profileName": "EPHB4 over exp"
            },
            "therapy": {
                "id": 5604,
                "therapyName": "Cisplatin + NVP-BHG712",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8798,
                    "pubMedId": 26390965,
                    "title": "EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26390965"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10809,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Uprosertib (GSK2141795) inhibited the growth of melanoma cells harboring AKT1 E17K in culture (PMID: 24735930).",
            "molecularProfile": {
                "id": 643,
                "profileName": "AKT1 E17K"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8844,
                    "pubMedId": 24735930,
                    "title": "Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24735930"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10830,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of CEP-9722 and Temodar (temozolomide) inhibited Parp activity and resulted in partial response in a patient with melanoma (PMID: 24880570).",
            "molecularProfile": {
                "id": 27810,
                "profileName": "PARP1 pos PARP2 pos"
            },
            "therapy": {
                "id": 5654,
                "therapyName": "CEP-9722 + Temozolomide",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2482,
                    "pubMedId": 24880570,
                    "title": "Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24880570"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10889,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Alvocidib (flavopiridol) treatment resulted in stable disease in 44% (7/16) of patients with melanoma, but no objective response (PMID: 15122079).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 628,
                "therapyName": "Alvocidib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8902,
                    "pubMedId": 15122079,
                    "title": "Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15122079"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10891,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 5673,
                "therapyName": "GSK2636771 + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4556,
                    "pubMedId": 26645196,
                    "title": "Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26645196"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10894,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Kisqali (ribociclib) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with 2.3% (3/132) of patients demonstrating partial response, including a patient with wild-type BRAF/NRAS melanoma harboring CCND1 amplification (PMID: 27542767).",
            "molecularProfile": {
                "id": 1420,
                "profileName": "CCND1 amp"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7226,
                    "pubMedId": 27542767,
                    "title": "A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27542767"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17042,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cell lines were sensitive to treatment with Mekinist (trametinib) in culture, demonstrating decreased cell viability, colony formation, and pathway activity, and increased cell cycle arrest (PMID: 30819666).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10895,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease in 29% (2/7) of patients with NRAS mutated melanoma (PMID: 22805292; NCT00687622).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 233,
                    "pubMedId": 22805292,
                    "title": "Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22805292"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10896,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",
            "molecularProfile": {
                "id": 3375,
                "profileName": "NRAS Q61L"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 180,
                    "pubMedId": 23414587,
                    "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10897,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",
            "molecularProfile": {
                "id": 646,
                "profileName": "NRAS Q61K"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 180,
                    "pubMedId": 23414587,
                    "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10898,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",
            "molecularProfile": {
                "id": 3043,
                "profileName": "NRAS Q61R"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 180,
                    "pubMedId": 23414587,
                    "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10957,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with GDC-0425 followed by Gemzar (gemcitabine) resulted in a partial response in a patient with melanoma (PMID: 27815358).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5734,
                "therapyName": "GDC-0425 + Gemcitabine",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 8959,
                    "pubMedId": 27815358,
                    "title": "Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27815358"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11037,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, V158411 induced DNA damage and cell-cycle arrest, and inhibited growth of a melanoma cell line in culture (PMID: 27829224).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5824,
                "therapyName": "V158411",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9030,
                    "pubMedId": 27829224,
                    "title": "Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27829224"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11041,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma xenograft model harboring BRAF V600E demonstrated tumor regression when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9035,
                    "pubMedId": null,
                    "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11043,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",
            "molecularProfile": {
                "id": 27896,
                "profileName": "BRAF V600E PTEN mut"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9035,
                    "pubMedId": null,
                    "title": "Abstract B100: ASN003, a unique B-RAF inhibitor with additional selective activity against PI3K and mTOR kinases, shows strong antitumor activity in multiple xenograft models",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B100.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11044,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9034,
                    "pubMedId": null,
                    "title": "ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186123.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11050,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312).",
            "molecularProfile": {
                "id": 27900,
                "profileName": "KIT D816V NRAS Q61R"
            },
            "therapy": {
                "id": 1450,
                "therapyName": "Pembrolizumab + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11053,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",
            "molecularProfile": {
                "id": 27904,
                "profileName": "CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H"
            },
            "therapy": {
                "id": 5833,
                "therapyName": "Carboplatin + Imatinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11054,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312).",
            "molecularProfile": {
                "id": 27905,
                "profileName": "ATM mut NRAS Q61R"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9046,
                    "pubMedId": 28514312,
                    "title": "Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28514312"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11073,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Advexin (Ad5CMV-p53) and an unspecified anti-PD-1 antibody resulted in a synergistic effect and abscopal effect in an immune therapy resistant syngeneic melanoma mouse model, demonstrating decreased tumor growth and improved survival compared to either agent alone (J Clin Oncol 35, 2017 (suppl; abstr e14610)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5854,
                "therapyName": "Ad5CMV-p53 gene + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9064,
                    "pubMedId": null,
                    "title": "Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy",
                    "url": "http://abstracts.asco.org/199/AbstView_199_194552.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11096,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of KRT-232 (AMG 232), Mekinist (trametinib), and Tafinlar (dabrafenib) in 6 patients with metastatic cutaneous melanoma harboring a BRAF V600 mutation resulted in 4 patients with a partial response and 2 patients with stable disease, and of the 6 patients, all experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1453,
                "therapyName": "Dabrafenib + KRT-232 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9073,
                    "pubMedId": null,
                    "title": "Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM)",
                    "url": "http://abstracts.asco.org/199/AbstView_199_181299.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11099,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of KRT-232 (AMG 232) and Mekinist (trametinib) in 15 patients with metastatic cutaneous melanoma without a BRAF V600 mutation resulted in a partial response in 2 patients, stable disease in 11 patients, and progressive disease in 2 patients, and of the 15 patients, 11 experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1454,
                "therapyName": "KRT-232 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9073,
                    "pubMedId": null,
                    "title": "Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM)",
                    "url": "http://abstracts.asco.org/199/AbstView_199_181299.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11112,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination therapy of Tecentriq (atezolizumab), Zelboraf (vemurafenib), and Cotellic (cobimetinib) in patients with metastatic melanoma harboring a BRAF V600 mutation resulted in a best objective response rate of 71.8% (28/39), with a complete response in 20.5% (8/39), a median progression-free survival of 12.9 months, a median overall survival not yet reached, and median duration of confirmed response of 17.4 months (PMID: 31171876; NCT01656642).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4825,
                "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9081,
                    "pubMedId": null,
                    "title": "Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186773.html"
                },
                {
                    "id": 15863,
                    "pubMedId": 31171876,
                    "title": "Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31171876"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17733,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Toripalimab (JS001) demonstrated safety and preliminary efficacy, resulted in an objective response rate of 18.2% (4/22) and a disease control rate of 45.5% (10/22, 1 complete response, 4 partial response, 6 stable disease) in patients with advanced melanoma (PMID: 30642373; NCT02836795).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15756,
                    "pubMedId": 30642373,
                    "title": "Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30642373"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11173,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, JS001 demonstrated safety and preliminary activity in patients with melanoma, renal cell carcinoma, or urothelial carcinoma, with an overall response rate (ORR) of 22% (7/32; 1 complete response (melanoma), 6 partial responses), and an ORR of 20% and 25% and DCR of 53% and 50% in patients with acral or mucosal melanoma, respectively (J Clin Oncol 35, 2017 (suppl; abstr 3067)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9134,
                    "pubMedId": null,
                    "title": "A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors",
                    "url": "http://abstracts.asco.org/199/AbstView_199_189353.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11223,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PET-16 and Zelboraf (vemurafenib) synergistically inhibited growth of melanoma cell lines in culture, resulted in enhanced tumor growth inhibition in cell ine xenograft models (PMID: 26984758).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5911,
                "therapyName": "PET-16 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8968,
                    "pubMedId": 26984758,
                    "title": "HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26984758"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11854,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).",
            "molecularProfile": {
                "id": 19852,
                "profileName": "KIT exon11"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9871,
                    "pubMedId": 28843487,
                    "title": "STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28843487"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11229,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response of 38.5% (10/26) and a progression free survival of 5.4 months in melanoma patients harboring KIT exon 11 mutations (PMID: 28327988).",
            "molecularProfile": {
                "id": 19852,
                "profileName": "KIT exon11"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11230,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response in 7.7% (1/13) of melanoma patients harboring KIT exon 13 mutations (PMID: 28327988).",
            "molecularProfile": {
                "id": 26977,
                "profileName": "KIT exon13"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11855,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).",
            "molecularProfile": {
                "id": 26977,
                "profileName": "KIT exon13"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9871,
                    "pubMedId": 28843487,
                    "title": "STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28843487"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11231,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including three melanoma patients harboring KIT L576P demonstrating a partial response (PMID: 28327988).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11232,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient co-harboring KIT L576P and KIT W557R demonstrating a partial response and a progression free survival of 5.3 months and overall survival of 14.7 months when treated with Tasigna (nilotinib) (PMID: 28327988).",
            "molecularProfile": {
                "id": 27931,
                "profileName": "KIT W557R KIT L576P"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11233,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT K642E demonstrating a partial response and a progression free survival of 5.8 months and overall survival of 18.6 months (PMID: 28327988).",
            "molecularProfile": {
                "id": 1660,
                "profileName": "KIT K642E"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11234,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V559D demonstrating a partial response and progression free survival of 28.3 months and overall survival of 28.3 months (PMID: 28327988).",
            "molecularProfile": {
                "id": 1641,
                "profileName": "KIT V559D"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11235,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), including a melanoma patient harboring KIT V559A demonstrating a partial response and progression-free survival of 19.4 months and overall survival of 32.9 months (PMID: 28327988).",
            "molecularProfile": {
                "id": 1640,
                "profileName": "KIT V559A"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11236,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V560D demonstrating a partial response and progression free survival of 8.6 months and overall survival of 23.5 months (PMID: 28327988).",
            "molecularProfile": {
                "id": 1698,
                "profileName": "KIT V560D"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11238,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT W557R demonstrating a partial response and progression free survival of 35.4 months and overall survival of 35.4 months (PMID: 28327988).",
            "molecularProfile": {
                "id": 995,
                "profileName": "KIT W557R"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11415,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Encorafenib (LGX818) and Kisqali (ribociclib) combination treatment resulted in confirmed partial response in 7.1% (2/28), unconfirmed partial response in 10.7% (3/28), and stable disease in 35.7% (10/28) of patients with melanoma harboring BRAF V600E (PMID: 28351928).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1260,
                "therapyName": "Encorafenib + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9298,
                    "pubMedId": 28351928,
                    "title": "Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28351928"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11455,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Epacadostat resulted in stable disease in 13% (7/52) of patients with advanced solid tumors for greater than or equal to 16 weeks, including two patients with melanoma who previously failed on immunotherapy (PMID: 28053021).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2575,
                "therapyName": "Epacadostat",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9452,
                    "pubMedId": 28053021,
                    "title": "First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28053021"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11459,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Varlilumab resulted in stable disease in three patients with melanoma for 3.8, 7.3, and 11.5 months, respectively (PMID: 28463630).",
            "molecularProfile": {
                "id": 28056,
                "profileName": "CD27 positive"
            },
            "therapy": {
                "id": 2525,
                "therapyName": "Varlilumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9482,
                    "pubMedId": 28463630,
                    "title": "Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28463630"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11565,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mitochondrial Hsp90 inhibitor G-TPP and the broad BH3 mimetic Navitoclax (ABT-263) synergistically inhibited viability of melanoma cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6064,
                "therapyName": "G-TPP + Navitoclax",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11566,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the mitochondrial Hsp90 inhibitor G-TPP and the broad BH3 mimetic Obatoclax (GX015-070) synergistically inhibited viability of established melanoma cells in culture (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6065,
                "therapyName": "G-TPP + Obatoclax",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11567,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of the mitochondrial Hsp90 inhibitor G-TPP and the Bcl-xL inhibitor WEHI-539 resulted in increased apoptosis of melanoma cell lines in culture (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6066,
                "therapyName": "G-TPP + WEHI-539",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11569,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of the mitochondrial Hsp90 inhibitor G-TPP and the Bcl2 inhibitor Venclexta (venetoclax) resulted in increased apoptosis of melanoma cell lines in culture (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6067,
                "therapyName": "G-TPP + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11570,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of the mitochondrial Hsp90 inhibitor G-TPP and the Mcl-1 inhibitor A-1210477 resulted in increased apoptosis of melanoma cell lines in culture (PMID: 28522750).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6068,
                "therapyName": "A-1210477 + G-TPP",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9648,
                    "pubMedId": 28522750,
                    "title": "Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11654,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF D594G in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 989,
                "profileName": "BRAF D594G"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11656,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).",
            "molecularProfile": {
                "id": 28179,
                "profileName": "BRAF G466E HRAS Q61K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9692,
                    "pubMedId": 28783719,
                    "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28783719"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11693,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11694,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11823,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment in a patient with metastatic melanoma resulted in regression of the lung metastasis, which harbored KIT V559A; however, neither the primary tumor or lymph node metastasis responded, which had wild-type KIT (PMID: 19812602).",
            "molecularProfile": {
                "id": 1640,
                "profileName": "KIT V559A"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9862,
                    "pubMedId": 19812602,
                    "title": "Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19812602"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11901,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, IMO-2125 treatment resulted in clinical benefit in 67% (6/9, 1 complete response, 2 partial response, 3 stable disease) of patients with melanoma refractory to a PD-1 or PD-L1 inhibitor (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 1187P; NCT02644967).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4243,
                "therapyName": "IMO-2125",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9893,
                    "pubMedId": null,
                    "title": "A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma",
                    "url": "http://www.esmo.org/Conferences/ESMO-2017-Congress/Programme"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11955,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquisition of an AGAP3-BRAF fusion was identified in a melanoma patient harboring BRAF V600E who developed resistance to Zelboraf (vemurafenib), and expression of AGAP3-BRAF in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11958,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AGAP3-BRAF in melanoma cells harboring BRAF V600E resulted in reduced response to Mekinist (trametinib) at high concentration compared to cells harboring V600E alone in culture (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11961,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, acquisition of a CSTF3-BRAF fusion was identified in a melanoma patient harboring BRAF V600E who developed progressive disease after treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 28539463).",
            "molecularProfile": {
                "id": 28369,
                "profileName": "CSTF3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11967,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",
            "molecularProfile": {
                "id": 448,
                "profileName": "KRAS mutant"
            },
            "therapy": {
                "id": 5747,
                "therapyName": "KO-947",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9707,
                    "pubMedId": null,
                    "title": "KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors",
                    "url": "http://cancerres.aacrjournals.org/content/77/13_Supplement/5168.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12057,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, INU-152 reduced MEK and ERK phosphorylation and growth of a melanona cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 28645859).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6241,
                "therapyName": "INU-152",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9993,
                    "pubMedId": 28645859,
                    "title": "Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28645859"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12070,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a melanoma patient harboring BRAF K601E demonstrated a partial response and a progression free survival of 32 weeks when treated with Mekinist (trametinib) (PMID: 23248257; NCT01037127).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10005,
                    "pubMedId": 23248257,
                    "title": "Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23248257"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12068,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient harboring BRAF K601E demonstrated a 48% reduction in lymphadenopathy when treated with Mekinist (trametinib) and after more than 36 months of treatment showed a complete response (PMID: 28344857).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8660,
                    "pubMedId": 28344857,
                    "title": "Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36\u00a0months.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28344857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12069,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, no responses were demonstrated among three melanoma patients with non-V600 BRAF mutations, including two patients harboring BRAF K601E, following treatment with Tafinlar (dabrafenib), compared to a confirmed response rate of 50% in patients harboring BRAF V600 mutations (PMID: 22608338).",
            "molecularProfile": {
                "id": 655,
                "profileName": "BRAF K601E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 467,
                    "pubMedId": 22608338,
                    "title": "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22608338"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12087,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Cotellic (cobimetinib) treatment resulted in a confirmed partial response in six melanoma patients harboring BRAF V600E (PMID: 27424159).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10025,
                    "pubMedId": 27424159,
                    "title": "A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27424159"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12133,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Encorafenib (LGX818) treatment resulted in an overall response rate (ORR) of 60% (15/25) and a median progression-free survival (mPFS) of 12.4 months in BRAF inhibitor-na\u00efve melanoma patients harboring BRAF mutations, and an ORR of 22% (6/29) and mPFS of 1.9 months in BRAF inhibitor-pretreated patients (PMID: 28611198; NCT01436656).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10108,
                    "pubMedId": 28611198,
                    "title": "Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28611198"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28495,
                "profileName": "BRAF V600E MAP2K1 I111N"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12151,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12152,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12153,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28495,
                "profileName": "BRAF V600E MAP2K1 I111N"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21627,
                "profileName": "BRAF V600E MAP2K1 L115P"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12155,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12156,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K2 Q218P in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28496,
                "profileName": "BRAF V600E MAP2K2 Q218P"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12158,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 21654,
                "profileName": "BRAF V600E MAP2K1 V211D"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12159,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 17135,
                "profileName": "BRAF V600E MAP2K1 C121S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12160,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28497,
                "profileName": "BRAF V600E MAP2K1 E203K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12161,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28497,
                "profileName": "BRAF V600E MAP2K1 E203K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12162,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28498,
                "profileName": "BRAF V600E MAP2K1 P124L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12163,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28498,
                "profileName": "BRAF V600E MAP2K1 P124L"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12164,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12165,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 22096,
                "profileName": "BRAF V600E MAP2K1 Q56P"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12166,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28497,
                "profileName": "BRAF V600E MAP2K1 E203K"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12167,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 Q218P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28496,
                "profileName": "BRAF V600E MAP2K2 Q218P"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12221,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EBI-907 inhibited BRAF and ERK signaling, resulted in growth inhibition of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 26810733).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6368,
                "therapyName": "EBI-907",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10177,
                    "pubMedId": 26810733,
                    "title": "EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26810733"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12263,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15453,
                    "pubMedId": null,
                    "title": "Cotellic (cobimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12269,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15453,
                    "pubMedId": null,
                    "title": "Cotellic (cobimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12270,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (coBRIM) that supported FDA approval, treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months, compared to 7.2 months with Zelboraf (vemurafenib) plus placebo, among patients with BRAF V600-mutated metastatic melanoma, and BRAF V600E and BRAF V600K are on the companion diagnostic (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15453,
                    "pubMedId": null,
                    "title": "Cotellic (cobimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12282,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 treatment resulted in tumor regression in BRAF mutant-melanoma cell line xenograft models (PMID: 28775144).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 6418,
                "therapyName": "ST-162",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12283,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST-162 resulted in tumor regression in a melanoma cell line xenograft model co-harboring mutations in BRAF and PTEN (PMID: 28775144).",
            "molecularProfile": {
                "id": 21306,
                "profileName": "BRAF mut PTEN mut"
            },
            "therapy": {
                "id": 6418,
                "therapyName": "ST-162",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10258,
                    "pubMedId": 28775144,
                    "title": "A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28775144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12287,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277).",
            "molecularProfile": {
                "id": 1650,
                "profileName": "KIT D820Y"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12289,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib mesylate) failed to inhibit MNK pathway activation and proliferation of melanoma cell lines harboring KIT D820Y in culture (PMID: 29035277).",
            "molecularProfile": {
                "id": 1650,
                "profileName": "KIT D820Y"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12290,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cell lines harboring KIT D820Y in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).",
            "molecularProfile": {
                "id": 1650,
                "profileName": "KIT D820Y"
            },
            "therapy": {
                "id": 6429,
                "therapyName": "SEL201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12291,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SEL201 inhibited MNK pathway signaling and growth of melanoma cells harboring KIT L576P in culture, and suppressed tumor metastasis in xenograft models (PMID: 29035277).",
            "molecularProfile": {
                "id": 1670,
                "profileName": "KIT L576P"
            },
            "therapy": {
                "id": 6429,
                "therapyName": "SEL201",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10273,
                    "pubMedId": 29035277,
                    "title": "MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29035277"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12292,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Tafinlar (dabrafenib), SCH772984, and Mekinist (trametinib) resulted in durable inhibition of Erk signaling and proliferation of melanoma cells overexpressing BRAF V600E in culture (PMID: 28714990).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6430,
                "therapyName": "Dabrafenib + SCH772984 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 10283,
                    "pubMedId": 28714990,
                    "title": "An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28714990"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12556,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CA-170 activated peripheral T cells and inhibited tumor growth in mouse models of melanoma (Ann Oncol. 2017 Sep 18; 28 (Suppl_5): Abstract 1141PD).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5885,
                "therapyName": "CA-170",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10429,
                    "pubMedId": null,
                    "title": "CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study",
                    "url": "https://academic.oup.com/annonc/article/28/suppl_5/mdx376.007/4109221"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12623,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with RAF265 in melanoma patients resulted in an objective response rate of 12.1% (8/66), including a partial response in four patients harboring BRAF V600E, two partial responses and one complete response in patients with wild-type BRAF, and one complete response in a patient with unknown mutational status (PMID: 28719152).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 884,
                "therapyName": "RAF265",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10503,
                    "pubMedId": 28719152,
                    "title": "A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28719152"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12653,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DT01 treatment enhanced the sensitivity of radiotherapy, resulting in an objective response in 59% (45/76) of lesions from 21 melanoma patients, including 23 complete responses (PMID: 27140316; NCT01469455).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6550,
                "therapyName": "DT01 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10538,
                    "pubMedId": 27140316,
                    "title": "First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27140316"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12656,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, lesions from melanoma patients treated with BQ788 demonstrated decreased expression of EDNRB, reduced cell proliferation, and in one patient treated for more than one week, inhibition of lesion growth (PMID: 26330458; NCT02442466).",
            "molecularProfile": {
                "id": 28810,
                "profileName": "EDNRB positive"
            },
            "therapy": {
                "id": 6551,
                "therapyName": "BQ788",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10543,
                    "pubMedId": 26330458,
                    "title": "First-in-Human Proof-of-Concept Study: Intralesional Administration of BQ788, an Endothelin Receptor B Antagonist, to Melanoma Skin Metastases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26330458"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12701,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a best response of stable disease in six melanoma patients and a partial response in three melanoma patients all harboring a BRAF mutation (PMID: 29247021).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12703,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with BVD-523 (ulixertinib) resulted in a best response of stable disease in six melanoma patients and a partial response in three melanoma patients all harboring an NRAS mutation (PMID: 29247021).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10607,
                    "pubMedId": 29247021,
                    "title": "First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29247021"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12835,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (COMBI-v) that supported FDA approval, the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved overall survival rate at 12 months (72% vs 65%, HR=0.69, p=0.005), median progression-free survival (11.4 vs 7.3 months, HR=0.56, p<0.001), and objective response rate (64% vs 51%, p<0.001) compared to Zelboraf (vemurafenib) in melanoma patients harboring BRAF V600E or V600K (PMID: 25399551; NCT01597908).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10781,
                    "pubMedId": 25399551,
                    "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25399551"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15458,
                    "pubMedId": null,
                    "title": "Tafinlar (dabrafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=202806"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12838,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 468,
                    "pubMedId": 22663011,
                    "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22663011"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15457,
                    "pubMedId": null,
                    "title": "Mekinist (trametinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12839,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (METRIC) that supported FDA approval, Mekinist (trametinib) treatment, as compared to Deticine (dacarbazine) or Taxol (paclitaxel) treatment, resulted in improved progression-free survival of 4.8 months versus 1.5 months and an overall six month survival rate of 81% versus 67% in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 22663011; NCT01245062).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 468,
                    "pubMedId": 22663011,
                    "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22663011"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15457,
                    "pubMedId": null,
                    "title": "Mekinist (trametinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204114"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13300,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knocking-out PBRM1 in melanoma cells sensitized cells to immune therapy consisted of anti-CTLA4 and anti-PD-1 antibodies in culture and in cell line xenograft models, potentially due to increased sensitivity to T cell-mediated cytotoxicity and a favorable tumor microenvironment (PMID: 29301958).",
            "molecularProfile": {
                "id": 2740,
                "profileName": "PBRM1 loss"
            },
            "therapy": {
                "id": 6804,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11072,
                    "pubMedId": 29301958,
                    "title": "A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29301958"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-6051a inhibited MAPK, PI3K, and PLCgamma-1 signaling in transformed melanocytes expressing ETV6-NTRK3 in culture (PMID: 27477320).",
            "molecularProfile": {
                "id": 2514,
                "profileName": "ETV6 - NTRK3"
            },
            "therapy": {
                "id": 6869,
                "therapyName": "DS-6051a",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11065,
                    "pubMedId": 27477320,
                    "title": "NTRK3 kinase fusions in Spitz tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27477320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DS-6051a inhibited MAPK, PI3K, and PLCgamma-1 signaling in transformed melanocytes expressing MYO5A-NTRK3 in culture (PMID: 27477320).",
            "molecularProfile": {
                "id": 29161,
                "profileName": "MYO5A - NTRK3"
            },
            "therapy": {
                "id": 6869,
                "therapyName": "DS-6051a",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11065,
                    "pubMedId": 27477320,
                    "title": "NTRK3 kinase fusions in Spitz tumours.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27477320"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13823,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BA3021 (CAB-ROR2-ADC) inhibited growth of Ror2-positive melanoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Apr 2018, Vol 59, Abstract 833).",
            "molecularProfile": {
                "id": 29507,
                "profileName": "ROR2 positive"
            },
            "therapy": {
                "id": 6906,
                "therapyName": "BA3021",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11293,
                    "pubMedId": null,
                    "title": "Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/833"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 inhibited Erk signaling and proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 29343524).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14047,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 inhibited Erk signaling in melanoma cells harboring NRAS Q61K in culture (PMID: 29343524).",
            "molecularProfile": {
                "id": 646,
                "profileName": "NRAS Q61K"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14049,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RAF709 inhibited Erk signaling and proliferation of melanoma cells harboring NRAS Q61L in culture (PMID: 29343524).",
            "molecularProfile": {
                "id": 3375,
                "profileName": "NRAS Q61L"
            },
            "therapy": {
                "id": 6995,
                "therapyName": "RAF709",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11434,
                    "pubMedId": 29343524,
                    "title": "Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29343524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14181,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, combination of Indoximod and Keytruda (pembrolizumab) resulted in an objective response rate of 55.7% (39/70, 13 complete response), with a median progression-free survival of 12.4 months in patients with advanced melanoma (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 9512-9512; NCT02073123).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6586,
                "therapyName": "Indoximod + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11491,
                    "pubMedId": null,
                    "title": "Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9512"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14218,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, LN-144 treatment resulted in an objective response rate of 33% (3/9, 1 complete response, 2 partial response) in patients with advanced metastatic melanoma (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 3045-3045; NCT02360579).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 7043,
                "therapyName": "LN-144",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11522,
                    "pubMedId": null,
                    "title": "Efficacy of single administration of tumor-infiltrating lymphocytes (TIL) in heavily pretreated patients with metastatic melanoma following checkpoint therapy.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3045"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14235,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453) and both BRAF V600E and V600K are on the companion diagnostic.",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11562,
                    "pubMedId": 29573941,
                    "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29573941"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16337,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14457,
                    "pubMedId": 30219628,
                    "title": "Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30219628"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14236,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, NKTR-214 and Opdivo (nivolumab) combination treatment demonstrated safety and preliminary efficacy, resulted in radiographic response in one and complete response in another patient with melanoma (Journal of Clinical Oncology 35, no. 15_suppl; NCT02983045).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5076,
                "therapyName": "Nivolumab + NKTR-214",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11563,
                    "pubMedId": null,
                    "title": "A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e14040"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14563,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 A35N in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30183,
                "profileName": "BRAF V600E MAPK1 A35N"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14566,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 C127I in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30182,
                "profileName": "BRAF V600E MAPK1 C127I"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14567,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 C40P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30184,
                "profileName": "BRAF V600E MAPK1 C40P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14568,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 C40P in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30184,
                "profileName": "BRAF V600E MAPK1 C40P"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14571,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 C40R in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30185,
                "profileName": "BRAF V600E MAPK1 C40R"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14572,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 C65F in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30186,
                "profileName": "BRAF V600E MAPK1 C65F"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14573,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 C65W in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30187,
                "profileName": "BRAF V600E MAPK1 C65W"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14574,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 C65Y in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30188,
                "profileName": "BRAF V600E MAPK1 C65Y"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14575,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 C65Y in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30188,
                "profileName": "BRAF V600E MAPK1 C65Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14576,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 D100M in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30194,
                "profileName": "BRAF V600E MAPK1 D100M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14578,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 D124T in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30195,
                "profileName": "BRAF V600E MAPK1 D124T"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14579,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 D44H in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30196,
                "profileName": "BRAF V600E MAPK1 D44H"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14580,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 D44H in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30196,
                "profileName": "BRAF V600E MAPK1 D44H"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14581,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E33P in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30197,
                "profileName": "BRAF V600E MAPK1 E33P"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E60Q in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30198,
                "profileName": "BRAF V600E MAPK1 E60Q"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14583,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E60S in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30199,
                "profileName": "BRAF V600E MAPK1 E60S"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14584,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E71A in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30200,
                "profileName": "BRAF V600E MAPK1 E71A"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14588,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E71A in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30200,
                "profileName": "BRAF V600E MAPK1 E71A"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14589,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E71C in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30201,
                "profileName": "BRAF V600E MAPK1 E71C"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14590,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E71G in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30202,
                "profileName": "BRAF V600E MAPK1 E71G"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14591,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E71P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30204,
                "profileName": "BRAF V600E MAPK1 E71P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E71K in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30203,
                "profileName": "BRAF V600E MAPK1 E71K"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14593,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 E71K in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30203,
                "profileName": "BRAF V600E MAPK1 E71K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14594,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 F59G in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30205,
                "profileName": "BRAF V600E MAPK1 F59G"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14595,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 F59P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30206,
                "profileName": "BRAF V600E MAPK1 F59P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14596,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 F59R in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30207,
                "profileName": "BRAF V600E MAPK1 F59R"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 F59S in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30208,
                "profileName": "BRAF V600E MAPK1 F59S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 F59R in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30207,
                "profileName": "BRAF V600E MAPK1 F59R"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14599,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 F59S in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30208,
                "profileName": "BRAF V600E MAPK1 F59S"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14600,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G169D in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30209,
                "profileName": "BRAF V600E MAPK1 G169D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14601,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G169D in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30209,
                "profileName": "BRAF V600E MAPK1 G169D"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14602,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G32P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30210,
                "profileName": "BRAF V600E MAPK1 G32P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14628,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37A in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30211,
                "profileName": "BRAF V600E MAPK1 G37A"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14629,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37A in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30211,
                "profileName": "BRAF V600E MAPK1 G37A"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37C in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30212,
                "profileName": "BRAF V600E MAPK1 G37C"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37C in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30212,
                "profileName": "BRAF V600E MAPK1 G37C"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14632,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37D in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30213,
                "profileName": "BRAF V600E MAPK1 G37D"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37D in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30213,
                "profileName": "BRAF V600E MAPK1 G37D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37K in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30214,
                "profileName": "BRAF V600E MAPK1 G37K"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37K in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30214,
                "profileName": "BRAF V600E MAPK1 G37K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37N in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30215,
                "profileName": "BRAF V600E MAPK1 G37N"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30216,
                "profileName": "BRAF V600E MAPK1 G37P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14638,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37S in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30217,
                "profileName": "BRAF V600E MAPK1 G37S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14639,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37S in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30217,
                "profileName": "BRAF V600E MAPK1 G37S"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14640,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37T in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30218,
                "profileName": "BRAF V600E MAPK1 G37T"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14641,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 G37T in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30218,
                "profileName": "BRAF V600E MAPK1 G37T"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14642,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I103Q in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30219,
                "profileName": "BRAF V600E MAPK1 I103Q"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14643,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I103W in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30220,
                "profileName": "BRAF V600E MAPK1 I103W"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14645,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I103Y in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30221,
                "profileName": "BRAF V600E MAPK1 I103Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14646,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31C in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30222,
                "profileName": "BRAF V600E MAPK1 I31C"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14647,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31D in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30224,
                "profileName": "BRAF V600E MAPK1 I31D"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14648,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31E in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30225,
                "profileName": "BRAF V600E MAPK1 I31E"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14649,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31H in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30226,
                "profileName": "BRAF V600E MAPK1 I31H"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14651,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31K in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30227,
                "profileName": "BRAF V600E MAPK1 I31K"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14652,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31L in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30228,
                "profileName": "BRAF V600E MAPK1 I31L"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14653,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31M in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30229,
                "profileName": "BRAF V600E MAPK1 I31M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14655,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31N in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30230,
                "profileName": "BRAF V600E MAPK1 I31N"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14657,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31Q in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30231,
                "profileName": "BRAF V600E MAPK1 I31Q"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31R in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30232,
                "profileName": "BRAF V600E MAPK1 I31R"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14660,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31W in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30233,
                "profileName": "BRAF V600E MAPK1 I31W"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14661,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I31Y in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30234,
                "profileName": "BRAF V600E MAPK1 I31Y"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I347F in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30235,
                "profileName": "BRAF V600E MAPK1 I347F"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I347H in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30236,
                "profileName": "BRAF V600E MAPK1 I347H"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I347M in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30237,
                "profileName": "BRAF V600E MAPK1 I347M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14666,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I347W in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30238,
                "profileName": "BRAF V600E MAPK1 I347W"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14667,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I347Y in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30239,
                "profileName": "BRAF V600E MAPK1 I347Y"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14668,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I347W in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30238,
                "profileName": "BRAF V600E MAPK1 I347W"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I347Y in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30239,
                "profileName": "BRAF V600E MAPK1 I347Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56D in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30240,
                "profileName": "BRAF V600E MAPK1 I56D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14671,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56E in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30244,
                "profileName": "BRAF V600E MAPK1 I56E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14672,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56G in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30245,
                "profileName": "BRAF V600E MAPK1 I56G"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56G in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30245,
                "profileName": "BRAF V600E MAPK1 I56G"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56H in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30246,
                "profileName": "BRAF V600E MAPK1 I56H"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56K in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30255,
                "profileName": "BRAF V600E MAPK1 I56K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14677,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30256,
                "profileName": "BRAF V600E MAPK1 I56P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14678,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56Q in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30257,
                "profileName": "BRAF V600E MAPK1 I56Q"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14679,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56Q in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30257,
                "profileName": "BRAF V600E MAPK1 I56Q"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14680,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56S in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30258,
                "profileName": "BRAF V600E MAPK1 I56S"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14681,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56S in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30258,
                "profileName": "BRAF V600E MAPK1 I56S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14682,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56W in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30259,
                "profileName": "BRAF V600E MAPK1 I56W"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14683,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 I56Y in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30260,
                "profileName": "BRAF V600E MAPK1 I56Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14684,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 K55G in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30261,
                "profileName": "BRAF V600E MAPK1 K55G"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14685,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L156G in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30262,
                "profileName": "BRAF V600E MAPK1 L156G"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14686,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L156N in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30263,
                "profileName": "BRAF V600E MAPK1 L156N"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14687,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L69R in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30264,
                "profileName": "BRAF V600E MAPK1 L69R"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14688,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L75E in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30265,
                "profileName": "BRAF V600E MAPK1 L75E"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L75H in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30266,
                "profileName": "BRAF V600E MAPK1 L75H"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L75P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30267,
                "profileName": "BRAF V600E MAPK1 L75P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L75R in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30268,
                "profileName": "BRAF V600E MAPK1 L75R"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14692,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L75W in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30269,
                "profileName": "BRAF V600E MAPK1 L75W"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14693,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 L75W in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30269,
                "profileName": "BRAF V600E MAPK1 L75W"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14694,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 M38P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30270,
                "profileName": "BRAF V600E MAPK1 M38P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14695,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 M98W in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30272,
                "profileName": "BRAF V600E MAPK1 M98W"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14711,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58A in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30278,
                "profileName": "BRAF V600E MAPK1 P58A"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14712,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58F in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30279,
                "profileName": "BRAF V600E MAPK1 P58F"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14714,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58G in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30280,
                "profileName": "BRAF V600E MAPK1 P58G"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14716,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58I in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30281,
                "profileName": "BRAF V600E MAPK1 P58I"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14718,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58K in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30282,
                "profileName": "BRAF V600E MAPK1 P58K"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14720,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58L in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30283,
                "profileName": "BRAF V600E MAPK1 P58L"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14723,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58M in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30285,
                "profileName": "BRAF V600E MAPK1 P58M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14728,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58N in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30286,
                "profileName": "BRAF V600E MAPK1 P58N"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14729,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58Q in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30288,
                "profileName": "BRAF V600E MAPK1 P58Q"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14731,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58R in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30289,
                "profileName": "BRAF V600E MAPK1 P58R"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14736,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58AS in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30290,
                "profileName": "BRAF V600E MAPK1 P58S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14738,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58T in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30291,
                "profileName": "BRAF V600E MAPK1 P58T"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14740,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58V in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30292,
                "profileName": "BRAF V600E MAPK1 P58V"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14741,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58W in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30293,
                "profileName": "BRAF V600E MAPK1 P58W"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14742,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58Y in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30294,
                "profileName": "BRAF V600E MAPK1 P58Y"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14746,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58A in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30278,
                "profileName": "BRAF V600E MAPK1 P58A"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14747,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58F in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30279,
                "profileName": "BRAF V600E MAPK1 P58F"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14749,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58G in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30280,
                "profileName": "BRAF V600E MAPK1 P58G"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14750,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58K in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30282,
                "profileName": "BRAF V600E MAPK1 P58K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14751,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58L in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30283,
                "profileName": "BRAF V600E MAPK1 P58L"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14752,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58M in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30285,
                "profileName": "BRAF V600E MAPK1 P58M"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14753,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58N in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30286,
                "profileName": "BRAF V600E MAPK1 P58N"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14754,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58R in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30289,
                "profileName": "BRAF V600E MAPK1 P58R"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14755,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58S in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30290,
                "profileName": "BRAF V600E MAPK1 P58S"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14756,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58W in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30293,
                "profileName": "BRAF V600E MAPK1 P58W"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14758,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 P58Y in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30294,
                "profileName": "BRAF V600E MAPK1 P58Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14762,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105F in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30295,
                "profileName": "BRAF V600E MAPK1 Q105F"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14765,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105I in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30296,
                "profileName": "BRAF V600E MAPK1 Q105I"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14768,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105T in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30298,
                "profileName": "BRAF V600E MAPK1 Q105T"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14769,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105V in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30299,
                "profileName": "BRAF V600E MAPK1 Q105V"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14770,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105W in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30300,
                "profileName": "BRAF V600E MAPK1 Q105W"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14771,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105Y in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30301,
                "profileName": "BRAF V600E MAPK1 Q105Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14772,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105N in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30297,
                "profileName": "BRAF V600E MAPK1 Q105N"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14773,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105V in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30299,
                "profileName": "BRAF V600E MAPK1 Q105V"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14778,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105W in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30300,
                "profileName": "BRAF V600E MAPK1 Q105W"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14780,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q105Y in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30301,
                "profileName": "BRAF V600E MAPK1 Q105Y"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14781,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q62P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30302,
                "profileName": "BRAF V600E MAPK1 Q62P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14782,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q62P in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30302,
                "profileName": "BRAF V600E MAPK1 Q62P"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14784,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 S57F in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30306,
                "profileName": "BRAF V600E MAPK1 S57F"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14786,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68D in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30310,
                "profileName": "BRAF V600E MAPK1 T68D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14787,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68N in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30316,
                "profileName": "BRAF V600E MAPK1 T68N"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14788,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68Y in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30319,
                "profileName": "BRAF V600E MAPK1 T68Y"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14791,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 V51H in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30322,
                "profileName": "BRAF V600E MAPK1 V51H"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14793,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36C in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30325,
                "profileName": "BRAF V600E MAPK1 Y36C"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14795,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36D in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30326,
                "profileName": "BRAF V600E MAPK1 Y36D"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14797,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36G in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30328,
                "profileName": "BRAF V600E MAPK1 Y36G"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14798,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36H in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30329,
                "profileName": "BRAF V600E MAPK1 Y36H"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14799,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36I in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30330,
                "profileName": "BRAF V600E MAPK1 Y36I"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14804,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36L in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30331,
                "profileName": "BRAF V600E MAPK1 Y36L"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14805,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36M in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30332,
                "profileName": "BRAF V600E MAPK1 Y36M"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14806,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36N in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30333,
                "profileName": "BRAF V600E MAPK1 Y36N"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14807,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36Q in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30334,
                "profileName": "BRAF V600E MAPK1 Y36Q"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14808,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36R in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30335,
                "profileName": "BRAF V600E MAPK1 Y36R"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14809,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36S in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30342,
                "profileName": "BRAF V600E MAPK1 Y36S"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14810,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36T in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30344,
                "profileName": "BRAF V600E MAPK1 Y36T"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14811,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36V in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30345,
                "profileName": "BRAF V600E MAPK1 Y36V"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14814,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64I in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30355,
                "profileName": "BRAF V600E MAPK1 Y64I"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14815,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64K in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30356,
                "profileName": "BRAF V600E MAPK1 Y64K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14817,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64L in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30357,
                "profileName": "BRAF V600E MAPK1 Y64L"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64M in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30358,
                "profileName": "BRAF V600E MAPK1 Y64M"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14820,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64R in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30361,
                "profileName": "BRAF V600E MAPK1 Y64R"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14822,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64V in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30364,
                "profileName": "BRAF V600E MAPK1 Y64V"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14824,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 V49A in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30321,
                "profileName": "BRAF V600E MAPK1 V49A"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14825,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 V51K in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30323,
                "profileName": "BRAF V600E MAPK1 V51K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14827,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y43E in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30348,
                "profileName": "BRAF V600E MAPK1 Y43E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14828,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y43W in melanoma cells harboring BRAF V600E conferred resistance to SCH772984-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30349,
                "profileName": "BRAF V600E MAPK1 Y43W"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14831,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 S57F in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30306,
                "profileName": "BRAF V600E MAPK1 S57F"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14833,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Q97R in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30303,
                "profileName": "BRAF V600E MAPK1 Q97R"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 R15P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30304,
                "profileName": "BRAF V600E MAPK1 R15P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14835,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 R67I in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30305,
                "profileName": "BRAF V600E MAPK1 R67I"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14837,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 S57G in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30307,
                "profileName": "BRAF V600E MAPK1 S57G"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14838,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 S57P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30308,
                "profileName": "BRAF V600E MAPK1 S57P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14841,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T110P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30309,
                "profileName": "BRAF V600E MAPK1 T110P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14843,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68D in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30310,
                "profileName": "BRAF V600E MAPK1 T68D"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14844,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68F in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30311,
                "profileName": "BRAF V600E MAPK1 T68F"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14845,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68H in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30312,
                "profileName": "BRAF V600E MAPK1 T68H"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14847,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68I in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30313,
                "profileName": "BRAF V600E MAPK1 T68I"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14848,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68L in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30314,
                "profileName": "BRAF V600E MAPK1 T68L"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14849,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68M in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30315,
                "profileName": "BRAF V600E MAPK1 T68M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14850,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68N in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30316,
                "profileName": "BRAF V600E MAPK1 T68N"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14851,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30317,
                "profileName": "BRAF V600E MAPK1 T68P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14852,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68Q in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30318,
                "profileName": "BRAF V600E MAPK1 T68Q"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14853,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 T68Y in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30319,
                "profileName": "BRAF V600E MAPK1 T68Y"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 V39A in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30320,
                "profileName": "BRAF V600E MAPK1 V39A"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14855,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 V51H in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30322,
                "profileName": "BRAF V600E MAPK1 V51H"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36A in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30324,
                "profileName": "BRAF V600E MAPK1 Y36A"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36C in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30325,
                "profileName": "BRAF V600E MAPK1 Y36C"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36D in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30326,
                "profileName": "BRAF V600E MAPK1 Y36D"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36E in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30327,
                "profileName": "BRAF V600E MAPK1 Y36E"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14860,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36G in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30328,
                "profileName": "BRAF V600E MAPK1 Y36G"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14861,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36H in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30329,
                "profileName": "BRAF V600E MAPK1 Y36H"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14862,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36I in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30330,
                "profileName": "BRAF V600E MAPK1 Y36I"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14863,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36L in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30331,
                "profileName": "BRAF V600E MAPK1 Y36L"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14864,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36M in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30332,
                "profileName": "BRAF V600E MAPK1 Y36M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14865,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36N in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30333,
                "profileName": "BRAF V600E MAPK1 Y36N"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14866,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36Q in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30334,
                "profileName": "BRAF V600E MAPK1 Y36Q"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14867,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36R in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30335,
                "profileName": "BRAF V600E MAPK1 Y36R"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14868,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36S in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30342,
                "profileName": "BRAF V600E MAPK1 Y36S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14869,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36T in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30344,
                "profileName": "BRAF V600E MAPK1 Y36T"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14870,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y36V in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30345,
                "profileName": "BRAF V600E MAPK1 Y36V"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14871,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64A in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30350,
                "profileName": "BRAF V600E MAPK1 Y64A"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14872,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64C in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30351,
                "profileName": "BRAF V600E MAPK1 Y64C"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14873,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64D in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30352,
                "profileName": "BRAF V600E MAPK1 Y64D"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14874,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64E in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30353,
                "profileName": "BRAF V600E MAPK1 Y64E"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14875,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64G in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30354,
                "profileName": "BRAF V600E MAPK1 Y64G"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64I in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30355,
                "profileName": "BRAF V600E MAPK1 Y64I"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14877,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64K in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30356,
                "profileName": "BRAF V600E MAPK1 Y64K"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64L in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30357,
                "profileName": "BRAF V600E MAPK1 Y64L"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64M in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30358,
                "profileName": "BRAF V600E MAPK1 Y64M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64P in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30359,
                "profileName": "BRAF V600E MAPK1 Y64P"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64Q in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30360,
                "profileName": "BRAF V600E MAPK1 Y64Q"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64R in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30361,
                "profileName": "BRAF V600E MAPK1 Y64R"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14883,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64S in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30362,
                "profileName": "BRAF V600E MAPK1 Y64S"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14884,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64T in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30363,
                "profileName": "BRAF V600E MAPK1 Y64T"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14885,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of MAPK1 Y64V in melanoma cells harboring BRAF V600E conferred resistance to VRT11E-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30364,
                "profileName": "BRAF V600E MAPK1 Y64V"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14891,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 K54R in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30379,
                "profileName": "BRAF V600E MAPK1 K54R"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14894,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 E322K were resistant to Tafinlar (dabrafenib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30380,
                "profileName": "BRAF V600E MAPK1 E322K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14895,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 E322V were resistant to Tafinlar (dabrafenib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30381,
                "profileName": "BRAF V600E MAPK1 E322V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14897,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 D321V were resistant to Tafinlar (dabrafenib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30382,
                "profileName": "BRAF V600E MAPK1 D321V"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14898,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 D321N were resistant to Tafinlar (dabrafenib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30383,
                "profileName": "BRAF V600E MAPK1 D321N"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 E81K were resistant to Tafinlar (dabrafenib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30384,
                "profileName": "BRAF V600E MAPK1 E81K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 P58G were resistant to Tafinlar (dabrafenib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30280,
                "profileName": "BRAF V600E MAPK1 P58G"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 S142L were resistant to Tafinlar (dabrafenib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30385,
                "profileName": "BRAF V600E MAPK1 S142L"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14902,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 R191H in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30386,
                "profileName": "BRAF V600E MAPK1 R191H"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 T185A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30387,
                "profileName": "BRAF V600E MAPK1 T185A"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14904,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 K54R in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30379,
                "profileName": "BRAF V600E MAPK1 K54R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14905,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 E322K were resistant to Mekinist (trametinib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30380,
                "profileName": "BRAF V600E MAPK1 E322K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 E322V were resistant to Mekinist (trametinib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30381,
                "profileName": "BRAF V600E MAPK1 E322V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 D321V were resistant to Mekinist (trametinib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30382,
                "profileName": "BRAF V600E MAPK1 D321V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14908,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 D321N were resistant to Mekinist (trametinib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30383,
                "profileName": "BRAF V600E MAPK1 D321N"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14909,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 E81K were resistant to Mekinist (trametinib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30384,
                "profileName": "BRAF V600E MAPK1 E81K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14910,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 P58G were resistant to Mekinist (trametinib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30280,
                "profileName": "BRAF V600E MAPK1 P58G"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14911,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAPK1 S142L were resistant to Mekinist (trametinib)-mediated growth inhibition in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30385,
                "profileName": "BRAF V600E MAPK1 S142L"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14912,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 R191H in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30386,
                "profileName": "BRAF V600E MAPK1 R191H"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14913,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 T185A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30387,
                "profileName": "BRAF V600E MAPK1 T185A"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14914,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 K54R in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30379,
                "profileName": "BRAF V600E MAPK1 K54R"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14915,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 E322K in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30380,
                "profileName": "BRAF V600E MAPK1 E322K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14916,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 E322V in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30381,
                "profileName": "BRAF V600E MAPK1 E322V"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 D321V in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30382,
                "profileName": "BRAF V600E MAPK1 D321V"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14918,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 D321N in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30383,
                "profileName": "BRAF V600E MAPK1 D321N"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14919,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 E81K in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30384,
                "profileName": "BRAF V600E MAPK1 E81K"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 S142L in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30385,
                "profileName": "BRAF V600E MAPK1 S142L"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 R191H in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30386,
                "profileName": "BRAF V600E MAPK1 R191H"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14922,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 T185A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30387,
                "profileName": "BRAF V600E MAPK1 T185A"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14923,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 Y187A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30388,
                "profileName": "BRAF V600E MAPK1 Y187A"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14924,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 Y233A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30389,
                "profileName": "BRAF V600E MAPK1 Y233A"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14925,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 E322K and Y233A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30179,
                "profileName": "BRAF V600E MAPK1 Y233A MAPK1 E322K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14926,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 D321V and Y233A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30180,
                "profileName": "BRAF V600E MAPK1 Y233A MAPK1 D321V"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14927,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E and expressing MAPK1 E81K and Y233A in culture (PMID: 27760319).",
            "molecularProfile": {
                "id": 30181,
                "profileName": "BRAF V600E MAPK1 E81K MAPK1 Y233A"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9750,
                    "pubMedId": 27760319,
                    "title": "Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27760319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14929,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines with Braf V600E and overexpression of Mertk were resistant to Zelboraf (vemurafenib) (PMID: 29050198).",
            "molecularProfile": {
                "id": 30390,
                "profileName": "BRAF V600E MERTK over exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11796,
                    "pubMedId": 29050198,
                    "title": "mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29050198"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17209,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I trials, Belvarafenib (HM95573) treatment resulted in partial response in 44% (4/9) of patients with NRAS-mutant melanoma in a dose escalation study, and partial response in 22% (2/9) of NRAS-mutant melanoma patients in a dose expansion study (J Clin Oncol 37, 2019 (suppl; abstr 3000); NCT02405065, NCT03118817).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15236,
                    "pubMedId": null,
                    "title": "Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_248211.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14946,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Belvarafenib (HM95573) treatment resulted in an unconfirmed partial response in a patient with NRAS mutant melanoma (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2570-2570; NCT02405065).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11833,
                    "pubMedId": null,
                    "title": "First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2570"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15100,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring AGK-BRAF showed a response when treated with Mekinist (trametinib), as demonstrated by decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 10262,
                "profileName": "AGK - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15080,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, SD-101 in combination with Keytruda (pembrolizumab) resulted in an overall response of 78% (7/9), an estimated 12-month progression-free survival rate of 88% (8/9), and an overall survival rate of 89% (8/9) in patients with unresectable or metastatic malignant melanoma na\u00efve to anti-PD-1 therapy, and an overall response of 15% (2/13) in patients received prior anti-PD-1 therapy (PMID: 30154193; NCT02521870).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5166,
                "therapyName": "Pembrolizumab + SD-101",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12440,
                    "pubMedId": 30154193,
                    "title": "SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30154193"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15101,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring AGK-BRAF showed response when treated with SCH772984, as demonstrated by decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 10262,
                "profileName": "AGK - BRAF"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15102,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring ARMC10-BRAF showed no response when treated with Zelboraf (vemurafenib), as demonstrated by a lack of decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 21310,
                "profileName": "ARMC10 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15103,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring ARMC10-BRAF showed response when treated with Mekinist (trametinib), as demonstrated by decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 21310,
                "profileName": "ARMC10 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15104,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring ARMC10-BRAF showed response when treated with SCH772984, as demonstrated by decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 21310,
                "profileName": "ARMC10 - BRAF"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15105,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring SEPTIN3-BRAF showed no response when treated with Zelboraf (vemurafenib), as demonstrated by a lack of decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 30744,
                "profileName": "SEPTIN3 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15106,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring SEPTIN3-BRAF showed no response when treated with Mekinist (trametinib), as demonstrated by a lack of decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 30744,
                "profileName": "SEPTIN3 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15107,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring SEPTIN3-BRAF showed no response when treated with Ulixertinib (BVD-523), as demonstrated by a lack of decreased tumor volume (PMID: 30254212).",
            "molecularProfile": {
                "id": 30744,
                "profileName": "SEPTIN3 - BRAF"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15109,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OTS167 treatment of melanoma cells overexpressing Melk decreased cell proliferation and growth (PMID: 29212029).",
            "molecularProfile": {
                "id": 21948,
                "profileName": "MELK over exp"
            },
            "therapy": {
                "id": 3951,
                "therapyName": "OTS167",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12642,
                    "pubMedId": 29212029,
                    "title": "MELK Promotes Melanoma Growth by Stimulating the NF-\u03baB Pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29212029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16441,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CheckMate 067) that supported FDA approval, combination of Opdivo (nivolumab) and Yervoy (ipilimumab) and Opdivo (nivolumab) alone demonstrated improved efficacy compared to Yervoy (ipilimumab) in patients with untreated advanced melanoma, resulted in a median overall survival unreached in the combination arm, 36.9 and 19.9 months in nivolumab and ipilimumab monotherapy arms, and a median progression-free survival of 11.5, 6.9, and 2.9 months respectively (PMID: 30361170; NCT01844505).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14513,
                    "pubMedId": 30361170,
                    "title": "Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30361170"
                },
                {
                    "id": 15569,
                    "pubMedId": null,
                    "title": "Opdivo (nivolumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554"
                },
                {
                    "id": 15570,
                    "pubMedId": null,
                    "title": "Yervoy (ipilimumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15157,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) resulted in improved overall response rate (ORR) and pathologic complete response rate (pCR) compared to Opdivo (nivolumab) monotherapy in patients with stage III or IV melanoma, with a ORR of 73% (8/11) and pCR of 45% (5/11), however, demonstrated higher toxicity (PMID: 30297909; NCT02519322).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1627,
                "therapyName": "Ipilimumab + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 12751,
                    "pubMedId": 30297909,
                    "title": "Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30297909"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15181,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MGC018 demonstrated anti-tumor activity in cell line xenograft models of CD276 (B7-H3)-positive melanoma (Cancer Res 2018;78(13 Suppl):Abstract nr 820).",
            "molecularProfile": {
                "id": 27908,
                "profileName": "CD276 positive"
            },
            "therapy": {
                "id": 7459,
                "therapyName": "MGC018",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12775,
                    "pubMedId": null,
                    "title": "Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15188,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Zelboraf (vemurafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15189,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Tafinlar (dabrafenib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15190,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to PLX8394-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15191,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to TAK-632-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15192,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB3245 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 7465,
                "therapyName": "BGB3245",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15193,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB3290 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 7464,
                "therapyName": "BGB3290",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCH772984 resulted in similar inhibition of Erk phosphorylation and colony formation in melanoma cells expressing BRAF L514V in cis with V600E and cells expressing BRAF V600E alone in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 2618,
                "therapyName": "SCH772984",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15195,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells expressing BRAF L514V in cis with V600E demonstrated decreased response to Mekinist (trametinib)-induced inhibition of Erk phosphorylation and colony formation compared to cells expressing BRAF V600E in culture (PMID: 29880583).",
            "molecularProfile": {
                "id": 30813,
                "profileName": "BRAF L514V BRAF V600E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 12771,
                    "pubMedId": 29880583,
                    "title": "A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29880583"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15208,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Yervoy (ipilimumab) treatment resulted in a 68% (17/25) overall survival advantage of melanoma patients with high tumor mutational burden (greater than 100 mutations), but high TMB was not independently predictive of response (PMID: 25409260).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12825,
                    "pubMedId": 25409260,
                    "title": "Genetic basis for clinical response to CTLA-4 blockade in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25409260"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15209,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Yervoy (ipilimumab) treatment resulted in an overall survival advantage in melanoma patients that were ipilimumab-naive with high tumor mutational burden (greater than 100 mutations) (PMID: 29033130; NCT01621490).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12826,
                    "pubMedId": 29033130,
                    "title": "Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29033130"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15506,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) inhibited ERK activation and proliferation of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15511,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) did not inhibit ERK phosphorylation or proliferation of a melanoma cell line harboring BRAF G469V (PMID: 29903896).",
            "molecularProfile": {
                "id": 1777,
                "profileName": "BRAF G469V"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15519,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15523,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G464E and KRAS G12D in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31087,
                "profileName": "BRAF G464E KRAS G12D"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15532,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15534,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15536,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15540,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15541,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased proliferation compared to Mekinist (trametinib) alone in a melanoma cell line harboring BRAF G464E and KRAS G12D in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31087,
                "profileName": "BRAF G464E KRAS G12D"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15547,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth of a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15561,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited growth of melanoma cells harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15564,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) treatment inhibited ERK activation and proliferation of melanoma cell lines harboring BRAF L597S in culture, but did not result in tumor shrinkage as a single agent in a melanoma patient-derived xenograft (PDX) model harboring BRAF L597S (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15567,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) treatment did not result in significant growth inhibition in a melanoma cell line harboring BRAF G469V and NRAS Q61K in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31086,
                "profileName": "BRAF G469V NRAS Q61K"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15611,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Imlygic (talimogene laherparepvec) treatment resulted in significantly improved durable response rate (16.3% vs 2.1%, OR=8.9, p<0.001), overall response rate (26.4% vs 5.7%), and median overall survival (23.3 vs 18.9 months, HR=0.79, p=0.051) compared to GM-CSF in patients with melanoma (PMID: 26014293; NCT00769704).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2695,
                "therapyName": "Talimogene laherparepvec",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 13489,
                    "pubMedId": 26014293,
                    "title": "Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26014293"
                },
                {
                    "id": 15674,
                    "pubMedId": null,
                    "title": "Imlygic (talimogene laherparepvec) FDA Drug Label",
                    "url": "https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/imlygic-talimogene-laherparepvec"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15612,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mektovi (binimetinib) increased growth inhibition in patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and resulted in tumor shrinkage in 67% of tumors, increased inhibition of ERK phosphorylation, and increased tumor growth delay compared to either agent alone in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF R239Q BRAF L597S"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15613,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) inhibited ERK activation and proliferation of patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and delayed tumor growth and induced shrinkage in 8% (1/12) of tumors in a melanoma patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF R239Q BRAF L597S"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15614,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) inhibited growth of patient-derived melanoma cells harboring BRAF L597S, as well as BRAF R239Q, in culture, and induced tumor shrinkage in 25% (3/12) of tumors and delayed tumor growth in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF R239Q BRAF L597S"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15615,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in increased growth inhibition in melanoma cell lines harboring BRAF L597S in culture, and resulted in tumor shrinkage in 89% (17/19) of tumors in a patient-derived xenograft (PDX) model harboring BRAF L597S, and treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a objective response with 34% tumor shrinkage in the patient from which the PDX model was derived from (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15616,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a patient-derived melanoma cell line harboring BRAF L597S, as well as well as BRAF R239Q, in culture, and resulted in tumor shrinkage in 100% (13/13) of subcutaneous tumors, and decreased growth of intracranial tumors in a patient-derived xenograft (PDX) model (PMID: 29903896).",
            "molecularProfile": {
                "id": 31114,
                "profileName": "BRAF R239Q BRAF L597S"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Braftovi (encorafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 7661,
                "therapyName": "Encorafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Braftovi (encorafenib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 796,
                "therapyName": "Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Tafinlar (dabrafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Zelboraf (vemurafenib) to treatment with Mekinist (trametinib) resulted in increased growth inhibition in a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15622,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture, and resulted in tumor shrinkage in 75% (8/12) subcutaneous tumors in one patient-derived xenograft (PDX) model harboring BRAF L597S that also harbored a BRAF variant of unknown significance, BRAF R239Q, however, was not sufficient to induce tumor shrinkage in a second PDX model with BRAF L597S, resulting only in tumor growth delay (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15623,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15624,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15625,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15626,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) inhibited growth of a melanoma cell line harboring BRAF K601E, as well as BRAF S363F, in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 31117,
                "profileName": "BRAF S363F BRAF K601E"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15627,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) inhibited growth of melanoma cell lines harboring BRAF L597S in culture (PMID: 29903896).",
            "molecularProfile": {
                "id": 994,
                "profileName": "BRAF L597S"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13465,
                    "pubMedId": 29903896,
                    "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29903896"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15705,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ulixertinib (BVD-523) inhibited Erk signaling in melanoma cells harboring BRAF V600E, resulted in cell cycle arrest in culture and tumor growth inhibition in cell line xenograft models (PMID: 28939558).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 997,
                "therapyName": "Ulixertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11466,
                    "pubMedId": 28939558,
                    "title": "Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28939558"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15734,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13705,
                    "pubMedId": 30630828,
                    "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15735,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600K (n=19) had increased tumor mutational burden and greater response rates (53% vs. 29%, p=0.059), progression-free survival (19 vs. 2.7 months, p=0.049), and overall survival (20.4 vs. 11.7 months, p=0.081) relative to patients with BRAF V600E (n=84) when treated with Keytruda (pembrolizumab) (n=17 and 62 for BRAF V600K and V600E, respectively) or Opdivo (nivolumab) (n=2 and 22 for BRAF V600K and V600E, respectively) (PMID: 30630828).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13705,
                    "pubMedId": 30630828,
                    "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15736,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13705,
                    "pubMedId": 30630828,
                    "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15737,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma harboring BRAF V600E (n=84) had decreased response rates (29% vs. 53%, p=0.059), progression-free survival (2.7 vs. 19 months, p=0.049), and overall survival (11.7 vs. 20.4 months, p=0.081) relative to patients with BRAF V600K (n=19) when treated with Keytruda (pembrolizumab) (n=62 and 17 for BRAF V600E and V600K, respectively) or Opdivo (nivolumab) (n=22 and 2 for BRAF V600E and V600K, respectively) (PMID: 30630828).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13705,
                    "pubMedId": 30630828,
                    "title": "Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30630828"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15865,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combined Zelboraf (vemurafenib) and XL888 treatment in patients with unresectable, BRAF inhibitor naive, metastatic melanoma harboring BRAF V600E (n=20) or V600K (n=1) resulted in complete and partial responses in 15% (3/20) and 60% (12/20) of evaluable patients, respectively, a 9.2-month median progression free survival, and a 34.6-month overall survival (PMID: 29674508).",
            "molecularProfile": {
                "id": 499,
                "profileName": "BRAF V600E/K"
            },
            "therapy": {
                "id": 1217,
                "therapyName": "Vemurafenib + XL888",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13853,
                    "pubMedId": 29674508,
                    "title": "Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29674508"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15983,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 did not inhibit Erk phosphorylation or proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15989,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 decreased RAS-GTP level, inhibited Erk phosphorylation and proliferation of melanoma cells harboring NF1 Q1336* in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 30104724).",
            "molecularProfile": {
                "id": 31354,
                "profileName": "NF1 Q1336*"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15992,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited proliferation of melanoma cells harboring both NF1 L161* and NF1 Q282* mutations in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 31361,
                "profileName": "NF1 L161* NF1 Q282*"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15993,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RMC-4550 inhibited proliferation of melanoma cells harboring NF1 F1464L in culture (PMID: 30104724).",
            "molecularProfile": {
                "id": 31357,
                "profileName": "NF1 F1464L"
            },
            "therapy": {
                "id": 7839,
                "therapyName": "RMC-4550",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14089,
                    "pubMedId": 30104724,
                    "title": "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30104724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16164,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma (n=321) and a high tumor mutational burden (TMB) (>30.7 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with an unspecified PD-L1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 5248,
                "therapyName": "unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16165,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma (n=321) and a high tumor mutational burden (TMB) (>30.7 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with an unspecified PD-1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 3890,
                "therapyName": "unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16167,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma (n=321) and a high tumor mutational burden (TMB) (>30.7 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with an unspecified CTLA-4 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 5489,
                "therapyName": "unspecified CTLA4 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16168,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma (n=321) and a high tumor mutational burden (TMB) (>30.7 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with a combination of an unspecified CTLA-4 antibody and an unspecified PD-1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 6804,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16169,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, patients with melanoma (n=321) and a high tumor mutational burden (TMB) (>30.7 mutations/Mb) demonstrated an improved overall survival and progression-free survival compared to those patients with a low TMB when treated with a combination of an unspecified CTLA-4 antibody and an unspecified PD-L1 antibody (PMID: 30643254).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 7906,
                "therapyName": "unspecified CTLA4 antibody + unspecified PD-L1 antibody",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14282,
                    "pubMedId": 30643254,
                    "title": "Tumor mutational load predicts survival after immunotherapy across multiple cancer types.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30643254"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16230,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) treatment in melanoma cell lines with NRAS overexpression, but without NRAS or BRAF mutations, resulted in reduced downstream signaling and proliferation in cultured cells (PMID: 29245078).",
            "molecularProfile": {
                "id": 28584,
                "profileName": "NRAS over exp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14368,
                    "pubMedId": 29245078,
                    "title": "Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29245078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600D and knockdown of NRAS demonstrated a decreased response to Mektovi (binimetinib) relative to cells without NRAS knockdown in culture (PMID: 29245078).",
            "molecularProfile": {
                "id": 31592,
                "profileName": "BRAF V600D NRAS dec exp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14368,
                    "pubMedId": 29245078,
                    "title": "Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29245078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16316,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mektovi (binimetinib) treatment resulted in reduced tumor growth and proliferation in two patient-derived xenograft (PDX) melanoma models with NRAS copy number gain and without BRAF or NRAS mutations (PMID: 29245078).",
            "molecularProfile": {
                "id": 18235,
                "profileName": "NRAS amp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14368,
                    "pubMedId": 29245078,
                    "title": "Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29245078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16439,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (CheckMate-066), Opdivo (nivolumab) treatment resulted in improved overall survival and response compared to treatment with Deticene (dacarbazine) in melanoma patients with wild-type BRAF, including a 3-year overall survival (OS) rate of 51.2% vs. 21.6%, a median OS of 37.5 months vs. 11.2 months, a complete response in 19% (40/210) vs. 1.4% (3/208), and a partial response in 23.8% (50/210) vs. 13% (27/208), respectively (PMID: 30422243; NCT01721772).",
            "molecularProfile": {
                "id": 4,
                "profileName": "BRAF wild-type"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14511,
                    "pubMedId": 30422243,
                    "title": "Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30422243"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16564,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a melanoma patient developed progressive disease after initial response to Tafinlar (dabrafinib) and Mekinist (trametinib) combination treatment, BRAF V47_D380del was identified as an acquired mutation in the progressing lesion along with mutations presented in both primary and progressing lesions, including BRAF V600E, PTEN G129E, CDKN2A/B loss, and TERT promoter mutations (PMID: 29171936).",
            "molecularProfile": {
                "id": 31680,
                "profileName": "BRAF V47_D380del"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14627,
                    "pubMedId": 29171936,
                    "title": "BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29171936"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JSH-150 inhibited proliferation of a melanoma cell line in culture (PMID: 30253346).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8108,
                "therapyName": "JSH-150",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14640,
                    "pubMedId": 30253346,
                    "title": "Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30253346"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16789,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, infusion of transgenic lymphocyte engineered to express NY-ESO-1-specific T-cell receptor together with NY-ESO-1 peptide-pulsed DC vaccine and Yervoy (ipilimumab) demonstrated initial antitumor activity at day 30 in 1 of 2 patients with CTAG1B (NY-ESO-1)-positive melanoma, but did not result in objective response at day 90 (PMID: 30573690; NCT01697527).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 8197,
                "therapyName": "Ipilimumab + NY-ESO-1 peptide vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14911,
                    "pubMedId": 30573690,
                    "title": "A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30573690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16942,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, melanoma patients with B2M loss of heterozygosity were threefold less likely to respond to Yervoy (ipilimumab) treatment, as compared to patients without loss of B2M (PMID: 29070816).",
            "molecularProfile": {
                "id": 32261,
                "profileName": "B2M loss"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11969,
                    "pubMedId": 29070816,
                    "title": "Resistance to checkpoint blockade therapy through inactivation of antigen presentation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29070816"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16943,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, melanoma patients with B2M loss of heterozygosity were threefold less likely to respond to Keytruda (pembrolizumab) treatment, as compared to patients without loss of B2M (PMID: 29070816).",
            "molecularProfile": {
                "id": 32261,
                "profileName": "B2M loss"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11969,
                    "pubMedId": 29070816,
                    "title": "Resistance to checkpoint blockade therapy through inactivation of antigen presentation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29070816"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16952,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14457,
                    "pubMedId": 30219628,
                    "title": "Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30219628"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16953,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453), and both BRAF V600E and V600K are on the companion diagnostic.",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11562,
                    "pubMedId": 29573941,
                    "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29573941"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16954,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) resulted in a median overall survival (OS) of 33.6 months, a 1-year OS rate of 77.5%, and a 2-year OS rate of 57.7% in patients with advanced melanoma harboring BRAF V600E/K mutations compared to a median OS of 16.9 months and 1- and 2-year OS rates of 63.1% and 43.2%, respectively, in the Zelboraf (vemurafenib) treated group (PMID: 30219628; NCT01909453).",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14457,
                    "pubMedId": 30219628,
                    "title": "Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30219628"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16955,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COLUMBUS) trial that supported FDA approval, Braftovi (encorafenib) in combination with Mektovi (binimetinib) demonstrated improved tolerability profile and efficacy, resulted in a progression-free survival of 14.9 months in patients with advanced melanoma harboring BRAF V600E/K mutations, comparing to 7.3 months in the Zelboraf (vemurafenib) group (HR=0.54, p<0.0001) (PMID: 29573941; NCT01909453) and both BRAF V600E and BRAF V600K are on the companion diagnostic.",
            "molecularProfile": {
                "id": 2,
                "profileName": "BRAF V600K"
            },
            "therapy": {
                "id": 1100,
                "therapyName": "Binimetinib + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11562,
                    "pubMedId": 29573941,
                    "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29573941"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15455,
                    "pubMedId": null,
                    "title": "Braftovi (encorafenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496"
                },
                {
                    "id": 15456,
                    "pubMedId": null,
                    "title": "Mektovi (binimetinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring an NRAS mutation were sensitive to the combination therapy of Ibrance (palbociclib) and Mekinist (trametinib) in culture, demonstrating reduced cell viability, colony formation, and pathway activity, and increased cell cycle arrest (PMID: 30819666).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17045,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing AKT1 were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32305,
                "profileName": "AKT1 pos NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing AKT2 were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32306,
                "profileName": "AKT2 pos NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17047,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, four of four NRAS-mutant melanoma cell lines expressing PIK3CA E545K were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32308,
                "profileName": "NRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17048,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of four NRAS-mutant melanoma cell lines expressing EGFR L858R were resistant to the combination treatment of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32309,
                "profileName": "EGFR L858R NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17049,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing AKT1 demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32305,
                "profileName": "AKT1 pos NRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17050,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing AKT2 demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32306,
                "profileName": "AKT2 pos NRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing PIK3CA H1047R demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32307,
                "profileName": "NRAS mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17052,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cell lines expressing PIK3CA E545K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32308,
                "profileName": "NRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17068,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, MIW815 (ADUS100), in combination with Spartalizumab (PDR001), demonstrated preliminary efficacy in PD-1 (PDCD1)-relapsed/refractory melanoma (J of Clin Oncol 37, 2019 (suppl; abstr 2507); NCT03172936).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6219,
                "therapyName": "MIW815 + Spartalizumab",
                "synonyms": "ADU-S100 + Spartalizumab"
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15188,
                    "pubMedId": null,
                    "title": "Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.2507"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17210,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In Phase I trials, Belvarafenib (HM95573) treatment resulted in partial response in a patients with BRAF-mutant melanoma in a dose escalation study, and partial response in 33% (2/6) of BRAF-mutant melanoma patients in a dose expansion study (J Clin Oncol 37, 2019 (suppl; abstr 3000); NCT02405065, NCT03118817).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 7209,
                "therapyName": "Belvarafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15236,
                    "pubMedId": null,
                    "title": "Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study.",
                    "url": "http://abstracts.asco.org/239/AbstView_239_248211.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17234,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, MBG453 and Spartalizumab (PDR001) combination treatment resulted in stable disease in 5 patients with melanoma, including cutaneous melanoma (n=2), uveal melanoma (n=2), and non-cutaneous melanoma (n=1) (AACR Annual Meeting 2019, Abstract CT183; NCT02608268).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8396,
                "therapyName": "MBG453 + Spartalizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15246,
                    "pubMedId": null,
                    "title": "Phase (Ph) I/II study of MBG453\u00b1 spartalizumab (PDR001) in patients (pts) with advanced malignancies",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/9834"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17248,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic melanoma harboring GOLGA4-RAF1 was sensitive to treatment with Mekinist (trametinib), demonstrating a significant extracranial response (PMID: 30835257).",
            "molecularProfile": {
                "id": 32399,
                "profileName": "GOLGA4 - RAF1"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15243,
                    "pubMedId": 30835257,
                    "title": "Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30835257"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17250,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of two NRAS-mutant melanoma cell lines with AKT1 expression demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32305,
                "profileName": "AKT1 pos NRAS mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17251,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, one of two NRAS-mutant melanoma cell lines expressing EGFR L858R demonstrated a decreased response to Mekinist (trametinib) when compared to control in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32309,
                "profileName": "EGFR L858R NRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17297,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment resulted in worsened condition and continued disease progression and metastasis in a patient with metastatic melanoma harboring KIT T632I (PMID: 31043947).",
            "molecularProfile": {
                "id": 2468,
                "profileName": "KIT T632I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15346,
                    "pubMedId": 31043947,
                    "title": "Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31043947"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17330,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of two NRAS-mutant melanoma cell lines with AKT2 expression demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32306,
                "profileName": "AKT2 pos NRAS mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17331,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of two NRAS-mutant melanoma cell lines expressing PIK3CA E545K demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32308,
                "profileName": "NRAS mut PIK3CA E545K"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17333,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, two of two NRAS-mutant melanoma cell lines expressing EGFR L858R were resistant to treatment with Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32309,
                "profileName": "EGFR L858R NRAS mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17335,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, four of four NRAS-mutant melanoma cell lines expressing KRAS G13D were resistant to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32505,
                "profileName": "KRAS G13D NRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17336,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cell lines expressing KRAS G13D were resistant to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32505,
                "profileName": "KRAS G13D NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17337,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cells expressing KRAS G13D demonstrated a decreased response to treatment with Ibrance (palbociclib) in culture when compared to control (PMID: 30819666).",
            "molecularProfile": {
                "id": 32505,
                "profileName": "KRAS G13D NRAS mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17338,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61L demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32506,
                "profileName": "NRAS Q61L NRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17339,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61L demonstrated resistance to the combination treatment with Mekinist (trametinib) and Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32506,
                "profileName": "NRAS Q61L NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61L demonstrated a decreased response to treatment with Ibrance (palbociclib) in culture when compared to control (PMID: 30819666).",
            "molecularProfile": {
                "id": 32506,
                "profileName": "NRAS Q61L NRAS mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17341,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32507,
                "profileName": "NRAS Q61K NRAS mut"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61K demonstrated resistance to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture (PMID: 30819666).",
            "molecularProfile": {
                "id": 32507,
                "profileName": "NRAS Q61K NRAS mut"
            },
            "therapy": {
                "id": 1368,
                "therapyName": "Palbociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17343,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NRAS-mutant melanoma cells expressing NRAS Q61K demonstrated a decreased response to treatment with Ibrance (palbociclib) in culture compared to control (PMID: 30819666).",
            "molecularProfile": {
                "id": 32507,
                "profileName": "NRAS Q61K NRAS mut"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15157,
                    "pubMedId": 30819666,
                    "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30819666"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17427,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PD-L1 (CD274) expression in primary melanomas, but not the PD-L1 status of advancing edges or metastases, was associated with higher 6-month objective response rate (35.7% in PD-L1 positive vs. 5% in PD-L1 negative; p=0.02) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma (PMID: 29973670).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15485,
                    "pubMedId": 29973670,
                    "title": "Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29973670"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17428,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, PD-L1 (CD274) expression in primary melanomas, but not the PD-L1 status of advancing edges or metastases, was associated with higher 6-month objective response rate (35.7% in PD-L1 positive vs. 5% in PD-L1 negative; p=0.02) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma (PMID: 29973670).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15485,
                    "pubMedId": 29973670,
                    "title": "Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29973670"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17429,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, NRAS mutations were associated with higher 6-month objective response rate (53.3% vs. 19.6% without NRAS mutations; p=0.019) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma, however, progression-free survival and overall survival were similar between patients with and without NRAS mutations (PMID: 29973670).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15485,
                    "pubMedId": 29973670,
                    "title": "Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29973670"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17430,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, NRAS mutations were associated with higher 6-month objective response rate (53.3% vs. 19.6% without NRAS mutations; p=0.019) following treatment with Keytruda (pembrolizumab) or Opdivo (nivolumab) in patients with metastatic melanoma, however, progression-free survival and overall survival were similar between patients with and without NRAS mutations (PMID: 29973670).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15485,
                    "pubMedId": 29973670,
                    "title": "Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29973670"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17901,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination therapy of Tecentriq (atezolizumab) and Zelboraf (vemurafenib) in patients with metastatic melanoma harboring a BRAF V600 mutation resulted in a best objective response rate of 76.5% (13/17), with a complete response in 17.6% (3/17), a median progression-free survival of 10.9 months, a median overall survival of 46.2 months, and median duration of confirmed response of 10.6 months (PMID: 31171876; NCT01656642).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1216,
                "therapyName": "Atezolizumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15863,
                    "pubMedId": 31171876,
                    "title": "Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31171876"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17953,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JQ1 reduced tumor growth in syngeneic mouse melanoma models (PMID: 31018997).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15920,
                    "pubMedId": 31018997,
                    "title": "SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31018997"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17959,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SF2523 reduced tumor growth and decreased lung metastasis in syngeneic mouse melanoma models (PMID: 31018997).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8652,
                "therapyName": "SF2523",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15920,
                    "pubMedId": 31018997,
                    "title": "SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31018997"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18272,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a combined analysis of patients with melanoma treated with either Opdivo (nivolumab), Keytruda (pembrolizumab), Yervoy (ipilimumab), or Tremelimumab showed patients with mutant TTN versus those without mutant TTN had a greater overall survival (691 days vs 325 days, respectively) (PMID: 31092729).",
            "molecularProfile": {
                "id": 32956,
                "profileName": "TTN mutant"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16089,
                    "pubMedId": 31092729,
                    "title": "Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18273,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a combined analysis of patients with melanoma treated with either Opdivo (nivolumab), Keytruda (pembrolizumab), Yervoy (ipilimumab), or Tremelimumab showed patients with mutant TTN versus those without mutant TTN had a greater overall survival (691 days vs 325 days, respectively) (PMID: 31092729).",
            "molecularProfile": {
                "id": 32956,
                "profileName": "TTN mutant"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16089,
                    "pubMedId": 31092729,
                    "title": "Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18274,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a combined analysis of patients with melanoma treated with either Opdivo (nivolumab), Keytruda (pembrolizumab), Yervoy (ipilimumab), or Tremelimumab showed patients with mutant TTN versus those without mutant TTN had a greater overall survival (691 days vs 325 days, respectively) (PMID: 31092729).",
            "molecularProfile": {
                "id": 32956,
                "profileName": "TTN mutant"
            },
            "therapy": {
                "id": 779,
                "therapyName": "Ipilimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16089,
                    "pubMedId": 31092729,
                    "title": "Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18275,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a combined analysis of patients with melanoma treated with either Opdivo (nivolumab), Keytruda (pembrolizumab), Yervoy (ipilimumab), or Tremelimumab showed patients with mutant TTN versus those without mutant TTN had a greater overall survival (691 days vs 325 days, respectively) (PMID: 31092729).",
            "molecularProfile": {
                "id": 32956,
                "profileName": "TTN mutant"
            },
            "therapy": {
                "id": 1652,
                "therapyName": "Tremelimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16089,
                    "pubMedId": 31092729,
                    "title": "Titin mutation associated with responsiveness to checkpoint blockades in solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31092729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18319,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, response to A-485 treatment was associated with high MITF expression in melanoma cell lines in culture (PMID: 30266801).",
            "molecularProfile": {
                "id": 33157,
                "profileName": "MITF positive"
            },
            "therapy": {
                "id": 6354,
                "therapyName": "A-485",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16130,
                    "pubMedId": 30266801,
                    "title": "Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266801"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18486,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ZT-12-037-01 treatment inhibited cell proliferation and colony formation in human melanoma cells expressing NRAS Q61R and STK19 D89N, and reduced tumor growth in a cell line xenograft model (PMID: 30712867).",
            "molecularProfile": {
                "id": 33327,
                "profileName": "NRAS Q61R STK19 D89N"
            },
            "therapy": {
                "id": 8729,
                "therapyName": "ZT-12-037-01",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15787,
                    "pubMedId": 30712867,
                    "title": "Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30712867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18487,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ZT-12-037-01 treatment induced apoptosis and inhibited cell proliferation and colony formation in culture and reduced tumor growth and increased survival in cell line xenograft models of melanoma harboring wild-type STK19 and NRAS Q61R (PMID: 30712867).",
            "molecularProfile": {
                "id": 33400,
                "profileName": "NRAS Q61R STK19 wild-type"
            },
            "therapy": {
                "id": 8729,
                "therapyName": "ZT-12-037-01",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15787,
                    "pubMedId": 30712867,
                    "title": "Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30712867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18488,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line expressing STK19 V134Y that also harbors NRAS Q61R demonstrated resistance to ZT-12-037-01 treatment in culture (PMID: 30712867).",
            "molecularProfile": {
                "id": 33321,
                "profileName": "STK19 V134Y"
            },
            "therapy": {
                "id": 8729,
                "therapyName": "ZT-12-037-01",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15787,
                    "pubMedId": 30712867,
                    "title": "Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30712867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18489,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line expressing STK19 L139F that also harbors NRAS Q61R demonstrated resistance to ZT-12-037-01 treatment in culture (PMID: 30712867).",
            "molecularProfile": {
                "id": 33322,
                "profileName": "STK19 L139F"
            },
            "therapy": {
                "id": 8729,
                "therapyName": "ZT-12-037-01",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15787,
                    "pubMedId": 30712867,
                    "title": "Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30712867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18530,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cell lines harboring BRAF V600E and wild-type STK19 demonstrated reduced inhibition of cell proliferation and induction of apoptosis compared to cells harboring NRAS Q61R and wild-type STK19 in culture when treated with ZT-12-037-01 (PMID: 30712867).",
            "molecularProfile": {
                "id": 33402,
                "profileName": "BRAF V600E STK19 wild-type"
            },
            "therapy": {
                "id": 8729,
                "therapyName": "ZT-12-037-01",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 15787,
                    "pubMedId": 30712867,
                    "title": "Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30712867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18845,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Kisqali (ribociclib) combination treatment resulted in enhanced tumor growth inhibition in xenograft models of melanoma cells expressing ZNF767-BRAF (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 4472,
                "therapyName": "Ribociclib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18846,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Kisqali (ribociclib) combination treatment resulted in enhanced growth inhibition of melanoma cells expressing ZNF767-BRAF in culture and in xenograft models (PMID: 28092667).",
            "molecularProfile": {
                "id": 21341,
                "profileName": "ZNF767 - BRAF"
            },
            "therapy": {
                "id": 1974,
                "therapyName": "Buparlisib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14048,
                    "pubMedId": 28092667,
                    "title": "Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28092667"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18847,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in disease progression within 2 months in a patient with melanoma harboring BRAF V600E and an acquired AGAP3-BRAF fusion (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18851,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AGAP3-BRAF in melanoma cells harboring BRAF V600E conferred resistance to PLX4720-induced inhibition of MAPK signaling and growth in culture (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18854,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) inhibited MAPK signaling and growth of melanoma cells harboring BRAF V600E and expressing AGAP3-BRAF in culture (PMID: 28539463).",
            "molecularProfile": {
                "id": 28367,
                "profileName": "AGAP3 - BRAF BRAF V600E"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9931,
                    "pubMedId": 28539463,
                    "title": "BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28539463"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19231,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-06840003 inhibited tumor growth in a syngeneic mouse model of melanoma (PMID: 30232146).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8945,
                "therapyName": "PF-06840003",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16799,
                    "pubMedId": 30232146,
                    "title": "Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30232146"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19249,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AsiDNA inhibited survival of melanoma cell lines in culture (PMID: 27559053).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8967,
                "therapyName": "AsiDNA",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16843,
                    "pubMedId": 27559053,
                    "title": "Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27559053"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19250,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AsiDNA treatment led to increased sensitivity to Lynparza (olaparib), resulting in decreased survival of melanoma cell lines in culture (PMID: 27559053).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8968,
                "therapyName": "AsiDNA + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16843,
                    "pubMedId": 27559053,
                    "title": "Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27559053"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19432,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination of CP-870,893 and Tremelimumab was well-tolerated, and metastatic melanoma patients treated with CP-870,893 and Tremelimumab combination therapy demonstrated an objective response rate of 27.3% (6/22; 2 complete and 4 partial responses), a median progression-free survival of 3.2 months, and median overall survival of 23.6 months, with a 45-month median follow-up (PMID: 30288340; NCT01103635).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9011,
                "therapyName": "CP-870,893 + Tremelimumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17017,
                    "pubMedId": 30288340,
                    "title": "Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30288340"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19435,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19436,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19437,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with melanoma harboring BRAF V600E developed progressive disease after 12 weeks of Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment, and progressed again after 106 weeks on anti-PD1 therapy including Opdivo (nivolumab) (90 weeks) followed by Keytruda (pembrolizumab), B2M V5Lfs*30, LRP1B W1344*, MAP2K2 F133L, NF2 Y66*, and TP53 C238F were identified in the post-progression biopsy in addition to BRAF V600E (PMID: 31082388).",
            "molecularProfile": {
                "id": 34105,
                "profileName": "B2M V5Lfs*30 BRAF V600E LRP1B W1344* MAP2K2 F133L NF2 Y66* TP53 C238F"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17019,
                    "pubMedId": 31082388,
                    "title": "Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31082388"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19523,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model with cutaneous melanoma harboring MAP3K1 E864* demonstrated reduced tumor volume when treated with Mektovi (binimetinib) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34165,
                "profileName": "MAP3K1 E864*"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19526,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model with cutaneous melanoma harboring MAP3K1 P938F demonstrated reduced tumor volume when treated with Mektovi (binimetinib) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34184,
                "profileName": "MAP3K1 P938F"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19528,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient-derived xenograft (PDX) model with cutaneous melanoma harboring MAP3K1 A122V demonstrated reduced tumor volume when treated with Mektovi (binimetinib) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34183,
                "profileName": "MAP3K1 A122V"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19670,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (MIRACULUM), Prolgolimab demonstrated safety and preliminary efficacy, resulted in an objective response rate (ORR) of 38% (24/63, 5 complete response (CR), 19 partial response (PR)) and a disease control rate (DCR) of 64% when administered at 1mg/kg Q2W, and an ORR of 29% (18/63, 2 CR, 16 PR) with a DCR of 46% when administered at 3mg/kg Q3W, in patients with advanced melanoma (Annals of Oncology, Volume 30, Issue Supplement_11, December 2019, Abstract 119P; NCT03269565).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9166,
                "therapyName": "Prolgolimab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17453,
                    "pubMedId": null,
                    "title": "Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma",
                    "url": "https://academic.oup.com/annonc/article-abstract/30/Supplement_11/mdz451.027/5675195?redirectedFrom=fulltext"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19720,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-1 antibody treatment supplemented with VE800 inhibited tumor growth in a transgenic mouse model of melanoma harboring PTEN loss and BRAF V600E (PMID: 30675064).",
            "molecularProfile": {
                "id": 23099,
                "profileName": "BRAF V600E PTEN loss"
            },
            "therapy": {
                "id": 9185,
                "therapyName": "unspecified PD-1 antibody + VE800",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17522,
                    "pubMedId": 30675064,
                    "title": "A defined commensal consortium elicits CD8 T cells and anti-cancer immunity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30675064"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19922,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment demonstrated safety and preliminary clinical activity, resulted in a confirmed response in 41% (9/22) of patients with melanoma, regardless of KRAS/BRAF status (PMID: 30918950; NCT01988896).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1343,
                "therapyName": "Atezolizumab + Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17616,
                    "pubMedId": 30918950,
                    "title": "Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30918950"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19991,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTAP deficiency was associated with sensitivity to GSK3368715 in melanoma cell lines in culture (PMID: 31257072).",
            "molecularProfile": {
                "id": 29040,
                "profileName": "MTAP loss"
            },
            "therapy": {
                "id": 9261,
                "therapyName": "GSK3368715",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17642,
                    "pubMedId": 31257072,
                    "title": "Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257072"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20161,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Ina Phase Ib/II trial, Lenvima (lenvatinib) and Keytruda (pembrolizumab) combination treatment demonstrated safety and efficacy, resulted in an objective response rate of 48% (10/21) in patients with metastatic melanoma, with a median duration of response of 12.5 months, and a median progression-free survival of 5.5 months (PMID: 31961766; NCT02501096).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4782,
                "therapyName": "Lenvatinib + Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17720,
                    "pubMedId": 31961766,
                    "title": "Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31961766"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20440,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COMBI-AD) trial, Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy compared to placebo resulted in more benefit (HR=0.49, p<0.0001) in TMB low patients with resected melanoma harboring BRAF V600E or V600K, than in TMB high (HR=0.75, p=0.27) patients, however, TMB was not associated with relapse-free survival in the combination treatment group (PMID: 32007138; NCT01682083).",
            "molecularProfile": {
                "id": 35176,
                "profileName": "BRAF V600E TMB low"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17843,
                    "pubMedId": 32007138,
                    "title": "Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32007138"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20441,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III (COMBI-AD) trial, Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy compared to placebo resulted in more benefit (HR=0.49, p<0.0001) in TMB low patients with resected melanoma harboring BRAF V600E or V600K, than in TMB high (HR=0.75, p=0.27) patients, however, TMB was not associated with relapse-free survival in the combination treatment group (PMID: 32007138; NCT01682083).",
            "molecularProfile": {
                "id": 35177,
                "profileName": "BRAF V600K TMB low"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17843,
                    "pubMedId": 32007138,
                    "title": "Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32007138"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20485,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Sirt6 expression through siRNA knockdown resulted in activation of IGF-1R/AKT pathway, conferred resistance to Tafinlar (dabrafenib) in melanoma cell lines and patient-derived melanoma cells harboring BRAF V600E in culture (PMID: 30143629).",
            "molecularProfile": {
                "id": 35191,
                "profileName": "BRAF V600E SIRT6 dec exp"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20486,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Sirt6 expression through siRNA knockdown resulted in activation of IGF-1R/AKT pathway, conferred resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in melanoma cell lines and patient-derived melanoma cells harboring BRAF V600E in culture (PMID: 30143629).",
            "molecularProfile": {
                "id": 35191,
                "profileName": "BRAF V600E SIRT6 dec exp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20490,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Sirt6 expression was identified in cells derived from patients with melanoma harboring BRAF V600E at times of disease progression while on Zelboraf (vemurafenib), and melanoma cell lines harboring BRAF V600E and with decreased Sirt6 expression through siRNA knockdown were resistance to Zelboraf (vemurafenib) in cell line xenograft models (PMID: 30143629).",
            "molecularProfile": {
                "id": 35191,
                "profileName": "BRAF V600E SIRT6 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20493,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Tafinlar (dabrafenib) and Linsitinib (OSI-906) enhanced inhibition of Igf1r and Akt phosphorylation, led to apoptosis and reduced proliferation in BRAF V600E melanoma cells with decreased Sirt6 expression via siRNA knockdown in culture, and tumor regression in cell line xenograft models (PMID: 30143629).",
            "molecularProfile": {
                "id": 35191,
                "profileName": "BRAF V600E SIRT6 dec exp"
            },
            "therapy": {
                "id": 9382,
                "therapyName": "Dabrafenib + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20495,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, increased Igfbp2 expression levels were detected at disease progression in patients with melanoma harboring BRAF V600E/K treated with Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy (PMID: 30143629).",
            "molecularProfile": {
                "id": 35204,
                "profileName": "BRAF V600E/K IGFBP2 over exp"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17876,
                    "pubMedId": 30143629,
                    "title": "SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30143629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20767,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ADP-A2M4 cells induced cytoxicity against MAGE-A4 positive melanoma cells in culture, and inhibited tumor growth, induced regression, and resulted in a 100% survival in cell line xenograft models (PMID: 32002290).",
            "molecularProfile": {
                "id": 32487,
                "profileName": "MAGEA4 positive"
            },
            "therapy": {
                "id": 7280,
                "therapyName": "ADP-A2M4 cells",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18034,
                    "pubMedId": 32002290,
                    "title": "Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32002290"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20954,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGI-134 treatment induced tumor regression, reduced formation of secondary lesions and increased survival in mouse models of melanoma (PMID: 31889898).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9446,
                "therapyName": "AGI-134",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18037,
                    "pubMedId": 31889898,
                    "title": "AGI-134: a fully synthetic \u03b1-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31889898"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21035,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600E was found to have BRAF V47_D380del and BCORL1 Q1076H mutations after acquiring resistance to Zelboraf (vemurafenib), and expression of BRAF V47_D380del and BCORL1 Q1076H in a BRAF V600E-positive melanoma cell line resulted in decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 29605720).",
            "molecularProfile": {
                "id": 35503,
                "profileName": "BCORL1 Q1076H BRAF V47_D380del BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18261,
                    "pubMedId": 29605720,
                    "title": "Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29605720"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21036,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of BRAF V47_D380del in a melanoma cell line harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 29605720).",
            "molecularProfile": {
                "id": 31704,
                "profileName": "BRAF V47_D380del BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18261,
                    "pubMedId": 29605720,
                    "title": "Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29605720"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21037,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of BCORL1 Q1076H resulted in decreased sensitivity to Zelboraf (vemurafenib) in a melanoma cell line harboring BRAF V600E in culture (PMID: 29605720).",
            "molecularProfile": {
                "id": 35504,
                "profileName": "BCORL1 Q1076H BRAF V600E"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18261,
                    "pubMedId": 29605720,
                    "title": "Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29605720"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21302,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of UNC2025 and Zelboraf (vemurafenib) resulted in greater inhibition of colony formation and apoptotic induction in melanoma cells harboring a BRAF mutation in culture and led to a higher degree of tumor growth inhibition in a patient derived xenograft (PDX) model of melanoma with a BRAF mutation when compared to either therapy alone (PMID: 30482852).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 9743,
                "therapyName": "UNC2025 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18602,
                    "pubMedId": 30482852,
                    "title": "Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30482852"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21303,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of UNC2025 and Cotellic (cobimetinib) resulted in greater inhibition of colony formation and apoptotic induction in melanoma cells harboring an NRAS mutation in culture when compared to either therapy alone (PMID: 30482852).",
            "molecularProfile": {
                "id": 3,
                "profileName": "NRAS mutant"
            },
            "therapy": {
                "id": 9744,
                "therapyName": "Cobimetinib + UNC2025",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18602,
                    "pubMedId": 30482852,
                    "title": "Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30482852"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21316,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGN-CD228A treatment delayed tumor growth in cell line xenograft models of melanoma (Cancer Res 2019;79(13 Suppl):Abstract nr 2688).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9761,
                "therapyName": "SGN-CD228A",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 18621,
                    "pubMedId": null,
                    "title": "SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2688"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00338377",
            "title": "Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00492505",
            "title": "Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2212,
                    "therapyName": "Cisplatin + Sorafenib + Tamoxifen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00538005",
            "title": "Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 2132,
                    "therapyName": "Bevacizumab + Oxaliplatin + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00700882",
            "title": "Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00720785",
            "title": "Natural Killer Cells and Bortezomib to Treat Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00925132",
            "title": "Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1737,
                    "therapyName": "Decitabine + Panobinostat + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00976573",
            "title": "Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",
            "phase": null,
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01028222",
            "title": "A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 829,
                    "therapyName": "Nilotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01176474",
            "title": "A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2696,
                    "therapyName": "NY-ESO-1 peptide vaccine",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01218867",
            "title": "Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 984,
                    "therapyName": "Anti-VEGFR2 CAR CD8 lymphocytes",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01239134",
            "title": "Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3613,
                    "therapyName": "TRX518",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01258855",
            "title": "Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 624,
                    "therapyName": "Aflibercept",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01274338",
            "title": "Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1299,
                    "therapyName": "Interferon alpha-2b",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01292655",
            "title": "Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2545,
                    "therapyName": "BMS-906024",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01303341",
            "title": "Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1724,
                    "therapyName": "Riluzole + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01307267",
            "title": "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6111,
                    "therapyName": "Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 5086,
                    "therapyName": "Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01321437",
            "title": "Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01323517",
            "title": "Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5900,
                    "therapyName": "Dactinomycin + Ipilimumab + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01325441",
            "title": "A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2586,
                    "therapyName": "Napabucasin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01351103",
            "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1937,
                    "therapyName": "LGK974",
                    "synonyms": null
                },
                {
                    "id": 7468,
                    "therapyName": "LGK974 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01366144",
            "title": "Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 954,
                    "therapyName": "Veliparib",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01391143",
            "title": "Safety Study of MGA271 in Refractory Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2863,
                    "therapyName": "MGA271",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01409174",
            "title": "IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 1141,
                    "therapyName": "Temozolomide",
                    "synonyms": null
                },
                {
                    "id": 1299,
                    "therapyName": "Interferon alpha-2b",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01425008",
            "title": "Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1034,
                    "therapyName": "MLN2480",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01436656",
            "title": "A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01449279",
            "title": "Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01480154",
            "title": "Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1393,
                    "therapyName": "Hydroxychloroquine + MK2206",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01495988",
            "title": "Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01497808",
            "title": "RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01512251",
            "title": "BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1322,
                    "therapyName": "Buparlisib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01519323",
            "title": "BRIM-P",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01533948",
            "title": "Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 649,
                    "therapyName": "Axitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01543698",
            "title": "A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1101,
                    "therapyName": "Binimetinib + Encorafenib + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01565837",
            "title": "Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma",
            "phase": "Phase II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01585415",
            "title": "Vemurafenib and White Blood Cell Therapy for Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 953,
                    "therapyName": "Vandetanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01586195",
            "title": "Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01603212",
            "title": "Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1188,
                    "therapyName": "Aldesleukin + Alpha 2 Interferon + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01619774",
            "title": "An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01621490",
            "title": "PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01625351",
            "title": "A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1207,
                    "therapyName": "Melphalan",
                    "synonyms": null
                },
                {
                    "id": 1206,
                    "therapyName": "Busulfan",
                    "synonyms": null
                },
                {
                    "id": 1205,
                    "therapyName": "Alemtuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01638676",
            "title": "A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1210,
                    "therapyName": "Metformin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01656642",
            "title": "A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf&#174;) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1216,
                    "therapyName": "Atezolizumab + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01657591",
            "title": "Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1217,
                    "therapyName": "Vemurafenib + XL888",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01659151",
            "title": "Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01667419",
            "title": "BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01682083",
            "title": "A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01682213",
            "title": "Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01683188",
            "title": "HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1229,
                    "therapyName": "Aldesleukin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01689974",
            "title": "Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01696045",
            "title": "Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01701037",
            "title": "Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01701674",
            "title": "Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01703507",
            "title": "Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01708941",
            "title": "Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1299,
                    "therapyName": "Interferon alpha-2b",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01721603",
            "title": "A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01726738",
            "title": "LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01738139",
            "title": "Ipilimumab and Imatinib Mesylate in Treating Participants With Metastatic or Unresectable Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1250,
                    "therapyName": "Imatinib + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01740297",
            "title": "Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 2695,
                    "therapyName": "Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01754376",
            "title": "Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1229,
                    "therapyName": "Aldesleukin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01763164",
            "title": "Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1154,
                    "therapyName": "Dacarbazine",
                    "synonyms": null
                },
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01765543",
            "title": "A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1256,
                    "therapyName": "Rifampin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01767454",
            "title": "Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1258,
                    "therapyName": "Dabrafenib + Ipilimumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1257,
                    "therapyName": "Dabrafenib + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01777776",
            "title": "Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1260,
                    "therapyName": "Encorafenib + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01781026",
            "title": "Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01781572",
            "title": "A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5,
                    "therapyName": "Binimetinib + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01810016",
            "title": "NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 2696,
                    "therapyName": "NY-ESO-1 peptide vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01813214",
            "title": "The Effects of Vemurafenib on Immunity in Patients With Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01820364",
            "title": "LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1260,
                    "therapyName": "Encorafenib + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 1337,
                    "therapyName": "Buparlisib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1336,
                    "therapyName": "BGJ398 + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1338,
                    "therapyName": "Capmatinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01826448",
            "title": "A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1339,
                    "therapyName": "Pexidartinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01827111",
            "title": "Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2978,
                    "therapyName": "Ipilimumab + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01835184",
            "title": "Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1235,
                    "therapyName": "Cabozantinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01841463",
            "title": "Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1238,
                    "therapyName": "Vemurafenib + Voruciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01843738",
            "title": "Radiation Use During Vemurafenib Treatment",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01844674",
            "title": "A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1241,
                    "therapyName": "Tizanidine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01876212",
            "title": "Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 717,
                    "therapyName": "Dasatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01876641",
            "title": "Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1259,
                    "therapyName": "Decitabine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01894672",
            "title": "BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01897116",
            "title": "A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1281,
                    "therapyName": "Hydroxychloroquine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01904123",
            "title": "A Phase I Trial of WP1066",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2784,
                    "therapyName": "WP1066",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01909453",
            "title": "Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 796,
                    "therapyName": "Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01940809",
            "title": "Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                },
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01941927",
            "title": "Trametinib With GSK2141795 in BRAF Wild-type Melanoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1298,
                    "therapyName": "Trametinib + Uprosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01942993",
            "title": "The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01943422",
            "title": "Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1300,
                    "therapyName": "Interferon alpha-2b + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01946789",
            "title": "A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3060,
                    "therapyName": "ALT-803",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01950195",
            "title": "SRS (Stereotactic Radiosurgery) Plus Ipilimumab",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01950390",
            "title": "Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1301,
                    "therapyName": "Bevacizumab + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01955460",
            "title": "Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9745,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + NGFR-transduced autologous T lymphocytes + TGFbDNRII-transduced autologous TILs",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01961115",
            "title": "INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2575,
                    "therapyName": "Epacadostat",
                    "synonyms": null
                },
                {
                    "id": 3016,
                    "therapyName": "MELITAC 12.1 Peptide Vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01966445",
            "title": "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2919,
                    "therapyName": "GSK2849330",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01967823",
            "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8359,
                    "therapyName": "Aldesleukin + Anti-NY ESO-1 mTCR PBL + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01968109",
            "title": "Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4196,
                    "therapyName": "Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01970358",
            "title": "A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3006,
                    "therapyName": "NeoVax melanoma vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01970527",
            "title": "Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01974258",
            "title": "Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1306,
                    "therapyName": "Onartuzumab + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 1307,
                    "therapyName": "Cobimetinib + Onartuzumab",
                    "synonyms": null
                },
                {
                    "id": 1308,
                    "therapyName": "Cobimetinib + Onartuzumab + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01978236",
            "title": "Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 3,
                    "therapyName": "Dabrafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01988896",
            "title": "A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01989585",
            "title": "Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1303,
                    "therapyName": "Dabrafenib + Navitoclax + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01993719",
            "title": "Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02009397",
            "title": "A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02009449",
            "title": "A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1161,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 755,
                    "therapyName": "Gemcitabine",
                    "synonyms": null
                },
                {
                    "id": 720,
                    "therapyName": "Docetaxel",
                    "synonyms": null
                },
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1105,
                    "therapyName": "Capecitabine",
                    "synonyms": null
                },
                {
                    "id": 1103,
                    "therapyName": "Paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 2621,
                    "therapyName": "Pegilodecakin",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02012231",
            "title": "Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1041,
                    "therapyName": "PLX8394",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02013804",
            "title": "A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3120,
                    "therapyName": "MEDI0680",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02014909",
            "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2054,
                    "therapyName": "CDX-3379",
                    "synonyms": null
                },
                {
                    "id": 2063,
                    "therapyName": "CDX-3379 + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 2064,
                    "therapyName": "CDX-3379 + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 2061,
                    "therapyName": "CDX-3379 + Cetuximab",
                    "synonyms": null
                },
                {
                    "id": 2062,
                    "therapyName": "CDX-3379 + Erlotinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02020707",
            "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02027935",
            "title": "Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02027961",
            "title": "Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1357,
                    "therapyName": "Dabrafenib + Durvalumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1358,
                    "therapyName": "Durvalumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02032810",
            "title": "Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1080,
                    "therapyName": "Panobinostat",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02036086",
            "title": "Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02039947",
            "title": "Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02043665",
            "title": "Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2974,
                    "therapyName": "coxsackievirus A21",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02047747",
            "title": "A Phase II Study of Dacomitinib in Progressive Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 714,
                    "therapyName": "Dacomitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02050321",
            "title": "A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1936,
                    "therapyName": "Acitretin + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02054520",
            "title": "Immunotherapy Study for Patients With Stage IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02065466",
            "title": "Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1380,
                    "therapyName": "Bevacizumab + Nab-paclitaxel + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02068079",
            "title": "A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1383,
                    "therapyName": "Trientine + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02073123",
            "title": "Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 2976,
                    "therapyName": "Indoximod",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02089685",
            "title": "Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 2624,
                    "therapyName": "Peginterferon alfa-2b",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02094872",
            "title": "Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02097225",
            "title": "Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1362,
                    "therapyName": "Dabrafenib + Onalespib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02097732",
            "title": "Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02107755",
            "title": "Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02110355",
            "title": "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1454,
                    "therapyName": "KRT-232 + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1453,
                    "therapyName": "Dabrafenib + KRT-232 + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02112032",
            "title": "Treatment of Advanced Melanoma With MK-3475 and Peginterferon",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2625,
                    "therapyName": "Peginterferon alfa-2b + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02115243",
            "title": "Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02117362",
            "title": "Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 2975,
                    "therapyName": "GR-MD-02",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02120222",
            "title": "Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02122861",
            "title": "A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3271,
                    "therapyName": "ID-LV305",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02126579",
            "title": "Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 3009,
                    "therapyName": "Long peptide vaccine 7",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02129075",
            "title": "CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3006,
                    "therapyName": "NeoVax melanoma vaccine",
                    "synonyms": null
                },
                {
                    "id": 3007,
                    "therapyName": "CDX-301",
                    "synonyms": null
                },
                {
                    "id": 1324,
                    "therapyName": "DEC-205-NY-ESO-1 fusion protein vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02130466",
            "title": "A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1450,
                    "therapyName": "Pembrolizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1448,
                    "therapyName": "Dabrafenib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1449,
                    "therapyName": "Dabrafenib + Pembrolizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02138292",
            "title": "A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1446,
                    "therapyName": "Digoxin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02141542",
            "title": "Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                },
                {
                    "id": 1176,
                    "therapyName": "MEDI3617",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02142218",
            "title": "Expanded Access Program With Nivolumab to Treat Melanoma",
            "phase": "Phase I",
            "recruitment": "No longer available",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02143050",
            "title": "Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1443,
                    "therapyName": "Dabrafenib + Metformin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02145910",
            "title": "Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02156804",
            "title": "A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02158520",
            "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1261,
                    "therapyName": "Bevacizumab + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02159066",
            "title": "LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1101,
                    "therapyName": "Binimetinib + Encorafenib + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 2216,
                    "therapyName": "Binimetinib + Capmatinib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 2215,
                    "therapyName": "Binimetinib + Buparlisib + Encorafenib",
                    "synonyms": null
                },
                {
                    "id": 2214,
                    "therapyName": "BGJ398 + Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02173093",
            "title": "Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2058,
                    "therapyName": "Aldesleukin + GD2Bi-a ATC + Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02174172",
            "title": "A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6252,
                    "therapyName": "Atezolizumab + Bevacizumab + Peg-interferon alfa-2a",
                    "synonyms": null
                },
                {
                    "id": 6253,
                    "therapyName": "Atezolizumab + Interferon alpha-2b",
                    "synonyms": null
                },
                {
                    "id": 6250,
                    "therapyName": "Atezolizumab + Peg-interferon alfa-2a",
                    "synonyms": null
                },
                {
                    "id": 6249,
                    "therapyName": "Atezolizumab + Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1975,
                    "therapyName": "Atezolizumab + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02178722",
            "title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02186249",
            "title": "Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy\u00ae) in Anti-CTLA-4 Treatment-Na\u00efve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)",
            "phase": "Phase III",
            "recruitment": "No longer available",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02196181",
            "title": "Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02200562",
            "title": "Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1257,
                    "therapyName": "Dabrafenib + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02210104",
            "title": "Adoptive Therapy Using Antigen-Specific CD4 T-Cells",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02224781",
            "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02230306",
            "title": "Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02231775",
            "title": "Combi-Neo Study for Stage IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02257424",
            "title": "The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02259231",
            "title": "RTA 408 Capsules in Patients With Melanoma - REVEAL",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 3062,
                    "therapyName": "Omaveloxolone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02263508",
            "title": "MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2695,
                    "therapyName": "Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02263898",
            "title": "Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02272855",
            "title": "A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2003,
                    "therapyName": "HF10 + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02296112",
            "title": "Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2,
                    "therapyName": "Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02298959",
            "title": "Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2369,
                    "therapyName": "Aflibercept + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02300935",
            "title": "Study of Trametinib and Nab-paclitaxel in Patients With Melanoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1268,
                    "therapyName": "Nab-paclitaxel + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02302339",
            "title": "A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3597,
                    "therapyName": "Glembatumumab vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02303990",
            "title": "RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02306850",
            "title": "Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02307149",
            "title": "Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2974,
                    "therapyName": "coxsackievirus A21",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02308020",
            "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315066",
            "title": "Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4333,
                    "therapyName": "PF-04518600",
                    "synonyms": null
                },
                {
                    "id": 4448,
                    "therapyName": "PF-04518600 + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02318771",
            "title": "Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02320058",
            "title": "A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02320305",
            "title": "MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3787,
                    "therapyName": "MART-1 antigen",
                    "synonyms": null
                },
                {
                    "id": 3889,
                    "therapyName": "GLA-SE + MART-1 antigen",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02327078",
            "title": "A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3059,
                    "therapyName": "Epacadostat + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02332668",
            "title": "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02334735",
            "title": "A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 3012,
                    "therapyName": "Melan-A/MART-1 peptide vaccine",
                    "synonyms": null
                },
                {
                    "id": 2696,
                    "therapyName": "NY-ESO-1 peptide vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02335918",
            "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2526,
                    "therapyName": "Nivolumab + Varlilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02339324",
            "title": "Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1299,
                    "therapyName": "Interferon alpha-2b",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02339571",
            "title": "Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1873,
                    "therapyName": "Sargramostim",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02346955",
            "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4246,
                    "therapyName": "CM-24",
                    "synonyms": null
                },
                {
                    "id": 4247,
                    "therapyName": "CM-24 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02360579",
            "title": "Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7043,
                    "therapyName": "LN-144",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02362594",
            "title": "Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02381314",
            "title": "Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3058,
                    "therapyName": "Ipilimumab + MGA271",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02382549",
            "title": "A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib (Mel61)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8248,
                    "therapyName": "6MHP vaccine + Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02385669",
            "title": "A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2620,
                    "therapyName": "6MHP vaccine",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02387125",
            "title": "A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4318,
                    "therapyName": "CMB305",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02388906",
            "title": "Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02400385",
            "title": "A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2626,
                    "therapyName": "Nivolumab + Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02404441",
            "title": "Phase I/II Study of PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02407171",
            "title": "Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02413827",
            "title": "A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2526,
                    "therapyName": "Nivolumab + Varlilumab",
                    "synonyms": null
                },
                {
                    "id": 1324,
                    "therapyName": "DEC-205-NY-ESO-1 fusion protein vaccine",
                    "synonyms": null
                },
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02423863",
            "title": "In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02425306",
            "title": "Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 2620,
                    "therapyName": "6MHP vaccine",
                    "synonyms": null
                },
                {
                    "id": 2595,
                    "therapyName": "Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02427893",
            "title": "Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma",
            "phase": "Phase III",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02428712",
            "title": "A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1041,
                    "therapyName": "PLX8394",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02432963",
            "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5547,
                    "therapyName": "MVAp53 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02434354",
            "title": "A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02437136",
            "title": "Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3354,
                    "therapyName": "Entinostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02452281",
            "title": "Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2973,
                    "therapyName": "Vitespen",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02452424",
            "title": "A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2736,
                    "therapyName": "Pembrolizumab + Pexidartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02460224",
            "title": "Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2887,
                    "therapyName": "LAG525",
                    "synonyms": null
                },
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02471846",
            "title": "A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2888,
                    "therapyName": "GDC-0919",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02475213",
            "title": "Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2864,
                    "therapyName": "MGA271 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02493361",
            "title": "Trial of pIL-12/MK-3475 in Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2990,
                    "therapyName": "IL-12 gene",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02498665",
            "title": "A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4320,
                    "therapyName": "DSP-7888",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02500576",
            "title": "MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5683,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02501096",
            "title": "Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02506153",
            "title": "High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1299,
                    "therapyName": "Interferon alpha-2b",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02509507",
            "title": "Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4035,
                    "therapyName": "Pembrolizumab + Talimogene laherparepvec",
                    "synonyms": null
                },
                {
                    "id": 2695,
                    "therapyName": "Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02519322",
            "title": "Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02521870",
            "title": "A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 3084,
                    "therapyName": "SD-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02526017",
            "title": "Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2840,
                    "therapyName": "Cabiralizumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02528357",
            "title": "GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5177,
                    "therapyName": "GSK3174998",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02543645",
            "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3086,
                    "therapyName": "Atezolizumab + Varlilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02553642",
            "title": "Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02554812",
            "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6045,
                    "therapyName": "Avelumab + PF-04518600",
                    "synonyms": null
                },
                {
                    "id": 8286,
                    "therapyName": "Avelumab + PD 0360324",
                    "synonyms": null
                },
                {
                    "id": 6043,
                    "therapyName": "Avelumab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 6044,
                    "therapyName": "Avelumab + PF-04518600 + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02557321",
            "title": "PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 879,
                    "therapyName": "PV-10",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02559492",
            "title": "INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3096,
                    "therapyName": "Epacadostat + Itacitinib",
                    "synonyms": null
                },
                {
                    "id": 3097,
                    "therapyName": "Itacitinib + Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02561234",
            "title": "A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6634,
                    "therapyName": "Pegzilarginase",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02565992",
            "title": "Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3136,
                    "therapyName": "coxsackievirus A21 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02574533",
            "title": "Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1157,
                    "therapyName": "FANG vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02575404",
            "title": "GR-MD-02 Plus Pembrolizumab in Melanoma Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2975,
                    "therapyName": "GR-MD-02",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576665",
            "title": "A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3211,
                    "therapyName": "Toca 511 + Toca FC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02587650",
            "title": "Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 789,
                    "therapyName": "Ceritinib",
                    "synonyms": null
                },
                {
                    "id": 1065,
                    "therapyName": "Capmatinib",
                    "synonyms": null
                },
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                },
                {
                    "id": 1455,
                    "therapyName": "Entrectinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02591654",
            "title": "MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02595866",
            "title": "Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02599402",
            "title": "Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02608268",
            "title": "Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 3560,
                    "therapyName": "MBG453",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02617849",
            "title": "Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02621021",
            "title": "A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628535",
            "title": "Safety Study of MGD009 in B7-H3-expressing Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6631,
                    "therapyName": "MGD009",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02637531",
            "title": "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 3363,
                    "therapyName": "IPI-549",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02639026",
            "title": "Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02639546",
            "title": "Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02643303",
            "title": "A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3385,
                    "therapyName": "Durvalumab + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 1652,
                    "therapyName": "Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02644369",
            "title": "Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02644967",
            "title": "A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4244,
                    "therapyName": "IMO-2125 + Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 4245,
                    "therapyName": "IMO-2125 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02646748",
            "title": "Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7159,
                    "therapyName": "Itacitinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8295,
                    "therapyName": "Parsaclisib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02650635",
            "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3413,
                    "therapyName": "Cyclophosphamide + Motolimod + Pegfilgrastim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02652455",
            "title": "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 3409,
                    "therapyName": "Aldesleukin + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 2055,
                    "therapyName": "Urelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02655822",
            "title": "Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5858,
                    "therapyName": "Atezolizumab + CPI-444",
                    "synonyms": null
                },
                {
                    "id": 3571,
                    "therapyName": "CPI-444",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02656706",
            "title": "BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02659540",
            "title": "A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02681549",
            "title": "Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2119,
                    "therapyName": "Bevacizumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02697591",
            "title": "An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4321,
                    "therapyName": "INCAGN01876",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02706353",
            "title": "APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3836,
                    "therapyName": "APX005M + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02711345",
            "title": "A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 6764,
                    "therapyName": "LTT462",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02714218",
            "title": "A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02716948",
            "title": "Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02718066",
            "title": "Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4689,
                    "therapyName": "Chidamide + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02719015",
            "title": "Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3943,
                    "therapyName": "Pembrolizumab + rAd-hCD40L",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02721459",
            "title": "XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3995,
                    "therapyName": "Cobimetinib + Vemurafenib + XL888",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02723006",
            "title": "Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4198,
                    "therapyName": "MLN2480 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4200,
                    "therapyName": "MLN1202 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4202,
                    "therapyName": "Ipilimumab + Nivolumab + Vedolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02723955",
            "title": "Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4409,
                    "therapyName": "GSK3359609",
                    "synonyms": null
                },
                {
                    "id": 4410,
                    "therapyName": "GSK3359609 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02736123",
            "title": "Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02740920",
            "title": "Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02743819",
            "title": "Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2106,
                    "therapyName": "Ipilimumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02748564",
            "title": "Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4165,
                    "therapyName": "Aldesleukin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02752074",
            "title": "A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4088,
                    "therapyName": "Epacadostat + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02760797",
            "title": "A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4181,
                    "therapyName": "Emactuzumab + RO7009789",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02796352",
            "title": "A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1167,
                    "therapyName": "Aldesleukin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02799095",
            "title": "A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4298,
                    "therapyName": "ALKS 4230",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02807844",
            "title": "Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5072,
                    "therapyName": "MCS110 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02812693",
            "title": "Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4376,
                    "therapyName": "Imatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02816021",
            "title": "Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2496,
                    "therapyName": "Azacitidine + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02818023",
            "title": "Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4406,
                    "therapyName": "Pembrolizumab + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02819843",
            "title": "A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2695,
                    "therapyName": "Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02823405",
            "title": "Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA)",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4436,
                    "therapyName": "Pembrolizumab + X4P-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02839694",
            "title": "Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3567,
                    "therapyName": "Decitabine + Tetrahydrouridine",
                    "synonyms": null
                },
                {
                    "id": 4592,
                    "therapyName": "Celecoxib + Decitabine + Tetrahydrouridine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02857270",
            "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4588,
                    "therapyName": "LY3214996",
                    "synonyms": null
                },
                {
                    "id": 4590,
                    "therapyName": "Gemcitabine + LY3214996 + Nab-paclitaxel",
                    "synonyms": null
                },
                {
                    "id": 4589,
                    "therapyName": "LY3214996 + Midazolam",
                    "synonyms": null
                },
                {
                    "id": 4591,
                    "therapyName": "Abemaciclib + LY3214996",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02858869",
            "title": "Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases",
            "phase": "Phase 0",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02870244",
            "title": "Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9751,
                    "therapyName": "Autologous TIL 13831 TCR transduced T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02880371",
            "title": "A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4608,
                    "therapyName": "ARRY-382 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02889861",
            "title": "IMCgp100-401 Rollover Study",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 3847,
                    "therapyName": "IMCgp100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02897765",
            "title": "A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 4733,
                    "therapyName": "NEO-PV-01 + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02908672",
            "title": "A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 4825,
                    "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02910700",
            "title": "Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4753,
                    "therapyName": "Nivolumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 4754,
                    "therapyName": "Dabrafenib + Nivolumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02915666",
            "title": "A Clinical Trial of Patients With Melanoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4778,
                    "therapyName": "Dabrafenib + Digoxin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02922764",
            "title": "A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6665,
                    "therapyName": "RGX-104",
                    "synonyms": null
                },
                {
                    "id": 6666,
                    "therapyName": "Nivolumab + RGX-104",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02923349",
            "title": "A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5831,
                    "therapyName": "INCAGN01949",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02935790",
            "title": "Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3312,
                    "therapyName": "Citarinostat + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02939300",
            "title": "Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02952248",
            "title": "A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5692,
                    "therapyName": "BI 754091",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02961283",
            "title": "Study of ASN003 in Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5827,
                    "therapyName": "ASN003",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02965716",
            "title": "Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4035,
                    "therapyName": "Pembrolizumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02967692",
            "title": "A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6023,
                    "therapyName": "Dabrafenib + Spartalizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02970981",
            "title": "Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02974725",
            "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8343,
                    "therapyName": "LXH 254 + Ribociclib",
                    "synonyms": null
                },
                {
                    "id": 8342,
                    "therapyName": "LXH 254 + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 6765,
                    "therapyName": "LTT462 + LXH 254",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02974803",
            "title": "Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02981303",
            "title": "Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5174,
                    "therapyName": "Pembrolizumab + PGG beta-glucan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02983006",
            "title": "Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5078,
                    "therapyName": "DS-8273a + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02983045",
            "title": "A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5076,
                    "therapyName": "Nivolumab + NKTR-214",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02989064",
            "title": "MAGE-A10c796T for Urothelial Cancer, Melanoma or Head and Neck Cancers",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02990416",
            "title": "A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 5137,
                    "therapyName": "A-dmDT390-bisFv(UCHT1) + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03003676",
            "title": "A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5173,
                    "therapyName": "Cyclophosphamide + ONCOS-102 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03005639",
            "title": "ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03021460",
            "title": "Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4917,
                    "therapyName": "Ibrutinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03025256",
            "title": "Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03026517",
            "title": "Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5270,
                    "therapyName": "Dabrafenib + Phenformin + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03033576",
            "title": "Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03050060",
            "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5301,
                    "therapyName": "Nelfinavir + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03068455",
            "title": "A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03088176",
            "title": "Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5481,
                    "therapyName": "Dabrafenib + Talimogene laherparepvec + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03089606",
            "title": "Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03092453",
            "title": "Dendritic Cell Vaccination in Patients With Advanced Melamona",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4891,
                    "therapyName": "Cyclophosphamide + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03098160",
            "title": "Immunotherapy Study of Evofosfamide in Combination With Ipilimumab",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 5745,
                    "therapyName": "Evofosfamide + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03101254",
            "title": "LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5512,
                    "therapyName": "Cobimetinib + LY3022855 + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03111901",
            "title": "Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4165,
                    "therapyName": "Aldesleukin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03122522",
            "title": "A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03126461",
            "title": "SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03131908",
            "title": "Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3518,
                    "therapyName": "GSK2636771 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03132675",
            "title": "pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment (PISCES)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6413,
                    "therapyName": "IL-12 gene + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03132922",
            "title": "MAGE-A4c1032T for Multi-Tumor",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7280,
                    "therapyName": "ADP-A2M4 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03149029",
            "title": "Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1449,
                    "therapyName": "Dabrafenib + Pembrolizumab + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 1450,
                    "therapyName": "Pembrolizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03159117",
            "title": "Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 5707,
                    "therapyName": "PF-06688992",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03161431",
            "title": "SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5786,
                    "therapyName": "SX-682",
                    "synonyms": null
                },
                {
                    "id": 5787,
                    "therapyName": "Pembrolizumab + SX-682",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03175432",
            "title": "Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03178851",
            "title": "A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03192345",
            "title": "A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5934,
                    "therapyName": "Cemiplimab + SAR439459",
                    "synonyms": null
                },
                {
                    "id": 5933,
                    "therapyName": "SAR439459",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03200847",
            "title": "Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5988,
                    "therapyName": "Pembrolizumab + Tretinoin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03207867",
            "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4741,
                    "therapyName": "PBF-509 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03236935",
            "title": "Phase Ib of L-NMMA and Pembrolizumab",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6097,
                    "therapyName": "L-NMMA + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03239145",
            "title": "Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6102,
                    "therapyName": "Pembrolizumab + Trebananib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03241927",
            "title": "Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03259425",
            "title": "Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6149,
                    "therapyName": "HF10 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03272464",
            "title": "Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6176,
                    "therapyName": "Dabrafenib + Itacitinib + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03273153",
            "title": "A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03276832",
            "title": "Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6220,
                    "therapyName": "Imiquimod + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03277352",
            "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6277,
                    "therapyName": "Epacadostat + INCAGN01876 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03289962",
            "title": "A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6234,
                    "therapyName": "RO7198457",
                    "synonyms": null
                },
                {
                    "id": 6235,
                    "therapyName": "Atezolizumab + RO7198457",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03301636",
            "title": "A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6587,
                    "therapyName": "Indoximod + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 6586,
                    "therapyName": "Indoximod + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03301896",
            "title": "Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6299,
                    "therapyName": "LHC165 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 6298,
                    "therapyName": "LHC165",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03311308",
            "title": "A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6581,
                    "therapyName": "Metformin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03311334",
            "title": "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6589,
                    "therapyName": "Atezolizumab + DSP-7888",
                    "synonyms": null
                },
                {
                    "id": 6588,
                    "therapyName": "DSP-7888 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03313778",
            "title": "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6349,
                    "therapyName": "mRNA-4157 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6348,
                    "therapyName": "mRNA-4157",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03325101",
            "title": "Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03329846",
            "title": "An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3569,
                    "therapyName": "BMS-986205 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03329950",
            "title": "A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7361,
                    "therapyName": "CDX-1140 + CDX-301",
                    "synonyms": null
                },
                {
                    "id": 7330,
                    "therapyName": "CDX-1140",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03332589",
            "title": "Study of E6201 for the Treatment of Central Nervous System Metastases (CNS)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1011,
                    "therapyName": "E6201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03336606",
            "title": "Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3838,
                    "therapyName": "MEDI0562",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03341143",
            "title": "Fecal Microbiota Transplant (FMT) in Melanoma Patients",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03347617",
            "title": "Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03361228",
            "title": "A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6492,
                    "therapyName": "Epacadostat + INCB001158",
                    "synonyms": null
                },
                {
                    "id": 6493,
                    "therapyName": "Epacadostat + INCB001158 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03384836",
            "title": "Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6576,
                    "therapyName": "Pembrolizumab + Propranolol",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03385486",
            "title": "Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6663,
                    "therapyName": "TBX-3400",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03396211",
            "title": "Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6577,
                    "therapyName": "Apatinib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03396952",
            "title": "Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2106,
                    "therapyName": "Ipilimumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03407170",
            "title": "Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03415126",
            "title": "A Study of ASN007 in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8304,
                    "therapyName": "ASN007",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03416335",
            "title": "A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8822,
                    "therapyName": "DSP-0509",
                    "synonyms": null
                },
                {
                    "id": 8823,
                    "therapyName": "DSP-0509 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03420508",
            "title": "Treating Patients With Melanoma and ALK Alterations With Ensartinib",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 961,
                    "therapyName": "Ensartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03425461",
            "title": "Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6516,
                    "therapyName": "Ipilimumab + VX15/2503",
                    "synonyms": null
                },
                {
                    "id": 6517,
                    "therapyName": "Nivolumab + VX15/2503",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03435640",
            "title": "A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6790,
                    "therapyName": "NKTR-214 + NKTR-262",
                    "synonyms": null
                },
                {
                    "id": 6791,
                    "therapyName": "Nivolumab + NKTR-214 + NKTR-262",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03445533",
            "title": "A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 4244,
                    "therapyName": "IMO-2125 + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03455764",
            "title": "A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6759,
                    "therapyName": "Dabrafenib + MCS110 + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03470922",
            "title": "A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03474497",
            "title": "Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6823,
                    "therapyName": "Aldesleukin + Pembrolizumab + Radiotherapy",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03476174",
            "title": "Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4165,
                    "therapyName": "Aldesleukin + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03484923",
            "title": "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6671,
                    "therapyName": "LAG525 + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 4492,
                    "therapyName": "Capmatinib + Spartalizumab",
                    "synonyms": null
                },
                {
                    "id": 5395,
                    "therapyName": "Canakinumab + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03501368",
            "title": "Study of Ceritinib in Patients With Unresectable Melanoma",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 789,
                    "therapyName": "Ceritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03502330",
            "title": "APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7073,
                    "therapyName": "APX005M + Cabiralizumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7072,
                    "therapyName": "APX005M + Cabiralizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03517488",
            "title": "A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6973,
                    "therapyName": "XmAb20717",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03525795",
            "title": "ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6942,
                    "therapyName": "CPI-1205 + Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03526185",
            "title": "A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6752,
                    "therapyName": "tumor infiltrating lymphocytes",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03538028",
            "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6977,
                    "therapyName": "INCAGN02385",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03543969",
            "title": "Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1657,
                    "therapyName": "Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03554083",
            "title": "Vemurafenib, Cobimetinib, and Atezolizumab in Treating Participants With High-Risk Stage III Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1343,
                    "therapyName": "Atezolizumab + Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 4825,
                    "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03565406",
            "title": "A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7050,
                    "therapyName": "Ipilimumab + Mocetinostat + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03568539",
            "title": "IBI308 in Subjects With Advanced/Metastatic Solid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6138,
                    "therapyName": "Sintilimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03580382",
            "title": "Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7105,
                    "therapyName": "CDX-3379 + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03590054",
            "title": "A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7282,
                    "therapyName": "Abexinostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03595683",
            "title": "Pembrolizumab and EDP1503 in Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7301,
                    "therapyName": "EDP1503 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03597282",
            "title": "A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5608,
                    "therapyName": "APX005M + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7507,
                    "therapyName": "Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 7506,
                    "therapyName": "APX005M + NEO-PV-01 + Nivolumab + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 7505,
                    "therapyName": "Nivolumab + Poly ICLC",
                    "synonyms": null
                },
                {
                    "id": 7504,
                    "therapyName": "NEO-PV-01 + Nivolumab + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03608020",
            "title": "A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5829,
                    "therapyName": "BMX-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03617328",
            "title": "Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9690,
                    "therapyName": "6MHP vaccine + Montanide ISA 51 + Poly ICLC + Varlilumab",
                    "synonyms": null
                },
                {
                    "id": 9691,
                    "therapyName": "6MHP vaccine + Montanide ISA 51 + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03620019",
            "title": "Denosumab + Pembrolizumab in Patients With Stage IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7297,
                    "therapyName": "Denosumab + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03621982",
            "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7369,
                    "therapyName": "Camidanlumab Tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03628677",
            "title": "A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8176,
                    "therapyName": "AB154",
                    "synonyms": null
                },
                {
                    "id": 8177,
                    "therapyName": "AB154 + GLS-010",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03629756",
            "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8016,
                    "therapyName": "AB928 + GLS-010",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03633110",
            "title": "Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7337,
                    "therapyName": "GEN-009",
                    "synonyms": null
                },
                {
                    "id": 7338,
                    "therapyName": "GEN-009 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03635983",
            "title": "A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5076,
                    "therapyName": "Nivolumab + NKTR-214",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03637803",
            "title": "MRx0518 and Pembrolizumab Combination Study",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7321,
                    "therapyName": "MRx0518 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03645928",
            "title": "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7516,
                    "therapyName": "LN-144 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6772,
                    "therapyName": "LN-145",
                    "synonyms": null
                },
                {
                    "id": 7517,
                    "therapyName": "LN-145 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03646617",
            "title": "Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03655756",
            "title": "pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9147,
                    "therapyName": "IFx-Hu2.0",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03656718",
            "title": "A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7453,
                    "therapyName": "Nivolumab + rHuPH20",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03679767",
            "title": "A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7175,
                    "therapyName": "INCMGA00012",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03681951",
            "title": "First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7708,
                    "therapyName": "GSK3145095",
                    "synonyms": null
                },
                {
                    "id": 7709,
                    "therapyName": "GSK3145095 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03698019",
            "title": "Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03712358",
            "title": "PVSRIPO for Patients With Unresectable Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7569,
                    "therapyName": "PVSRIPO",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03719131",
            "title": "Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7427,
                    "therapyName": "Ipilimumab + Nivolumab + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03719768",
            "title": "Avelumab With Radiotherapy in Patients With Leptomeningeal Disease",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03724968",
            "title": "Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03727789",
            "title": "CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3940,
                    "therapyName": "CBL0137",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03743766",
            "title": "Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na\u00efve to Prior Immunotherapy in the Metastatic Setting",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4196,
                    "therapyName": "Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 4197,
                    "therapyName": "Nivolumab + Relatlimab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03752398",
            "title": "A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9200,
                    "therapyName": "XmAb23104",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03757689",
            "title": "Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03758781",
            "title": "IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7122,
                    "therapyName": "Cyclophosphamide + IRX-2 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03765229",
            "title": "An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3354,
                    "therapyName": "Entinostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03767348",
            "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7820,
                    "therapyName": "Nivolumab + RP1",
                    "synonyms": null
                },
                {
                    "id": 7819,
                    "therapyName": "RP1",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03769155",
            "title": "VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6517,
                    "therapyName": "Nivolumab + VX15/2503",
                    "synonyms": null
                },
                {
                    "id": 6516,
                    "therapyName": "Ipilimumab + VX15/2503",
                    "synonyms": null
                },
                {
                    "id": 3738,
                    "therapyName": "VX15/2503",
                    "synonyms": null
                },
                {
                    "id": 7632,
                    "therapyName": "Ipilimumab + Nivolumab + VX15/2503",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03772899",
            "title": "Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT03776136",
            "title": "Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03809624",
            "title": "Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma (PDL1x41BB)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8934,
                    "therapyName": "INBRX-105",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03815058",
            "title": "A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7779,
                    "therapyName": "Pembrolizumab + RO7198457",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03816332",
            "title": "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8592,
                    "therapyName": "Ipilimumab + Nivolumab + Prednisone + Tacrolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03816345",
            "title": "Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03820986",
            "title": "Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4782,
                    "therapyName": "Lenvatinib + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03829501",
            "title": "Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7826,
                    "therapyName": "Atezolizumab + KY1044",
                    "synonyms": null
                },
                {
                    "id": 7825,
                    "therapyName": "KY1044",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03834623",
            "title": "Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4611,
                    "therapyName": "CC-122 + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03849469",
            "title": "A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7902,
                    "therapyName": "Pembrolizumab + XmAb22841",
                    "synonyms": null
                },
                {
                    "id": 7901,
                    "therapyName": "XmAb22841",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03864042",
            "title": "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7997,
                    "therapyName": "Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole",
                    "synonyms": null
                },
                {
                    "id": 7995,
                    "therapyName": "Modafinil",
                    "synonyms": null
                },
                {
                    "id": 7996,
                    "therapyName": "Bupropion + Rosuvastatin",
                    "synonyms": null
                },
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03871348",
            "title": "A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9295,
                    "therapyName": "SAR441000",
                    "synonyms": null
                },
                {
                    "id": 9296,
                    "therapyName": "Cemiplimab + SAR441000",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03873818",
            "title": "Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2106,
                    "therapyName": "Ipilimumab + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03878719",
            "title": "Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03891953",
            "title": "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8612,
                    "therapyName": "DKY709",
                    "synonyms": null
                },
                {
                    "id": 8613,
                    "therapyName": "DKY709 + Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03894618",
            "title": "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8683,
                    "therapyName": "SL-279252",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03901573",
            "title": "High-Risk Skin Cancers With Atezolizumab Plus NT-I7",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9321,
                    "therapyName": "Atezolizumab + NT-I7",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03903640",
            "title": "Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03911869",
            "title": "An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1100,
                    "therapyName": "Binimetinib + Encorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03922880",
            "title": "Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8216,
                    "therapyName": "ADI-PEG 20 + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03925350",
            "title": "Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03929029",
            "title": "Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 6699,
                    "therapyName": "Ipilimumab + NeoVax + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03936959",
            "title": "A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 9537,
                    "therapyName": "LY3434172",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03957551",
            "title": "Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5680,
                    "therapyName": "Cabozantinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03958383",
            "title": "IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 8413,
                    "therapyName": "hu14.18-IL2",
                    "synonyms": null
                },
                {
                    "id": 8414,
                    "therapyName": "hu14.18-IL2 + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8415,
                    "therapyName": "hu14.18-IL2 + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03964233",
            "title": "A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5806,
                    "therapyName": "BI 754091 + BI 754111",
                    "synonyms": null
                },
                {
                    "id": 8524,
                    "therapyName": "BI 754091 + BI 754111 + BI 907828",
                    "synonyms": null
                },
                {
                    "id": 8525,
                    "therapyName": "BI 754091 + BI 907828",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03970382",
            "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8527,
                    "therapyName": "NeoTCR-P1 T-cells + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8526,
                    "therapyName": "NeoTCR-P1 T-cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03972046",
            "title": "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 5481,
                    "therapyName": "Dabrafenib + Talimogene laherparepvec + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03977467",
            "title": "Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5983,
                    "therapyName": "Atezolizumab + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 7491,
                    "therapyName": "Atezolizumab + Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                },
                {
                    "id": 8440,
                    "therapyName": "Atezolizumab + Bevacizumab + Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 8439,
                    "therapyName": "Atezolizumab + Bevacizumab + Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03978611",
            "title": "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8442,
                    "therapyName": "Ipilimumab + Relatlimab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03980314",
            "title": "A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03991130",
            "title": "High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5139,
                    "therapyName": "Aldesleukin + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03999749",
            "title": "A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 8505,
                    "therapyName": "Ipilimumab + Nivolumab + Tocilizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04007744",
            "title": "Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8531,
                    "therapyName": "Pembrolizumab + Sonidegib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04013854",
            "title": "Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04020185",
            "title": "Safety and Efficacy Study of IMSA101 in Refractory Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9540,
                    "therapyName": "IMSA101 + unspecified PD-L1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9539,
                    "therapyName": "IMSA101 + unspecified PD-1 antibody",
                    "synonyms": null
                },
                {
                    "id": 9538,
                    "therapyName": "IMSA101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04042506",
            "title": "SBRT as a Vaccination for Metastatic Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04044859",
            "title": "Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9445,
                    "therapyName": "ADP-A2M4CD8 cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04059588",
            "title": "A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9648,
                    "therapyName": "2141 V-11",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04060407",
            "title": "CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI)",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8698,
                    "therapyName": "CD24Fc + Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04068181",
            "title": "Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4035,
                    "therapyName": "Pembrolizumab + Talimogene laherparepvec",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04074967",
            "title": "Study of ARRY-614 Plus Either Nivolumab or Ipilimumab",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8707,
                    "therapyName": "Ipilimumab + Pexmetinib",
                    "synonyms": null
                },
                {
                    "id": 8706,
                    "therapyName": "Nivolumab + Pexmetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04091750",
            "title": "Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2068,
                    "therapyName": "Cabozantinib + Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 2067,
                    "therapyName": "Cabozantinib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04093323",
            "title": "Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8764,
                    "therapyName": "alphaDC1 + Celecoxib + Interferon alpha-2b + Rintatolimod",
                    "synonyms": null
                },
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                },
                {
                    "id": 5248,
                    "therapyName": "unspecified PD-L1 antibody",
                    "synonyms": null
                },
                {
                    "id": 3890,
                    "therapyName": "unspecified PD-1 antibody",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04096638",
            "title": "Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8759,
                    "therapyName": "Nivolumab + SB 11285",
                    "synonyms": null
                },
                {
                    "id": 8758,
                    "therapyName": "SB 11285",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04109456",
            "title": "IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9575,
                    "therapyName": "BI 853520 + Cobimetinib",
                    "synonyms": null
                },
                {
                    "id": 3599,
                    "therapyName": "BI 853520",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04114136",
            "title": "Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 5302,
                    "therapyName": "Metformin + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6581,
                    "therapyName": "Metformin + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8813,
                    "therapyName": "Pembrolizumab + Rosiglitazone",
                    "synonyms": null
                },
                {
                    "id": 8812,
                    "therapyName": "Nivolumab + Rosiglitazone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04119024",
            "title": "Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9726,
                    "therapyName": "Aldesleukin + Anti-IL13RA2 CAR T cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04123470",
            "title": "A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8838,
                    "therapyName": "Atezolizumab + LOAd703",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04125719",
            "title": "PVSRIPO in Combination With Nivolumab in Melanoma (PPD1)",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 8853,
                    "therapyName": "Nivolumab + PVSRIPO",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04129515",
            "title": "NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04139902",
            "title": "PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor TSR-022 and PD-1 Inhibitor Dostarlimab (TSR-042)",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 7522,
                    "therapyName": "TSR-022 + TSR-042",
                    "synonyms": null
                },
                {
                    "id": 6320,
                    "therapyName": "TSR-042",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04140526",
            "title": "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8898,
                    "therapyName": "ONC-392",
                    "synonyms": null
                },
                {
                    "id": 8899,
                    "therapyName": "ONC-392 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04145622",
            "title": "Study of DS-7300a in Participants With Advanced Solid Malignant Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9154,
                    "therapyName": "DS-7300a",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04148937",
            "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8894,
                    "therapyName": "LY3475070",
                    "synonyms": null
                },
                {
                    "id": 8895,
                    "therapyName": "LY3475070 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04152018",
            "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8931,
                    "therapyName": "PF-06801591 + PF-06940434",
                    "synonyms": null
                },
                {
                    "id": 8930,
                    "therapyName": "PF-06940434",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04152863",
            "title": "Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 3136,
                    "therapyName": "coxsackievirus A21 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04187833",
            "title": "Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9038,
                    "therapyName": "Nivolumab + Talazoparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04198766",
            "title": "Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9075,
                    "therapyName": "INBRX-106",
                    "synonyms": null
                },
                {
                    "id": 9076,
                    "therapyName": "INBRX-106 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04208958",
            "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer (Consortium-IO)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9184,
                    "therapyName": "Nivolumab + Vancomycin + VE800",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04219254",
            "title": "A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9327,
                    "therapyName": "BI-1206 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04294576",
            "title": "Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9460,
                    "therapyName": "BJ-001 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 9459,
                    "therapyName": "BJ-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04310397",
            "title": "Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1066,
                    "therapyName": "Dabrafenib + Trametinib",
                    "synonyms": null
                },
                {
                    "id": 6023,
                    "therapyName": "Dabrafenib + Spartalizumab + Trametinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04311710",
            "title": "A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U)",
            "phase": "Phase Ib/II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 9635,
                    "therapyName": "Ipilimumab + Nivolumab + rHuPH20",
                    "synonyms": null
                }
            ]
        }
    ]
}